Onkološki Inštitut Ljubljana EPIDEMIOLOGIJA IN REGISTER RAKA EPIDEMIOLOGY AND CANCER REGISTRY Rak v Sloveniji 2016 Cancer in Slovenia Rak v Sloveniji 2016 Cancer in Slovenia Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Naslov / Title Rak v Sloveniji 2016 / Cancer in Slovenia 2016 Uredniški odbor / Editorial Board Vesna Zadnik, glavna urednica / editor-in-chief Gorana Gašljevic, Marko Hočevar, Urška Ivanuš, Katja Jarm, Vera Pompe-Kirn, Primož Strojan, Sonja Tomšič, Branko Zakotnik in Tina Žagar Računalniška obdelava / EDP analysis Tina Žagar, Katarina Lokar in Miran Mlakar Oblikovanje in priprava za tisk / Design & Typesetting Studio N, studio za oblikovanje in grafično pripravo, Ljubljana Tisk / Printing GRAFEX d.o.o., Izlake Izdajatelj / Published by Onkološki inštitut Ljubljana / Insitute of Oncology Ljubljana, Slovenia Epidemiologija in register raka / Epidemiology and Cancer Registry Register raka Republike Slovenije / Slovenian Cancer Registry Naklada / Published in 600 izvodov / 600 copies Nasvet za citiranje / Recommended reference Rak v Sloveniji 2016. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2019. Cancer in Slovenia 2016. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry, 2019. Osebje Registra raka Republike Slovenije / Staff of the Slovenian Cancer Registry Vesna Zadnik, vodja / head Maruška Ferjančič, Andrej Kirn, Andrej Krašovec, Katarina Lokar, Darja Strle, Fani Škrlec, Polona Škulj, Nataša Šturm, Urška Tomšič in Tina Žagar Naslov / Correspondence to Register raka Republike Slovenije / Slovenian Cancer Registry Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija Telefon / Phone: + 386 1 5879 450 E-pošta / E-mail: register@onko-i.si Spletna stran / Web site: http://www.onko-i.si/rrs/ http://www.slora.si/ http://www.onko-i.si/crs/ http://www.slora.si/en/ 2 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Vsebina Contents Uvod..............................................................................................7 Viri podatkov in metode registracije.....................................................9 Viri podatkov....................................................................................9 Priprava podatkov za računalniško obdelavo................................................... 10 Kakovost podatkov RRRS in popolnost registracije.............................................. 11 Statistične metode.......................................................................... 12 Incidenca in umrljivost......................................................................... 12 Grobe in starostno specifične stopnje.......................................................... 12 Starostno standardizirane stopnje.............................................................. 12 Kumulativne stopnje in kumulativno tveganje..................................................13 Prevalenca..................................................................................... 13 Preživetje...................................................................................... 14 Prebivalstvo Slovenije.......................................................................15 Rak v Sloveniji 2016..........................................................................16 Zahvala......................................................................................... 20 Introduction...................................................................................21 Data sources and methods of registration............................................23 Data sources...................................................................................23 Preparation of data for computer processing................................................... 24 Data quality and completeness of registration..................................................25 Statistical methods..........................................................................27 Incidence and mortality........................................................................27 Crude and age specific rates................................................................... 27 Age standardised rates.........................................................................27 Cumulative incidence rate and cumulative risk................................................. 28 Prevalence.....................................................................................28 Survival........................................................................................ 28 Population of Slovenia......................................................................30 Cancer in Slovenia 2016....................................................................31 Acknowledgment........................................................................... 35 Reference / References.....................................................................36 3 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Slike / Figures Slika 1: Breme raka, Slovenija 2016............................................................. 38 Figure 1: Cancer burden, Slovenia 2016. Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2016..............38 Figure 2: Percentage distribution of all cancer sites by age group and by sex, Slovenia 2016. Slika 3: Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2016............................................... 39 Figure 3: The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2016. Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950-2016................. 40 Figure 4: Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950-2016. Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950-2016................. 41 Figure 5: Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950-2016. Slika 6: Pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2007-2011 in 2012-2016 po spolu..........................................42 Figure 6: Five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2007-2011 and 2012-2016 by sex. Slika 7a: Časovni trend grobe letne incidenčne stopnje raka materničnega vratu (C53) po stadijih s povrečno letno spremembo za tri obdobja: pred pričetkom presejalnega programa ZORA (1987-1996), v času pilotnega presejanja (1997-2002) in od pričetka presejalnega programa ZORA (2003-2016), Slovenija 1987-2016.....................................44 Figure 7a: Time trend of crude annual incidence rates for cervical cancer (C53) by stage with avarage annual change for three periods: before the start of screening program ZORA (1987-1996), during pilot screening (1997-2002) and since the start of screening programme ZORA (2003-2016), Slovenia 1987-2016. Slika 7b: Delež žensk z rakom materničnega vratu (C53) glede na udeležbo v presejalnem programu ZORA in FIGO stadij, Slovenija 2012-2016....................................44 Figure 7b: Proportion of women with cervical cancer (C53) according to attendance in organised screening programme ZORA and FIGO stage, Slovenia 2012-2016. Slika 7c: Čisto preživetje bolnic z rakom materničnega vratu starih 20-64 let s 95 % intervalom zaupanja glede na udeležbo v presejalnem programu ZORA, Slovenija 2012-2016......45 Figure 7c: Net survival of cervical cancer (women aged 20-64 years) with 95% confidence interval according to attendance in organised screening programme ZORA, Slovenia 2012-2016. Slika 7d: Čisto preživetje bolnic z rakom materničnega vratu starih 20-64 let po FIGO stadiju glede na udeležbo v presejalnem programu ZORA, Slovenija 2012-2016............... 45 Figure 7d: Net survival of cervical cancer (women aged 20-64 years) by FIGO stage according to attendance in organised screening programme ZORA, Slovenia 2012-2016. Slika 8a: Časovni trend grobe letne incidenčne stopnje raka dojk pri ženskah (C50) po stadijih s povrečno letno spremembo za dve obdobji: pred pričetkom presejalnega programa DORA (1987-2010) in od pričetka presejalnega programa DORA (2011-2016), Slovenija 1987-2016................................................................... 46 Figure 8a: Time trend of crude annual incidence rates for breast cancer in women (C50) by stage with avarage annual change for two periods: before the start of screening program DORA (1987-2010) and since the start of screening programme DORA (2011-2016), Slovenia 1987-2016. Slika 8b: Delež žensk z rakom dojke (C50) glede na udeležbo v presejalnem programu DORA in UICC stadij, Slovenija 2012-2016....................................................... 46 Figure 8b: Proportion of women with breast cancer (C50) according to attendance in organised screening programme DORA and UICC stage, Slovenia 2012-2016. 4 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Slika 8c: Čisto preživetje bolnic z rakom dojk starih 50-69 let s 95 % intervalom zaupanja glede na udeležbo v presejalnem programu DORA, Slovenija 2012-2016............... 47 Figure 8c: Net survival of breast cancer (women aged 50-69 years) with 95% confidence interval according to attendance in organised screening programme DORA, Slovenia 2012-2016. Slika 8d: Čisto preživetje bolnic z rakom dojk starih 50-69 let po UICC stadiju glede na udeležbo v presejalnem programu DORA, Slovenija 2012-2016 .................................. 47 Figure 8d: Net survival of breast cancer (women aged 50-69 years) by UICC stage according to attendance in organised screening programme DORA, Slovenia 2012-2016. Slika 9a: Časovni trend grobe letne incidenčne stopnje raka debelega črevesa in danke (C18-C20) za oba spola skupaj po stadijih s povrečno letno spremembo za dve obdobji: pred pričetkom presejalnega programa Svit (1987-2009) in od pričetka presejalnega programa Svit (2010-2016), Slovenija 1987-2016......................... 48 Figure 9a: Time trend of crude annual incidence rates for colon and rectum cancers (C18-C20) for both sexes together by stage with avarage annual change for two periods: before the start of screening program Svit (1987-2009) and since the start of screening programme Svit (2010-2016), Slovenia 1987-2016. Slika 9b: Delež bolnikov z rakom debelega črevesa in danke (C18-C20) glede na udeležbo v presejalnem programu Svit in UICC stadij, Slovenija 2012-2016........................... 48 Figure 9b: Proportion of patients with colon and rectum cancer (C18-C20) according to attendance in organised screening programme Svit and UICC stage, Slovenia 2012-2016. Slika 9c: Čisto preživetje bolnikov z rakom debelega črevesa in danke starih 50-74 let s 95 % intervalom zaupanja glede na udeležbo v presejalnem programu Svit, Slovenija 2012-2016................................................................... 49 Figure 9c: Net survival of colorectal cancer (patients aged 50-74 years) with 95% confidence interval according to attendance in organised screening programme Svit, Slovenia 2012-2016. Slika 9d: Čisto preživetje bolnikov z rakom debelega črevesa in danke starih 50-74 let po UICC stadiju glede na udeležbo v presejalnem programu Svit, Slovenija 2012-2016......49 Figure 9d: Net survival of colorectal cancer (patients aged 50-74 years) by UICC stage according to attendance in organised screening programme Svit, Slovenia 2012-2016. Podatki v tabelah / Data in tables Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 2007-2016 in 2019...................50 Table 1: Opazovana in ocenjena incidenca raka, Slovenija 2007-2016 in 2019. Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2016.......... 51 Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2016. Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2016.....52 Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2016. Tabela 4: Incidenca raka po lokaciji, spolu in starosti, Slovenija 2016..............................56 Table 4: Cancer incidence by site, by sex and by age, Slovenia 2016. Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter komulativna stopnja (KS) po lokaciji in spolu, Slovenija 2016............................60 Table 5: Crude and age specific cancer incidence rate per 100,000 and comulative rate (CR) by site and by sex, Slovenia 2016. Tabela 6a: Incidenca po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2016......66 Table 6a: Incidence by statistical regions, by sex and by selected primary cancer site, Slovenia 2016. Tabela 6b: Starostno standardizirana incidenčna stopnja po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2016............................................ 67 Table 6b: Age standardised incidence rate by statistical regions, by sex and by selected primary cancer site, Slovenia 2016. 5 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 7: Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2016................................................................. 68 Table 7: Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2016. Tabela 8: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2016..............................................77 Table 8: Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2016. Tabela 9: Incidenca ne-Hodgkinovih limfomov po lokaciji, spolu in starosti, Slovenija 2016....... 80 Table 9: Incidence of non-Hodgkin's malignant lymphomas by site, by sex and by age, Slovenia 2016. Tabela 10: Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, po spolu, Slovenija 2016..........................81 Table 10: Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), by sex, Slovenia 2016. Tabela 11a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2016, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemsko terapijo ali obsevani, po izbrani primarni lokaciji raka. . . .83 Table 11a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2016, that were treated by surgery, systemic therapy or radiotherapy during their first treatment by selected primary cancer site. Tabela 11b: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2016, ki so bili v okviru prvega zdravljenja operirani, po izbrani primarni lokaciji raka in bolnici posega...................................... 84 Table 11b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2016, that were treated by surgery during their first treatment by selected primary cancer site and treatment institution. Tabela 11c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2016, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje, po izbrani primarni lokaciji raka in bolnici zdravljenja....................... 85 Table 11c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2016, that were treated by systemic therapy during their first treatment by selected primary cancer site and treatment institution. Tabela 12: Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2016............. 86 Table 12: Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2016. Tabela 13: Umrljivost za rakom po lokaciji, spolu in starosti, Slovenija 2016.........................87 Table 13: Cancer mortality by site, by sex and by age, Slovenia 2016. Tabela 14: Eno-, tro- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2012-2016 po spolu................................... 91 Table 14: One-, three- and five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in period 2012-2016 by sex. Izbor publikacij / Selected publications...............................................92 6 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Uvod Register raka Republike Slovenije (RRRS) je eden najstarejših populacijskih registrov raka v Evropi. Leta 1950 ga je na Onkološkem inštitutu Ljubljana (OI) ustanovila in do leta 1975 vodila pokojna profesorica dr. Božena Ravnihar. Njeno delo je prevzela profesorica dr. Vera Pompe Kirn, ki je do upokojitve leta 2003 skrbela za nadaljnje uveljavljanje RRRS v domačem in mednarodnem merilu. Od leta 2003 je RRRS z Enoto za epidemiologijo posebna služba OI, ki se imenuje Epidemiologija in register raka; do leta 2018 jo je vodila dr. Maja Primic Žakelj. V njej delujejo še bolnišnični register OI, ki omogoča podrobnejši pregled nad bolniki, zdravljenimi na OI (ne glede na to, kje imajo stalno prebivališče), in RRRS oskrbuje z velikim delom podatkov, državni register za vodenje in spremljanje organiziranega presejalnega programa za raka materničnega vratu (Register ZORA) in od leta 2007 informacijski sistem za vabljenje žensk in epidemiološko spremljanje organiziranega presejalnega programa za raka dojk (Register DORA). Podatki o raku, incidenci, preživetju in prevalenci, ki se zbirajo v RRRS, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje RS, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje državnega programa obvladovanja raka (DPOR) na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, bolnišnične zmogljivosti); dragoceni so tudi za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov. Redna letna poročila RRRS so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih z obdelanimi podatki RRRS. Ker nas omejuje tehnologija zbiranja podatkov, saj je njihovih virov več, je za dokončanje letne zbirke podatkov, njihovo analizo in objavo rezultatov potreben čas, ki je pri nas in v drugih državah podoben, običajno 2 do 3 leta. V poročilih pa zadnja leta objavimo tudi pričakovano incidenco raka v letu, ko je poročilo izdano (v tokratnem poročilu za leto 2019); izračunana je s posebno statistično metodo za napovedovanje incidence raka. RRRS je prva letna poročila izdal v letih 1953-1957 za leta 1951-1955. Prva analiza podatkov za leto 1950 je bila objavljena v Zdravstvenem vestniku leta 1951. Podatki za leta 1957-1971 so bili objavljeni v periodičnih publikacijah Svetovne zdravstvene organizacije Epidemiological and Vital Statistics in v World Health Statistics Report. Od leta 1965 so bili podatki spet redno objavljani v posebnih letnih poročilih z naslovom Rak v Sloveniji (1965-1977 in 2007-2014), v vmesnem obdobju (1978-2006) pod imenom Incidenca raka v Sloveniji, in sicer v slovenskem in angleškem jeziku. Poleg letnih poročil so bile objavljene tudi 4 monografije: Zemljevidi incidence raka v Sloveniji 1978-1987, Preživetje bolnikov z rakom v Sloveniji 1963-1990, Preživetje bolnikov z rakom v Sloveniji 1983-1997 in Preživetje bolnikov z rakom, zbolelih v letih 1991-2005 v Sloveniji. Seznam drugih pomembnejših del, objavljenih v zadnjih petih letih, je v dodatku na koncu poročila. Podatki RRRS so vključeni v številne mednarodne podatkovne zbirke in projekte. Objavljeni so v vseh devetih zvezkih in v deseti elektronski verziji knjige Rak na petih kontinentih (Cancer Incidence in Five Continents), ki jo izdaja Mednarodna 7 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 agencija za raziskovanje raka, in v podatkovnih zbirkah ECO, GLOBOCAN in ACCIS. Preživetje slovenskih bolnikov je obdelano v mednarodnih raziskavah EUROCARE- 2, EUROCARE-3, EUROCARE-4, EUROCARE-5, EUROCARE-6, CONCORD-1, CONCORD-2, CONCORD-3, RARECARE in EUNICE. Leta 2010 smo v celoti prenovili računalniško bazo in posodobili obdelavo podatkov v RRRS. Od takrat deluje tudi interaktivni spletni portal, ki smo ga poimenovali SLORA po začetnih črkah besed »Slovenija in rak«. Dostopen je na elektronskem naslovu www.slora.si. Omogoča preprost in hiter dostop do večine podatkov o raku v Sloveniji, ki jih zbirata RRRS do zaključenega leta obdelave, trenutno 2016 (incidenca, prevalenca in preživetje), in Nacionalni inštitut za javno zdravje RS (umrljivost). S hitrim dostopom do tujih baz omogoča tudi primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in v svetu. Dodane so tudi obširne strokovne razlage, ki pojasnjujejo podatke in seznanjajo uporabnike z nevarnostnimi dejavniki raka, možnostmi zgodnjega odkrivanja in uspešnostjo zdravljenja raka. Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 8 Viri podatkov in metode registracije Viri podatkov Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve RRRS (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00, št. 47/15 in 31/18). Osnovni vir podatkov so prijavnice rakave bolezni. Registru jih pošiljajo iz vseh bolnišnic in diagnostičnih centrov v Sloveniji, iz ordinacij osnovnega zdravstvenega varstva pa le izjemoma, če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje. Dopolnilni vir podatkov so zdravniška poročila o vzroku smrti, ki nam jih pošilja Nacionalni inštitut za javno zdravje RS ter podatki o diagnosticiranih rakih, ki jih zabeležijo v treh državnih presejalnih programih: ZORA za odkrivanje predrakavih in zgodnjih rakavih sprememb na materničnem vratu, DORA za odkrivanje raka dojk in Svit za odkrivanje predrakavih sprememb in raka na debelem črevesu in danki. S prijavnicami zbiramo osebne podatke, podatke o vrsti bolezni (anatomsko mesto raka, histološka oz. citološka diagnoza, stadij po TNM ali drugi klinični klasifikaciji) in o vrsti zdravljenja. Veliko časa porabimo za poizvedbe o bolnikih, za katere na prijavnicah niso zapisani popolni ali ustrezni podatki ter za tiste 0 katerih dobimo prvo informacijo šele iz enega od dopolnilnih virov. Za izračun prevalence in preživetja bolnikov potrebujemo podatek, ki se imenuje vitalno stanje (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo iz Centralnega registra prebivalstva (CRP), in sicer za vse osebe iz RRRS. Od leta 2010 smo po prenovi računalniške baze s posebej varovano spletno tehnologijo neposredno povezani s CRP, zato ta podatek dobimo dnevno. Pri izgubljenih osebah upoštevamo kot datum izgube datum zadnje prijave oz. datum izgube, kot velja v CRP, odvisno od tega, kateri datum je kasnejši. Od leta 1985, odkar RRRS prejema od CRP enotno matično številko občana (EMŠO), je v RRRS delež izgubljenih manjši od 1 %; pri bolnikih, registriranih v zadnjem desetletju, je znašal le 0,1 %. Podrobne analize prostorske razporeditve raka nam omogoča točno opredeljevanje naslovov bolnikov z rakom in redna povezava z Registrom prostorskih enot (RPE) Geodetske uprave RS. V Tabeli 6 tako prikazujemo breme raka na ravni 12 statističnih regij kot so bile v slovenskem prostoru v veljavi leta 2016. 9 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Priprava podatkov za računalniško obdelavo Podatke, prispele v RRRS na prijavnicah, posebej usposobljene medicinske sestre najprej kodirajo v skladu z mednarodnimi in v RRRS dogovorjenimi pravili. Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10), pred tem pa smo uporabljali osmo. Pri uvrščanju med maligne bolezni je treba opozoriti še na klasifikacijo morfologije neoplazem, za katero uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo. Od leta 2012 uporabljamo njeno tretjo izdajo z dopolnitvami iz leta 2011. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne, in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST ) uvrščamo med posebne histološke vrste šele od leta 2001. V skladu z novimi pravili mejno malignih tumorjev jajčnikov ne uvrščamo več v kategorijo C56, pač pa v D39.1. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski šifri C96.7) in policitemije, ki jih od 2001 uvrščamo v skupino C94. Z razvojem molekularne in genske tehnologije je mogoče natančneje opredeliti vrsto celičnih sprememb, ki nastanejo pri malignomih krvotvornega in limfatičnega tkiva, in jih zato bolj usmerjeno zdraviti. S tem se veča tudi število različnih vrst bolezni, njihovo razvrščanje pa se vedno bolj izpopolnjuje. Svetovna zdravstvena organizacija je leta 2001 objavila posebno klasifikacijo, ki opredeljuje malignome krvotvornega in limfatičnega tkiva glede na imunofenotip, genetske spremembe in klinično sliko. Leta 2008 je bila ta klasifikacija posodobljena in v kliniki zamenjuje številne dodatne klasifikacije malignomov krvotvornega in limfatičnega tkiva. Povzema jo tudi Mednarodna klasifikacija bolezni za onkologijo (3. izdaja, dopolnitev 2011). V Tabeli 10 razvrščamo neoplazme limfatičnega tkiva tudi v skladu z verzijo 2008 klasifikacije Svetovne zdravstvene organizacije. Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961-1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelijske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03). Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih poročilih pri solidnih tumorjih uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave - od popisa operacije do obdukcije, če bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev praviloma sledi klasifikaciji TNM. V omejen stadij je tako praviloma uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2. Pri dojki, kožnem melanomu in ščitnici so v omejen stadij vključeni tudi tumorji T3; pri materničnem vratu, materničnem telesu in sarkomih, ter pri jajčniku, jajcevodu in trofoblastnih tumorjih 10 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 v omejen stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je primer, pri katerem je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že v oddaljenih bezgavkah ali organih (M1). V bazi RRRS hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, če je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Ginekološke tumorje tako opredeljujemo tudi po klasifikaciji FIGO, pri kožnem melanomu pa beležimo tudi velikost po Clarku in Breslowu. Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor. Kakovost podatkov RRRS in popolnost registracije Kakovost podatkov registrov raka opredeljujejo naslednji kazalniki: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalcev so prikazane v Tabeli 3. Popolnost registracije kaže delež vseh novih primerov raka na področju, ki ga pokriva register in ki so vključeni v podatkovno zbirko registra. Neposredno jo je mogoče meriti samo s posebnimi raziskavami, namenjenimi oceni popolnosti, npr. s ponovnim pregledom odpustnih diagnoz in popisov bolezni v bolnišnicah ali ambulantah na določenem območju. V Sloveniji takih raziskav zaenkrat še nismo delali, veliko pa nam k popolnosti zajema pomagajo kolegi kliniki, ki jih zanima, kakšno je preživetje bolnikov, zdravljenih pri njih; ko nam pošljejo podatke o svojih skupinah bolnikov, v njih velikokrat najdemo take, ki jih v podatkovni zbirki RRRS še ni. Na splošno velja, da je popolnost podatkov večja tam, kjer ima register dostop do zdravniških poročil o vzroku smrti. Za tiste, ki so umrli za rakom, pa (še) niso zapisani v registru, RRRS tako išče dodatne podatke. Na ta način se izboljša popolnost registracije rakov s slabo napovedjo izida, ne pa manj usodnih. Domnevamo, da je v Sloveniji - in tudi v drugih evropskih populacijskih registrih raka - manj popolna registracija nemelanomskega kožnega raka in tistih malignomov, ki se zdravijo samo ambulantno. 11 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Statistične metode Incidenca in umrljivost Incidenca in umrljivost pomenita absolutno število vseh na novo ugotovljenih primerov kake bolezni oz. število vseh umrlih za to boleznijo v točno določeni populaciji v enem koledarskem letu. V incidenco raka ne štejemo novih primarnih rakov parnega organa iste lokacije, če je bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na območju Republike Slovenije ne glede na to, kje so bili bolniki zdravljeni. Za oceno incidence v letu 2019 (prikazano v Tabeli 1) je uporabljena metoda po Dybi in Hakulinenu, ki je primerna za napoved incidence v krajšem časovnem obdobju, saj upošteva samo obdobje diagnoze in starost; pri dolgoročnejših napovedih je treba upoštevati tudi vpliv rojstne kohorte. Pri časovnih trendih smo ocenjevali delež letne spremembe z Joinpoint regresijsko analizo. Uporabili smo Joinpoint Regression Program (Verzija 4.1.1 - Avgust 2014), ki je narejen na podlagi metodologije, ki jo je razvil Kim s sodelavci. Grobe in starostno specifične stopnje Groba incidenčna stopnja je število novih primerov bolezni, preračunano na 100.000 oseb opazovane populacije, groba umrljivostna stopnja pa število umrlih na 100.000 oseb opazovane populacije. Natančneje sta stopnji definirani kot število novih primerov bolezni (oz. število umrlih) v določenem časovnem obdobju, praviloma enem letu (= incidenca oz. umrljivost), deljeno s številom oseb, ki so v istem obdobju izpostavljene tveganju, da zbolijo oz. umrejo zaradi določene bolezni; izražamo jo na 100.000 človek-let. Starostno specifična stopnja (incidenčna oz. umrljivostna stopnjo) se izračuna na enak način, vendar za posamezno starostno skupino. Starostno standardizirane stopnje Če analiziramo incidenco (ali umrljivost) v daljšem časovnem obdobju, v katerem se lahko starostna struktura prebivalstva v času spreminja, ali če primerjamo incidenco (ali umrljivost) med populacijami z različno starostno strukturo, je treba uporabiti eno od metod starostne standardizacije. Starostno standardizirana stopnja je teoretična incidenčna (oz. umrljivostna) stopnja, ki bi jo opazili, če bi bila starostna struktura opazovane populacije taka kot v standardni populaciji. V Tabeli2 poleg grobe incidenčne stopnje rakavih bolezni v Sloveniji prikazujemo še starostno standardizirane stopnje na svetovno, evropsko in slovensko standardno populacijo z metodo neposredne standardizacije. Starostno standardizirane umrljivostne stopnje so dostopne na spletišču SLORA. V Tabeli 6b je za primerjavo incidenčnih stopenj med slovenskimi statističnimi regijami uporabljen slovenski standard, starostna struktura prebivalcev Slovenije ob popisu leta 2002. Uporabljena standardna populacija je Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 vedno enaka za oba spola, kar v posameznih primerih lahko privede do nepričakovanih rezultatov, ko so standardizirane stopnje pri enem spolu (ponavadi pri moških, ki so v povprečju mlajši) večje od grobih stopenj, pri drugem spolu pa manjše. Kumulativne stopnje in kumulativno tveganje Kumulativna incidenčna (ali umrljivostna) stopnja (KS) (prikazana v zadnjem stolpiču Tabele 5) je petkratna vsota starostno specifičnih incidenčnih (ali umrljivostnih) stopenj po petletnih starostnih skupinah do 74. leta starosti, preračunana na 100 prebivalcev. Je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativno stopnjo smo uporabili za prikaz časovnega trenda incidence in umrljivosti v spodnjem delu Slike 4. Kumulativno tveganje (KT) je verjetnost posameznika, da zboli za rakom v izbranem starostnem obdobju, npr. do 74. leta starosti, če ne umre prej zaradi drugih vzrokov. Kumulativno tveganje izražamo v odstotkih. Če je KS manjša kot 10/100, jo lahko uporabimo za približek kumulativnemu tveganju. Pri večjih kumulativnih stopnjah pa kumulativno tveganje izračunamo iz kumulativne stopnje po obrazcu: KT = 100 (1 - e-KS/100). Kumulativno incidenčno stopnjo raka dojk pri ženskah 8,2/100 tako lahko uporabimo za oceno kumulativnega tveganja raka dojk, ki je v tem primeru 8,2-odstotno. To pomeni, da bo 8,2 % deklic (ali približno ena od 12), rojenih leta 2016, do 74. leta starosti verjetno zbolelo za rakom dojk. Prevalenca Prevalenca je število vseh bolnikov z rakom, ki so bili živi na izbrani datum, ne glede na to, kdaj so zboleli. Celotna prevalenca obsega vse bolnike, ne glede na to, kako dolgo pred datumom izračuna so zboleli, medtem ko delna prevalenca šteje samo bolnike, ki so zboleli v določenem obdobju, npr. 1, 5 ali 10 let pred datumom, na katerega to mero računamo. Pri raku so ta obdobja še zlasti pomembna, saj odsevajo število bolnikov v različnih fazah poteka bolezni, npr. enoletna vključuje bolnike v času prvega zdravljenja, triletna bolnike v obdobju rednih kontrolnih kliničnih pregledov, petletna in zlasti še desetletna pa vključuje bolnike, za katere vsaj pri večini rakavih bolezni menimo, da so ozdravljeni. Nekateri bolniki zbolijo za več kot eno rakavo boleznijo, zato je vsota prevalenc bolnikov po posameznih vrstah raka večja kot skupna prevalenca, pri kateri štejemo samo bolnike ne glede na število posameznih rakavih diagnoz. 13 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Preživetje Pri skupinah bolnikov preživetje predstavlja delež bolnikov, ki so po izbranem časovnem obdobju od postavitve diagnoze še živi. Možnosti in metod za izračun preživetja je več. Osnovna in hkrati najpreprostejša mera preživetja je tako imenovano opazovano preživetje, kjer v izračun vključimo vse smrti, tudi tiste, ki jih ni povzročilo rakavo obolenje. Za oceno preživetij bolnikov z rakom, v kateri upoštevamo kot vzrok smrti le proučevanega raka, v populacijskih izračunih uporabljamo metode relativnega in čistega preživetja. Uradni vzroki smrti namreč niso dovolj točni, da bi bil izračun vzročno specifičnega opazovanega preživetja na populacijski ravni dovolj zanesljiv. Relativno in čisto preživetje se izračunata s statističnim primerjanjem opazovanega preživetja proučevane skupine bolnikov in preživetjem, ki ga glede na spol in starost v določenem obdobju pričakujemo v celotni populaciji, iz katere prihajajo bolniki (t.i. pričakovano preživetje). Pričakovano preživetje se izračuna na podlagi podatkov o splošni umrljivosti, ki se v obliki tablic umrljivosti za posamezno državo rutinsko objavljajo v okviru demografske statistike; za naše izračune so uporabljene slovenske letne popolne momentne tablice umrljivosti. Od leta 2014 naprej v letnih poročilih prikazujemo čisto preživetje izračunano po metodi Pohar-Perme, do takrat pa smo prikazovali preživetje izračunano po metodi Ederer-II, ki je ena od metod relativnega preživetja. Opozarjamo še, da metoda čistega preživetja, uporabljena za izračun preživetja, prikazanega v tem poročilu, ni enaka tisti, s katero je mogoče prikazati preživetje na spletnem portalu SLORA. Na spletnem portalu SLORA prikazujemo opazovano preživetje in pa relativno preživetje izračunano po Hakulinenovi metodi. Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 14 Prebivalstvo Slovenije Prebivalstvo Slovenije Podatki o številu prebivalcev in o starostni strukturi so pomembni pri izračunavanju in interpretiranju večine kazalnikov bremena raka. Za Slovenijo je točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja Centralni register prebivalstva, je mogoče dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih poročilih uporabljamo podatek o prebivalcih na datum 1. julij posameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statističnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo za leto 2016 so v spodnji tabeli. Starostna skupina Skupaj Moški Ženske 0-4 106.470 54.702 51.768 5-9 108.822 56.051 52.771 10-14 92.088 47.422 44.666 15-19 94.096 48.592 45.504 20-24 102.894 52.896 49.998 25-29 126.359 65.460 60.899 30-34 142.579 74.566 68.013 35-39 157.116 82.583 74.533 40-44 151.701 79.105 72.596 45-49 147.540 75.693 71.847 50-54 154.697 78.506 76.191 55-59 149.119 75.011 74.108 60-64 145.188 72.625 72.563 65-69 120.038 57.838 62.200 70-74 85.053 38.072 46.981 75-79 76.609 31.964 44.645 80+ 103.872 32.786 71.086 Skupaj 2.064.241 1.023.872 1.040.369 Statistična regija Skupaj Moški Ženske Pomurska 115.818 56.939 58.879 Podravska 321.493 159.690 161.803 Koroška 71.010 35.623 35.387 Savinjska 254.824 127.598 127.226 Zasavska 57.466 28.324 29.142 Posavska 75.694 38.084 37.610 JV Slovenija 142.672 71.971 70.701 Osrednjeslovenska 537.893 263.149 274.744 Gorenjska 203.654 100.881 102.773 Primorsko-notranjska 52.593 26.624 25.969 Goriška 117.931 58.970 58.961 Obalno-Kraška 113.193 56.019 57.174 Slovenija 2.064.241 1.023.872 1.040.369 Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2016. Pri razporeditvi prebivalcev v posamezne statistične regije (spodnja tabela) je uporabljen le podatek o stalnem naslovu oseb in ne tudi začasnem, kot je upoštevan v pripravi števila prebivalcev po klasični »statistični« definiciji. Prebivalci Slovenije po statističnih regijah in spolu na dan 1. 7. 2016. 15 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Rak v Sloveniji 2016 Leta 2016 je v Sloveniji za rakom zbolelo 15.072 ljudi, 8.117 moških in 6.955 žensk. (Slika 1), umrlo pa 6.247 ljudi, 3.522 moških in 2.725 žensk. Od rojenih leta 2016 bosta do 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk (Tabela 5). Konec decembra 2016 je živelo 107.093 ljudi (48.641 moških in 58.452 žensk), ki so kadar koli od ustanovitve RRRS zboleli za rakom (Slika 1). Ocenjujemo, da je leta 2019 za rakom zbolelo skoraj 16.000 prebivalcev Slovenije, približno 8.700 moških in 7.100 žensk. Ocene incidence za posamezne lokacije raka so prikazane v Tabeli 1 skupaj s povprečnimi petletnimi vrednostmi za zadnje 10-letno obdobje. Ogroženost z rakom se zmerno veča in je največja v starejših letih; od vseh bolnikov z rakom je leta 2016 kar 63 % moških in 60 % žensk zbolelo po 65. letu starosti. Pri otrocih in mladostnikih (do 20. leta) obsegajo rakave bolezni manj kot 1 % vseh primerov raka (Slika 2). Ker se slovensko prebivalstvo stara, je samo zaradi vedno večjega deleža starejših pričakovati, da se bo število novih primerov raka še naprej večalo. Ker na incidenco raka najbolj vpliva starostna struktura prebivalstva, so za verodostojnejšo primerjavo z drugimi državami z različno starostno strukturo v Tabeli2 poleg grobih stopenj izračunane tudi starostno standardizirane. Glede na to, da so v uporabi različni standardi, smo za namene različnih primerjav uporabili tri standardne populacije svetovno, evropsko in slovensko. Pet najpogostejših vrst raka pri nas - nemelanomski kožni, rak prostate, debelega črevesa in danke, dojke in pljuč - obsega 60 % vseh novih primerov rakavih bolezni (Slika 3). Raki teh organov so povezani z nezdravim življenjskim slogom, čezmernim sončenjem, nepravilno prehrano, kajenjem in čezmernim pitjem alkoholnih pijač, zato je ogroženost z njimi treba zmanjšati z ukrepi primarne preventive. Pri moških je bil z 21 % vseh novih primerov na prvem mestu rak prostate. Pri ženskah predstavljata vsak po petino primerov vseh rakov nemelanomski kožni rak in rak dojk (Slika 3). Od leta 1950 se je groba incidenčna stopnja raka v Sloveniji zvečala za 780 % pri moških in za 520 % pri ženskah; v zadnjih 10 letih se je pri moških večala povprečno za 2,3 % letno, pri ženskah pa za 1,9 %. Groba umrljivostna stopnja se je pri moških v zadnjih 10-ih letih večala povprečno za 0,8 % letno, pri ženskah pa za 0,9 % (Slika 4). Več kot polovica zvečanja incidence gre na račun staranja prebivalstva. Kumulativna incidenčna stopnja se je v zadnjih 10-ih letih pri moških večala v povprečju le za 0,2 % letno, pri ženskah pa za 0,9 %. Kumulativna umrljivostna stopnja se od leta 1985 pri obeh spolih manjša (Slika 4), v zadnjih 10-ih letih pri moških za 2,3 % letno, pri ženskah pa za 0,6 %. Manjšanje verjetnosti smrti za rakom ob večanju incidence kaže, da je zdravljenje uspešnejše in da vse več bolnikov ozdravi in/ali živi z rakom, medtem ko jih je prej več umrlo zaradi rakave bolezni. Vse povprečne letne spremembe, z izjemo kumulativne incidence pri moških, so statistično značilne pri stopnji tveganja 0,05. Časovni trend pogostejših rakov pri moških kaže, da se je incidenčna stopnja pljučnega raka večala vse do začetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri vrednosti okoli 90/100.000. Strmo pa pljučnega raka prehitevata rak prostate (povečanje za 3,0 % povprečno letno) in kožni nemelanomski rak (povečanje za 5,4 % povprečno letno). Izjemno povečanje incidence raka prostate v zadnjem 16 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 desetletju ni posledica kakega novega nevarnostnega dejavnika, pač pa predvsem vse širše rabe testa za določanje za prostato specifičnega antigena (PSA) pri zdravih moških in odkrivanja velikega števila primerov, ki bi drugače ostali vse življenje prikriti. Podatki za zadnja leta kažejo, da smo vrh incidence raka prostate vseeno najverjetneje že dosegli. Tudi časovne spremembe v pojavljanju raka debelega črevesa in danke je potrebno ocenjevati z upoštevanjem sprememb v diagnostiki - leta 2009 smo namreč v Sloveniji uvedli Državni program presejanja in zgodnjega odkrivanja predrakavih sprememb in raka na debelem črevesu in danki (Svit). Incidenca raka debelega črevesa in danke se je pri moških med leti 2007 in 2010 povečevala za 7,5 % letno, od leta 2010 do 2016 pa pada za 3,8 % letno. Pri ženskah se večajo incidenčne stopnje raka dojk (za 1,7 % povprečno letno), kože, razen melanoma (za 4,0 % povprečno letno), pljučnega raka (za 4,9 % povprečno letno) in raka materničnega telesa (za 2,7 % povprečno letno). Incidenčna stopnja raka materničnega vratu se od uvedbe Državnega presejalnega programa za odkrivanje predrakavih in zgodnjih rakavih sprememb na materničnem vratu (ZORA) strmo manjša (za 2,5 % povprečno letno v zadnjih desetih letih). Podobno kot pri moških se tudi pri ženskah zaradi uvedbe presejalnega programa Svit spreminja časovni trend pojavljanja raka debelega črevesa in danke - med leti 2007 in 2010 se je incidenca povečevala za 1,7 % letno, od leta 2010 do 2016 pa pada za 2,9 % letno. Povprečne letne odstotne spremembe so prikazane ob krivuljah na Sliki 5. Slika6 prikazuje petletno čisto preživetje bolnikov z vsemi (razen kožnega) in izbranimi raki, zbolelih v letih 2012-2016 po spolu. Za primerjavo je prikazano tudi relativno preživetje bolnikov, zbolelih v predhodnem petletnem obdobju (2007-2011). Pri moških se je skupno preživetje povečalo za 3 odstotne točke, predvsem zaradi večjega odkrivanja in boljšega prijavljanja raka prostate nižjih stadijev, ki so povezani z boljšo prognozo, saj je preživetje bolnikov, zbolelih v zadnjem obdobju, večje skoraj za 4 odstotne točke. Med pogostejšimi raki se je v zadnjem obdobju značilno povečalo tudi preživetje zbolelih za pljučnim rakom. Ker se 95 % intervala zaupanja ne prekrivata, lahko zaključimo, da je razlika statistično značilna. Petletno čisto preživetje bolnic, zbolelih v letih 2012-2016 prvič presega 60 %. Pri ženskah se je med pogostejšimi raki statistično značilno povečalo preživetje bolnic s pljučnim rakom (prvič presega 20 %), za 3 % pa je v zadnjem obdobju višje tudi preživetje zbolelih za rakom dojke. Posebno pozornost v letošnjem poročilu posvečamo dosežkom treh državnih presejalnih programov ZORA, DORA in Svit kot jih lahko spremljamo s podatki RRRS. Na Sliki 7a (ZORA), Sliki8a (DORA) in Sliki 9a (Svit) so za vsak presejalni rak posebej predstavljeni časovni trendi grobih incidenčnih stopenj med leti 1987 in 2016. Prikazane so spremembe v incidenci, ki so nastale z uvedbo programov. Tako se je incidenca raka materničnega vratu začela zmanjševati že z uvedbo pilota ZORA leta 1997; od uvedbe nacionalnega programa ZORA leta 2003 do leta 2016 pa se je več kot prepolovila. Podobno ugotavljamo pri programu Svit: Incidenca raka debelega črevesa in danke se je do uvedbe presejalnega programa povečevala, od takrat pa pri obeh spolih strmo pada. V trendu incidence raka dojk po uvedbi programa DORA ni opaziti sprememb, saj je DORA edini izmed treh presejalnih programov, ki ne odkriva predrakavih sprememb in z njim tako incidence ne zmanjšujemo. 17 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Na Sliki 7b (ZORA), Sliki 8b (DORA) in Sliki 9b (Svit) prikazujemo razliko v stadiju ob diagnozi med raki, ki so bili odkriti v presejalnih programih in tistimi, ki so bili diagnosticirani izven presejanega programa. Pri vseh treh presejalnih programih se jasno vidi odlično izpolnjevanje enega od osnovnih ciljev programov - zgodnje odkrivaje bolezni, saj so raki odkriti v presejalnem programu statistično značilno nižjih stadijev. Pri interpretaciji teh rezultatov pa se je potrebno zavedati, da so intervalni raki (raki, ki jih odkrijemo po negativnem izvidu presejalnega testa) v analizi podatkov RRRS razporejeni v skupino diagnosticirani izven presejanega programa. Sliki 7c in d (ZORA), Sliki 8c in d (DORA) in Sliki 9c in d (Svit) prikazujemo razliko v preživetju med bolniki, ki jim je bil rak odkrit v presejalnem programu in tistimi, ki so bili diagnosticirani izven presejanega programa. V vseh treh primerih imajo boljše preživetje bolniki, pri katerih je bil rak ugotovljen v presejalnem programu. Razlike ostajajo tudi, če primerjamo preživetje ločeno glede na stadij ob diagnozi. Ta rezultat vsekakor zahteva dodatne analize, saj iz v RRRS dostopnih podatkov ni možno zaključiti ali je obravnava bolnikov odkritih v presejalnem programu ustreznejša, koliko k rezultatu prispeva razvrstitev intervalnih rakov ipd. Pri večini bolnikov je diagnoza bolezni potrjena mikroskopsko. Iz Tabele 3 je razvidno, da je bila leta 2016 pri 95,1 % od 15.072 na novo registriranih primerov raka diagnoza potrjena mikroskopsko (histološko ali citološko), pri 4,7 % pa z drugimi preiskavami. Spodbudno je, da je že več let le 0,2 % primerov v RRRS vpisanih samo na osnovi zdravniškega poročila o vzroku smrti; RRRS verjetno niso bili prijavljeni ker niso bili zdravljeni v bolnišnici zaradi starosti ali napredovale bolezni. Iz Tabele 3 je poleg načina postavitve diagnoze razvidno tudi število vseh novih primerov po posameznih mestih raka, v Tabeli4je prikazano razporejanje teh primerov po 5-letnih starostnih skupinah, v Tabeli5 pa so te vrednosti preračunane v starostno specifične stopnje na 100.000 prebivalcev. V Tabeli 6a je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Ta števila so pomembna za načrtovanje zdravstvenih zmogljivosti. Starostno standardizirane vrednosti v Tabeli 6b pa kažejo razlike v ogroženosti z rakom v posameznih regijah, saj te niso posledica razlik v številu in starostni strukturi prebivalcev. V letu 2015 so se spremenile meje štirih statističnih regij (savinjske, posavske, osrednjeslovenske in zasavske), zato je potrebna pozornost pri primerjavi in interpretaciji podatkov iz prejšnjih let. Kakšna je bila morfološka slika malignomov pri 14.337 primerih, pri katerih je bila diagnoza potrjena mikroskopsko, kaže Tabela 7. V njej so posebej prikazani primeri, ki so potrjeni histološko (96 %), in tisti, ki so bili potrjeni samo citološko (4 %). Tabela 8 prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Uporabljena je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno z operacijo in tudi obdukcijo, če bolnik ni bil poprej zdravljen. Tabela 9 kaže starostno porazdelitev ekstranodalnih in nodalnih lokacij ne-Hodgkinovih malignih limfomov. Ker je število ekstranodalnih lokacij majhno, so prikazane le absolutne številke. 18 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 V Tabeli 10 je prikazana porazdelitev neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, ki jo uporabljajo kliniki in patologi. Tabela 11 prikazuje osnovne podatke o zdravljenju bolnikov; objavljamo le podatke o prvem kurativnem zdravljenju. Ker je veliko bolnikov zdravljenih na več načinov, je vsota bolnikov po vrsti zdravljenja večja od števila novih primerov. Iz Tabele 11a je razvidno, kako so bili bolniki zdravljeni, v Tabelah 11b in 11c pa, v katerih zdravstvenih ustanovah so bili bolniki v okviru prvega zdravljenja operirani in/ali zdravljeni s sistemskimi zdravili; z obsevanjem so bili z redkimi izjemami (tujina) zdravljeni samo na Onkološkem inštitutu Ljubljana. Tabela 12 prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2016. Poleg celotne prikazujemo tudi delno, to je 1-, 3-, 5- in 10-letno prevalenco. Uradne podatke o umrljivosti za rakom v letu 2016 prikazujemo v Tabeli 13; zbira jih Nacionalni inštitut za javno zdravje RS. Grobe in starostno standardizirane stopnje so na voljo na spletišču Slora. V Tabeli 14 so prikazana 1-, 3- in 5- letna čista preživetja bolnikov zbolelih med leti 2012 in 2016. 19 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Zahvala Zdravniki, medicinske sestre in administrativno osebje iz slovenskih bolnišnic in drugih zdravstvenih ustanov so RRRS dokaj vestno pošiljali prijavnice s podatki o novih primerih raka, o poteku bolezni in usodi bolnikov. Dopolnili so nam tudi morebitne pomanjkljive prijave. Podatke, ki so za RRRS nujni, a jih ni bilo mogoče najti v bolnišnicah, so nam z zavzetim delom priskrbeli družinski in splošni zdravniki. Za bolnike, ki so bili obravnavani na Onkološkem inštitutu Ljubljana, sta podatke prispevali sodelavki Bolnišničnega registra Onkološkega inštituta Ljubljana, Maruška Ferjančič in Polona Škulj, podatke za vse kožne tumorje pa Agata Čampa, sodelavka Kliničnega registra kožnega melanoma. Poročila bi skorajda ne mogli napraviti, njegovi podatki pa bi bili bistveno manj verodostojni, ko bi ne imeli naklonjenega sodelovanja Centralnega registra prebivalstva RS, Nacionalnega inštituta za javno zdravje RS in Statističnega urada RS. Odgovore na vsa strokovna vprašanja nam priskrbijo zdravniki specialisti z Onkološkega inštituta Ljubljana. V prav posebno pomoč pa so vsi strokovni nasveti s področja patologije, ki nam jih nudi dr. Gorana Gašljevic, dr. med., specialistka patologije. Vsem imenovanim in tudi drugim, ki so kakorkoli prispevali k temu poročilu, se najlepše zahvaljujemo. Uredniški odbor Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 20 Introduction Slovenian Cancer Registry (SCR) is one of the oldest population based cancer registries in Europe. It was founded at the Institute of Oncology Ljubljana (10) in 1950 by the late Professor Bozena Ravnihar, who headed it till 1975. She was succeeded by Professor Vera Pompe-Kirn, who contributed a lot to the further development of the SCR as well as its recognition at the national and international level all until her retirement in 2003. Since 2003, the SCR has been merged with the Unit of Epidemiology into a single Epidemiology and Cancer Registry service. It was led by dr. Maja Primic Zakelj until 2018. Besides the SCR, the new service also comprises the hospital-based Cancer Registry of the 10, which contributes a considerable part of information to the SCR and facilitates a more detailed overview of patients treated at the 10, irrespective of their permanent residence. In 2003 a new national registry in charge of coordinating and monitoring the organised cervical cancer screening programme (Registry ZORA) has been established, while an information system to support organized breast screening program has been established in 2007 (Registry DORA). The data on cancer collected by the SCR, incidence, survival and prevalence, serve together with mortality data collected by the National Institute of Public Health of RS as the basis for assessing the cancer burden in the country.They are important for planning and evaluation of the National Cancer Control Plan (NCCP), in the field of primary and secondary prevention, diagnostics, treatment and rehabilitation, for planning facilities and funding needed for cancer control (personnel, equipment and hospital capacities) as well as for clinical and epidemiological research in Slovenia and in international multicentric studies and for evaluation of effectiveness of cancer screening programs. The Annual Reports of the SCR are one of the regular ways of disseminating information on cancer among professionals and other interested groups. As we are limited by the technology of data collection from a variety of sources, data collection, their linking and publication is rather time consuming (here and elsewhere) and usually takes two to three years. Over the last few years the estimated numbers and rates forthe expected incidence in the yearthe Annual Report is published (in this report forthe year 2019) are presented; they are calculated by a special statistical method. The first annual reports of the SCR forthe period 1951-1955 were issued during the years 1953-1957. The first data analysis forthe year 1950 was published InZdravstveni vestnikln 1951.The data forthe period 1957-1971 were appearing in the periodicals Epidemiological and Vital Statistics Report and World Health Statistics Report, both edited by the World Health Organization. From 1965 onwards, the data have been appearing regularly in special bi-lingual (Slovene-English) annual reports, entitled Cancer in Slovenia in years 1965-1977 and 2007-2014, and Cancer Incidence in Slovenia in the period 1978-2006. Besides Annual Reports, four special publications have been published: Atlas of Cancer Incidence in Slovenia 1978-1987, Cancer Patients' Survival in Slovenia 1963-1990, Cancer Patients' Survival in Slovenia 1983-1997 and Survival of Cancer Patients, diagnosed in 1991-2005 in Slovenia. The list of other releva nt publications in last five years is at the end of this report. Data of the SCR are included in several international databases and projects.They have been published in all nine volumes and the tenth electronic version of the 21 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Cancer Incidence in Five Continents issued by the International Agency for Research on Cancer. The data are included in international databases ECO, GLOBOCAN and ACCIS. The survival of Slovenian cancer patients is analysed in the international studies EUROCARE-2, EUROCARE-3, EUROCARE-4, EUROCARE-5, EUROCARE-6, CONCORD-1, CONCORD-2, CONCORD-3, RARECARE and EUNICE. In 2010, the SCR's database has been upgraded and data processing modernized. At the same time an interactive web portal named SLORA was launched as well. The name comes from the first letters of the sentence in Slovenian language: "SLOvenia and RAk/cancer". It is available at www.slora.si/en/. It enables a simple access to data on cancer in Slovenia collected by the SCR (incidence, prevalence and survival; currently till 2016) and the National Institute of Public Health of Republic of Slovenia (RS) (mortality) as well as the comparisons with other countries in the European Union and in the world. It describes the data and offers its users professional explanations of cancer risk factors, screening and early detection and treatment outcomes. Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 22 Data sources and methods of registration Data sources Notification of cancer has been compulsory in Slovenia since the foundation of the SCR and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00, 47/15 and 31/18). The main sources of data are notifications of cancer, gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary health care centres in case the patient has not been referred for further diagnostic investigations and/or treatment. Complementary sources of information are death certificates that we get from National Institute of Public Health of Republic of Slovenia and data on diagnosed cancers that are recorded in three national screening programs: ZORA for the detection of pre-cancerous and early cancerous lesions of cervix uteri, DORA for early detection of breast cancer and Svit for the detection of pre- cancerous lesions and cancer of colon and rectum. The data gathered with notifications are identification data, data on the cancer disease (anatomic cancer site, histological or cytological diagnosis and stage by TNM or other clinical classification) and basic data on treatment. Where patients' data reported on notifications are not complete or adequate and where the only information about their disease is acquired from the death certificate, time consuming queries about patients must be performed by the SCR's staff. Calculation of patient prevalence and survival requires the patient's vital status (a person may be alive, dead or lost to follow-up). This data is obtained from the Central Population Registry for all persons registered in the SCR data base as alive. Since 2010, together with the upgrade of SCR's database, an on-line connection with the Central Population Registry has been established using a specially secured web technology. This enables an on-line connection and up-to-date vital status of all registered patients. In persons lost to follow-up the date of last notification or the date of loss obtained from the Central Population Registry, whichever first, is considered as the date of loss to follow-up. From 1985, since the uniform personal ID number has been used in Slovenia, the proportion of the lost to follow-up in SCR is below 1%, furthermore, in patients registered in the last decade being only 0.1%. Detailed analyses of the spatial distribution of cancer are enabled by accurately defined addresses of patients with cancer and regular connection to the Registry of Spatial Units of the Surveying and Mapping Authority. Table 6 shows cancer burden at the level of 12 statistical regions as in effect in Slovenia in 2016. 23 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Preparation of data for computer processing In SCR specially trained nurses code the data retrieved from notifications of cancer in accordance with the international and internal SCR guidelines. Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); before, the 8th revision was used (ICD-8). When classifying tumours as malignant, the behaviour digit of the morphology code of the third edition of International Classification of Diseases for Oncology has been used since the report for 2001. In this edition some changes were introduced in terms of morphology and behaviour code and some new morphology codes were added for tumours that till 2001 have not been coded separately. For example, gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to the new rules, ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56). According to the third edition, chronic myeloproliferative disorders and myelodisplastic syndromes as well as policytaemia are classified as malignant, the former two being assigned to C96.7 and the policytaemia is classified under the topography code C94 from year 2001 on. From year 2012 on, the third edition with 2011 updates is used. Development of molecular and genetic technologies enabled more detailed classification of the type of cellular changes, found in neoplasms of the lymphoid and haematopoietic tissues. Better and more detailed identification enables targeted treatment. All this correspond to greater number of disease types and its classification is constantly updating. In 2001, the World Health Organization published special classification of the lymphoid and haematopoietic tissue based on imunophenotype, genetic changes and clinical picture. The classification was updated in 2008 and replaced several other classifications of the lymphoid and haematopoietic tissue in clinical use. Furthermore, the International Classification of Diseases for Oncology 24 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 (third revision, 2011 update) follows this classification. Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue are systemized in Table 10 according to 2008 version of the classification of the World Health Organization. In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was registered. Thus, the comparison with the data for the period 1961-1992 is not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (D05) and since 1995, all reported intraepithelial carcinomas of the bladder (D09.0) and all malignant melanomas Clark I (D03) have been registered as well. For stage description, a simplified definition of stages at diagnosis is used for solid tumors, classifying them into localized, regional and distant stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. The simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumor has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer T3 tumor is also included in localized stage. In uterine cervix, corpus and sarcomas, ovarian cancer, tube and trophoblastic tumors only T1 tumor is included in localized stage. In all of these cases neither regional lymph node involvement nor distant metastases are found (N0, M0). The regional stage includes tumors classified as T3 and T4 (with aforementioned exceptions) and/or regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the distant stage (M1). Stage according to TNM or any other appropriate classification is also stored in the SCR database, if available. Gynecological tumors are thus defined also according to the FIGO classification and in skin melanoma size according to Clark's level and Breslow's thickness is registered. Malignant lymphomas are classified according to Ann-Arbor System. Data quality and completeness of registration The quality of information can be assessed by the following parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in Table 3. The completeness of registration shows the proportion of all new cancer cases in the region covered by the registry that are included in the registry's data base. It can be measured directly only by means of special surveys for the evaluation of completeness, e.g. by reviewing patients' records in the hospitals or outpatient clinics in a particular region. In Slovenia, no such surveys have been carried out so far. However, a considerable contribution towards the completeness of registration is made by our colleagues - clinicians, who send us the data on their groups of patients 25 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 in order to provide us with information about their vital status and among them we often find cases that have not been entered into the SCR database yet. In general, the registration is more complete where the registries have access to death certificates. This enables the registry to send out additional inquiries where disease for the deceased has not been entered into the database yet. This improves the completeness of registration of cancers with poor prognosis, but not also of less fatal ones. It is presumed that in Slovenia - as well as in other European population based cancer registries - registration is less complete in non-melanoma skin cancer and in malignomas that are treated on the out-patient basis only. Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 26 Statistical methods Incidence and mortality Incidence and mortality are absolute numbers of all newly diagnosed cases of any disease or number of deceased from this disease in a defined population in one calendar year. New primary cancers of the same histology in paired organs, e. g. in the left and right breast, are not comprised in the incidence figures, neither are any new cancers of the same histology appearing in the same organ, e.g. multiple lesions of the colon. The incidence registered by SCR includes only the data on patients with permanent residence in Slovenia, regardless of the country where they have been treated. The method by Dyba and Hakulinen was used for estimation of incidence in 2019 (presented in Table 1). This method is suitable for predictions in shorter time period, taking into account the period of diagnosis and age structure of population. For long-term predictions the cohort effect should be included also. For assessing time trends, the average annual change was calculated with joinpoint regression analysis by Joinpoint Regression Program (Version 4.1.1 - August 2014), which follows the models developed by Kim et all. Crude and age specific rates Crude incidence rate is the number of new cases per 100,000 inhabitants, while crude mortality rate is the number of deaths per 100,000 population. More precisely it is defined as number of new cases (or number of deaths) in a specified time interval, usually one calendar year (= incidence or mortality), divided by the number of persons at risk of disease (or death) in the same period; it is expressed per 100,000 person-years. The age specific rate (incidence or mortality rate) is calculated in the same way, but for each age group. Age standardized rates When analysing the incidence (or mortality) rate within longer time period (if the age structure of population changes) or comparing the incidence (or mortality) between populations with different age structure, age standardization is needed to adjust the rate for the effect of age. The age-standardized rate is a theoretical incidence (or mortality) rate assuming that the age structure in the observed population is the same as in the standard population. In Table2, besides crude cancer incidence rates, age standardized rates by direct method are presented, using World, European and Slovenian standard population. Age standardized mortality rates are also available at SLORA web-portal. In Table 6b the incidence rates in different statistical regions in Slovenia are compared using the Slovenian standard, which is the age structure of Slovenian 2002 census population. Because the standard population is always the same for both sexes, there are some situations where standardized rate is bigger than crude rate in one sex, usually in males who are on average younger, and smaller in the other. 27 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Cumulative incidence rate and cumulative risk The cumulative incidence (ormortality) rate (CR), (cumulative incidence rate is presented in the last column of Table 5) is five times the sum of the age-specific incidence (or mortality) rates over five-year age groups up to the age of 74 years, calculated per 100 inhabitants. The cumulative rate can be interpreted as a form of direct age standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. The cumulative incidence rate was also used to present the incidence time trend in the lower part of the Figure 4. The cumulative risk is the risk an individual would have of developing the disease in question during a certain age period, e.g. up to the age of 74, if no other causes of death were in operation. The cumulative risk is expressed as a percentage. If cumulative rate is lower than 10/100, its value is practically equal to that of the cumulative risk. When cumulative rate is greater than 10/100, it should be calculated as cumulative risk according to the following formula: CRisk = 100 (1 - e-KS/100). Cumulative incidence rate of breast cancer in females 8.2/100 can be used to estimate cumulative risk of breast cancer that is in this case 8.2%. This means that 8.2% of women born in 2016 (approximately one out of 12) are expected to develop breast cancer by their age of 74 in the absence of any other cause of death. Prevalence Prevalence is the number of all cancer patients that are alive on a given date, regardless of when they were diagnosed with cancer. Lifetime cancer prevalence is defined as all persons ever diagnosed with cancer and being alive at specific time date, while partial prevalence counts only those patients, diagnosed with cancer within a defined period of time e. g. 1, 5 or 10 years before the date on which prevalence is calculated. In cancer these periods are important, as they reflect the number of cancer cases in different course of disease, e. g. the one-year prevalence includes patients during their primary treatment, 1-4 years prevalence those requiring regular follow-up, while 5-9 and especially 10 and more years prevalence includes predominantly those considered cured from cancer. Some patients have more than one cancer, hence the sum of prevalence of cancer patients by individual cancer site is bigger than the prevalence of all cancer patients, as patients are counted only once regardless of the number of cancer diagnoses. Survival In groups of patients, the survival represents the proportion of patients still alive after a selected period of time from diagnosis. There are several options and methods for survival calculation. The basic and at the same time the simplest measure of survival is the so-called observed survival, where all deaths, also those 28 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 not caused by cancer, are included in the calculation. In order to evaluate the survival of cancer patients, which takes into account the cancer-specific deaths only, the methods of relative and net survival are used in population studies. The data on official causes of death are often insufficiently accurate for the calculation of the causal specific observed survival at the population level. Relative and net survival are calculated by statistical comparison of the observed survival in the group of patients under study and survival with respect to gender and age over a certain period of time in the population the patients come from (i.e. the expected survival). The expected survival is calculated from general mortality data and is published routinely in the form of country specific life tables within the framework of its vital statistics; for our calculations, the Slovenian complete yearly life tables are used. Since 2014 net survival is presented in the annual reports. It is calculated using the Pohar-Perme method. In previous years we calculated survival with the Ederer-II approach, which is one of the methods of relative survival. It should be noted that the method used for survival calculation in this report is different from the one used to present survival at web-portal SLORA. The SLORA web portal shows the observed survival and the relative survival computed by the Hakulinen method. 29 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Population of Slovenia Population data, especially the number and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration. Census has been performed nearly every 10 years, but till 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, the population data are available for any particular date from the Central Population Registry. In SCR Annual Reports the population data on July 1 of a particular year are used, which are obtained from Statistical Office of Republic of Slovenia. In the following table, numbers of inhabitants of Slovenia in 2016 by age and by sex are presented. Age Total Males Females Population of Slovenia 0-4 106,470 54,702 51,768 by age and by sex, July 1,2016. 5-9 108,822 56,051 52,771 10-14 92,088 47,422 44,666 15-19 94,096 48,592 45,504 20-24 102,894 52,896 49,998 25-29 126,359 65,460 60,899 30-34 142,579 74,566 68,013 35-39 157,116 82,583 74,533 40-44 151,701 79,105 72,596 45-49 147,540 75,693 71,847 50-54 154,697 78,506 76,191 In the numberof inhabitants 55-59 149,119 75,011 74,108 by statistical regions (follo- 60-64 145,188 72,625 72,563 wing table) the permanent, 65-69 120,038 57,838 62,200 but not the temporary 70-74 85,053 38,072 46,981 residence of the Slovenian 75-79 76,609 31,964 44,645 citizens is used, contrary to the standard "statistical" definition. 80+ 103,872 32,786 71,086 Total 2,064,241 1,023,872 1,040,369 Statistical region Total Males Females Population by Slovenian Pomurska 115,818 56,939 58,879 statistical regions and by sex, July 1, 2016. Podravska 321,493 159,690 161,803 Koroška 71,010 35,623 35,387 Savinjska 254,824 127,598 127,226 Zasavska 57,466 28,324 29,142 Posavska 75,694 38,084 37,610 JV Slovenija 142,672 71,971 70,701 Osrednjeslovenska 537,893 263,149 274,744 Gorenjska 203,654 100,881 102,773 Primorsko-notranjska 52,593 26,624 25,969 Goriška 117,931 58,970 58,961 Obalno-Kraška 113,193 56,019 57,174 Slovenia 2,064,241 1,023,872 1,040,369 30 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Cancer in Slovenia 2016 In 2016, 15,072 patients were diagnosed with cancer, 8,117 males and 6,955 females, and 6,247 patients died from cancer, 3,522 males and 2,725 females (Figure 1). From those born in 2016, one in two males and one in three females are expected to develop cancer by their age of 74 (Table 5). At the end of December 2016, there were 107,093 people (48,641 males and 58,452 females) alive who were diagnosed with cancer at any time since the foundation of the SCR (Figure 1). It is estimated that in 2019 there were almost 16,000 Slovenian inhabitants newly diagnosed with cancer, approximately 8,700 males and 7,100 females. The estimated incidence of different cancer sites together with 5-year average values in the last 10-year period are presented in Table 1. The risk of cancer is slowly increasing and is the highest in older age groups; from all cancer patients, diagnosed in 2016, 63% males and 60% females were aged 65 or more at diagnosis. Cancer among children and young adults (till the age of 20) accounts for less than 1% (Figure 2). As Slovenian population is ageing, it is expected that the cancer burden will continue to increase because of longer life expectancy. As cancer incidence depends on the age structure of a population, Table2 presents crude as well as age standardized rates. For the purposes of different comparisons with other countries and as different standard populations are used worldwide, three standard populations, World, European and Slovenian, were applied. First five most frequent cancers (non-melanoma skin, prostate, colorectal, lung and breast) comprise 60% of all new cancer cases (Figure 3). Cancer of these sites is associated with unhealthy lifestyle, such as excessive sunbathing, unhealthy diet, smoking and excessive alcohol consumption; the aim of primary prevention is to lower the risk associated with these factors. In males, the most frequent cancer site in 2016 was prostate (21% of all new cases). In females, breast cancer and non-melanoma skin cancer were the most frequent cancer sites with one fifth of all new cases each (Figure 3). Since 1950, the crude cancer incidence rate in Slovenia increased by 780% in males and by 520% in females. In the last 10 years, the average annual increase in males was 2.3% and 1.9% in females. The increase in crude mortality rate in the last 10 years was on average 0.8% per year in males and 0.9% per years in females (Figure 4). More than half of the crude incidence rate increase is a consequence of ageing of the population. In the last 10 years, the average annual increase in cumulative incidence rate in males was 0.2%, but 0.9% in females. Cumulative mortality rate is decreasing since 1985 in both sexes (Figure 4), in the last 10 years, in males on average by 2.3% and in females on average by 0.6% annually. The decreasing mortality despite increasing incidence indicates improvement in treatment of cancer patients. It is a proof that more and more are cured of or living with and not dying from cancer. All average annual changes with the exception of cumulative incidence in males are statistically significant at a risk level of 0.05. The time trends of common cancers in males show that lung cancer incidence was increasing till the beginning of the nineties, while it became stable onwards (around 90/100.000). Lung cancer was finally overcome by prostate cancer (average increase 31 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 by 3.0% per year) and by non-melanoma skin cancer (average increase by 5.4% per year). The huge increase in prostate cancer incidence rate in the last years is not due to some new risk factor, but more frequent use of prostate specific antigen (PSA) test as an opportunistic screening method, resulting in detection of many cancers that would have never progressed or would even not have been detected during lifetime without screening. The data for the last few years show that the incidence peak of prostate cancer has been reached. Similarly, the changes in the colorectal cancer incidence should be interpreted taking into consideration the changes in the diagnostic practice - in Slovenia the National colorectal cancer screening programme (Svit) has been introduced in 2009. The average annual increase in colorectal cancers in males in the period 2007-2010 was 7.5%, but there was an average annual decrease of 3.8% in the following years 2010-2016. In females, the incidence rate of breast (by 1.7% per year on average), lung (by 4.9% per year on average), non-melanoma skin (by 4.0% per year on average), and uterine cancer (by 2.7% per year on average) is increasing, while the incidence of cervical cancer is rapidly decreasing since the introduction of the National cervical cancer screening programme (ZORA); the average annual decrease in last ten years was 2.5%. Like in males also in females the colorectal cancer incidence time trends have been changed because the national screening programme Svit has been introduced: in the period 2007-2010 the incidence raised for 1.7% annually, but in the years 2010-2016 it decreased by 2.9% annually. The average annual percentage changes of incidence rates are presented in Figure 5. In Figure6, five-year net survival of all cancer patients (without patients with non-melanoma skin cancer) and patients with cancer of selected sites diagnosed in 2012-2016 is presented and compared to those diagnosed in 2007-2011. In males, the overall five-year net survival increased for 3 percentage points, especially because of better detection and reporting of earlier stage prostate cancer with better prognosis, as for these patients with the most common male cancer the survival increased by almost 4 percentage points. As 95% confidence intervals are not overlapping, it can be concluded that the difference is statistically significant. In females, the overall five-year net survival for the first time exceeds 60%. Among the common cancers, survival statistically significant increased in lung cancer patients (exceeding 20% for the first time), and in breast cancer survivors where it increased for 3% in recent years. In this year's report, special attention is given to the achievements of the three Slovenian national cancer screening programmes ZORA, DORA and Svit, as can be monitored by the SCR data. Figure 7a (ZORA), Figure 8a (DORA) and Figure 9a (Svit) show, for each screening cancer location, time trends of crude incidence rates between 1987 and 2016. The changes in incidence trends resulting from the introduction of the programmes are highlighted. Thus, the incidence of cervical cancer began to decline already after the introduction of the ZORA pilot in 1997. Further, the incidence has more than halved since the launch of the ZORA in 2003. Similarly, for the Svit: colorectal cancer incidence has been increasing until the introduction of the screening programme, and has declined steadily since then. There is no change in the trend of breast cancer incidence since the introduction of the DORA programme, as DORA is the only one of the three screening programmes that does not detect precancerous lesions and thus does not reduce the incidence. 32 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Figure 7b (ZORA), Figure 8b (DORA) and Figure 9b (Svit) show the difference in the stage at diagnosis between cancers detected in screening programme and those diagnosed outside the screening programme. All three screening programmes clearly show excellent fulfilment of one of the basic goals of each programme -early detection of diseases: cancers diagnosed in the screening programme are in significantly lower stages. Interpreting these results, however, it should be borne in mind that interval cancers (cancers that are detected after a negative screening test) are allocated to a group diagnosed outside the screening program in the analysis of SCR data. Figures 7c and d (ZORA), Figures 8c andd (DORA) and Figures 9c and d (Svit) show the difference in survival between patients diagnosed with cancer in the screening programme and those diagnosed outside the screening programme. In all three cases, patients with cancer identified in the screening programme are better off. Differences also remain when comparing survival separately by stage at diagnosis. This result certainly requires additional analysis, since from the data available in the SCR it is not possible to estimate whether the treatment of patients detected in the screening programme is more advantageous or how much the classification of interval cancers contributes to such result. In the majority of new cases, the diagnosis was confirmed microscopically. Table 3 shows that in 2016, in 95.1% from 15,072 newly diagnosed cancer cases, the diagnosis was confirmed by histology or by cytology, in 4.7% with other investigations. It is encouraging that for several years only 0.2% of cases in the SCR were registered from death certificates only. They were probably not reported to SCR because they represent the patients not treated in the hospital due to age or advanced disease. Table3 presents the number of new cases by cancer site by basis of diagnosis, while in Table4 their distribution by 5-year age group is presented. In Table5, there are age specific incidence rates for all and specific cancer sites. In Table 6a, the number of new cases of all and selected cancer sites by different statistical regions is presented. While these data are important for planning health care facilities, the age standardised rates in Table6b indicate the differences in the risk of cancer, as these differences are not due to different number and age structure of population in these regions. In 2015 the borders of four statistical regions changed (Savinjska, Posavska, Osrednjeslovenska and Zasavska) so the comparision and interpretation of data from previous years needs to be done carefully. The morphology of tumours in 14,337 microscopically diagnosed cases is presented in Table 7. In this table, cases confirmed by histology (96%) and by cytology only (4%) are presented separately. Table8 shows the distribution of cancer patients by stage at diagnosis. A simplified definition of stages at diagnosis is used, which takes into account all investigation methods, including surgery or autopsy in case the patient has not been treated before death. 33 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Age distribution of extra nodal and nodal sites of non-Hodgkin's malignant lymphomas is presented in Table 9. Owing to a small number of extra nodal sites, only the absolute numbers are given. Table 10 shows the distribution of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues, published by World Health Organization. Table 11 presents basic data on cancer patients' primary curative treatment. As in many cases combined treatment is applied, the sum of patients treated by different modalities is bigger than the number of new cases. Table 11a presents the mode of treatment of all cancer patients. Tables 11b and 11c show the hospital where patients had surgery and/or systemic treatment as primary treatment; radiotherapy is performed at the Institute of Oncology Ljubljana only (with few exceptions, irradiated abroad). In Table 12, prevalence of all cancer patients and patients with selected cancer diseases on December 31, 2016 is presented. Along with lifetime prevalence, there is also partial prevalence (1-, 3-, 5- and 10-years). In Table 13, there are official data on cancer mortality in 2016. The data for this table have been prepared at the National Institute of Public Health of the RS. Crude and age standardised mortality rates are available on the internet portal Slora (http://www.slora.si/en/). Table 14 shows 1-, 3-, 5-, and 10-years net survival of patients diagnosed between 2012 and 2016. Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 34 Acknowledgement Physicians, nurses, and the administrative staff from the Slovenian hospitals and other healthcare institutions have been conscientiously providing data on new cancer cases, on the course of each individual disease as well as of its eventual outcome. If data on new cases had been incomplete, they effectively sought and completed the missing information. If data necessary for the Registry had not been available in hospitals, they were kindly provided by the family and general physicians. The data of the patients diagnosed and treated at the Institute of Oncology Ljubljana were processed by Mrs. Maruska Ferjancic and Mrs. Polona Skulj from the Institute of Oncology's Hospital Registry. Data for melanoma and non-melanoma skin cancers were provided by Mrs. Agata Campa from the Slovenian Melanoma Clinical Registry. The Report could not be published - at least with the currently assured high credibility of data - without the traditional good cooperation of the Republic of Slovenia Population Registry, National Institute of Public Health of RS, and Statistical Office of RS. Answers to all expert questions are provided by clinical specialists from the Institute of Oncology Ljubljana. Expert advice in the field of pathology is especially helpful, and has been offered to us by dr. Gorana Gasljevic, MD. The Registry is grateful to the above mentioned as well as to all others who have contributed to the current Report. Editors 35 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Reference References - Ravnihar B, Gruden I. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za leto 1950. Zdrav Vestn 1951; 20: 264-77. - Epidemiological and vital statistics report. Geneva: World Health Organization, 1961-1966. - World health statistics report. Geneva: World Health Organization, 1970-1974. - Rak v Sloveniji (1965-77). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967-1980. - Incidenca raka v Sloveniji (1978-2001). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1981-2004. - Doll R, Payne P, Waterhouse J, eds. Cancer incidence in five continents. Vol 1. Berlin: Springer, 1966. - Doll R, Muir C, Waterhouse J, eds. Cancer incidence in five continents. Vol 2. Lyon: International Agency for Research on Cancer, 1970. - Waterhouse J, Muir C, Correa C, Powell J, eds. Cancer incidence in five continents. Vol 3. Lyon: International Agency for Research on Cancer, 1976 (IARC Sci Publ 15). - Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents. Vol 4. Lyon: International Agency for Research on Cancer, 1982 (IARC Sci Publ 42). - Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents. Vol 5. Lyon: International Agency for Research on Cancer, 1987 (IARC Sci Publ 88). - Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. Cancer incidence in five continents Lyon. Vol 6. International Agency for Research on Cancer, 1992 (IARC Sci Publ 120). - Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents. Vol 7. Lyon: International Agency for Research on Cancer, 1997 (IARC Sci Publ 143). - Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents. Vol 8. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 155). - Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, eds. Cancer incidence in five continents. Vol 9. Lyon: International Agency for Research on Cancer, 2007 (IARC Sci Publ 160). - Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Pineros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds. Cancer Incidence in Five Continents, Vol. X (electronic version) Lyon, IARC, 2013. URL: http://ci5.iarc.fr. - Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F.GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. URL: http://globocan.iarc.fr. - Steliarova-Foucher E, O'Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F: European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. URL: http://eco.iarc.fr. - Berrino F, Capocaccia R, Esteve J et al, eds. Survival of cancer patients in Europe: the EUROCARE-2 study. Lyon: International Agency for Research on Cancer, 1999. - Berrino F, Capocaccia R, Gatta G et al, eds. Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 2003: 14 (Suppl 5). - Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: Results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-83. - De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2013; 15: 23-34 - Gatta G, Botta L, Rossi S et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15: 35-47. - Coleman, MP, Quaresma, M, Berrino, F..., and the CONCORD Working Group. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008; 9: 730-756 - Allemani C, Weir HK, Carreira H ... and the CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015; 385: 977-1010. 36 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 - Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšic M and CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023-75. - Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011: 47; 2493-511. - Pompe-Kirn V, Primic Žakelj M, Ferligoj A, Škrk J. Zemljevidi incidence raka v Sloveniji 1978-1987 (Atlas of cancer incidence in Slovenia 1978-1987). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992. - Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. Preživetje bolnikov z rakom v Sloveniji 19631990 (Cancer patients' survival in Slovenia 1963-1990). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995. - Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetje bolnikov z rakom v Sloveniji 1983-1997 (Cancer patients' survival in Slovenia 1983-1997). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003. - Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991-2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991-2005 in Slovenia). Ljubljana: Onkološki inštitut, 2009. - Uredba o standardni klasifikaciji teritorialnih enot - SKTE. Ur. l. RS št. 28/2000. - Uredba komisije (EU) št. 1319/2013 o spremembi prilog k Uredbi (ES) št. 1059/2003 Evropskega parlamenta in Sveta o oblikovanju skupne klasifikacije statističnih teritorialnih enot (NUTS) - Savezni zavod za zdravstvenu zaštitu. Medunarodna klasifikacija bolesti, povreda i uzroka smrti. 8. revizija. Novi sad: Savezni zavod za zdravstvenu zaštitu, 1970. - Inštitut za varovanje zdravja RS. Mednarodna klasifikacija bolezni in sorodnih zdravstvenih problemov za statistične namene. 10. revizija (International statistical classification of diseaseses and related health problems). Ljubljana: Inštitut za varovanje zdravja, 1995. - World Health Organisation. International statistical classification of diseases and related health problems. Tenth revision, edition 2010 (4th edition). Geneva: WHO Press, 2011. - World Health Organisation. International classification of diseases for Oncology. 3rd Edition. Geneva: World Health Organisation, 2000. - World Health Organisation. International Classification of Diseases for Oncology, Third Edition, First Revision. Geneva: World Health Organization, 2013. - Swerdlow SH., Campo E, Harris NL et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO/IARC Classification of Tumours, 4th Edition, Volume 2. Geneva: World Health Organization, 2008. - Jensen OM, Parkin M et al, eds. Cancer registration: principles and methods. Lyon: International Agency for Research on Cancer, 1991. (IARC Sci Publ 95). - Dos Santos Silva I. Cancer epidemiology: principles and methods. Lyon: International Agency for Research on Cancer, 1999. - Moller B, Fekjaer H, Hakulinen T et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med 2003; 15: 2751-66. - SI-STAT podatkovni portal. Ljubljana, Statistični urad Republike Slovenije, 2014. URL: http://pxweb.stat.si/. - Dyba T, Hakulinen T, Paivarinta L. A simple non-linear model in incidence prediction. Statistics in Medicine 16: 2297-309, 1997. - Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Statistics in medicine 2000; 19(3): 335-51. - Pohar M, Stare J. Relative survival analysis in R. Computer Methods and Programs in Biomedicine 2006; 81: 272-8. - Perme MP, Stare J, Esteve J. On estimation in relative survival. Biometrics. 2012;68(1):113-20. - Žagar T. Lifetables for Slovenia 1982-2007. Rostock: Max Planck, 2008. URL: http://www.lifetable.de/cgi-bin/Country.plx?Country=Slovenia. - Del Turco MR, Ponti A, Bick U, Biganzoli L, Cserni G, Cutuli B et al. Quality indicators in breast cancer care. Eur J Cancer 2010; 46: 2344-56. - Projekt TRANSCAN/HIGHCARE: www.transcanfp7.eu/index.php/abstract/highcare.html. 37 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Slika 1: Breme raka, Slovenija 2016. Figure 1: Cancer burden, Slovenia 2016. Incidenca Incidence Umrljivost Mortality Prevalenca Prevalence 10.000 20.000 30.000 40.000 50.000 60.000 70.000 80.000 90.000 100.000 Število Number Moški in ženske / Males and females Moški / Males Ženske / Females Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2016. Figure 2: Percentage distribution of all cancer sites by age group and by sex, Slovenia 2016. MOŠKI / MALES ŽENSKE/FEMALES 0-19 20-34 let/years let/years 0,5% 1,5% 75+ let/years 30,4% 35-49 let/years 5,2% 0-19 20-34 let/years let/years 0,6% 2,0% 50-64 let/years 29,5% 75+ let/years 34,9% 35-49 let/years 9,9% 50-64 let/years 27,9% 65-74 let/years 32,8% 65-74 let/years 24,6% 38 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Slika 3: Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2016. Figure 3: The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2016. MOŠKI / MALES ŽENSKE / FEMALES Prostata Prostate Koža, razen melanoma Skin, non-melanoma Pljuča* Lung* Debelo črevo in danka* Colorectum* Glava in vrat* Head and neck* Koža, melanom Skin, melanoma Želodec Stomach Mehur Bladder Ledvica z ledvičnim mehom* Kidney with renal pelvis* Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma Ostalo Other Koža, razen melanoma Skin, non-melanoma Dojka Breast Debelo črevo in danka* Colorectum* Pljuča* Lung* Maternično telo Corpus uteri Koža, melanom Skin, melanoma Ne-Hodgkinovi limfomi Non-Hoagkin's lymphoma Trebušna slinavka Pancreas Želodec Stomach Ščitnica Thyroid gland Ostalo Other MOŠKI IN ŽENSKE / MALES AND FEMALES Koža, razen melanoma Skin, non-melanoma Prostata Prostate Pljuča* Lung* Debelo črevo in danka* Colorectum* Dojka Breast Koža, melanom Skin, melanoma Glava in vrat* Head and neck* Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma Želodec Stomach Ledvica z ledvičnim mehom* Kidney with renal pelvis* Ostalo Other 39 " Pojasnilo / Explanation: Glava in vrat / Head and neck (C00-C14, C30-C32) Debelo črevo in danka / Colorectum (C18-C20) Sapnik, sapnici in pljuča / Trachea, bronchus and lung (C33-C34) Ledvica z ledvičnim mehom / Kidney with renal pelvis (C64-C65) Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950-2016. Figure 4: Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950-2016. o 9 ° o o o O o o ■— o tu S s O 2 -t—1 ^ (L) ro "O -Q 2u 800 700 600 500 400 300 200 100 + 2,3*« k/ ' + 1,9*« + 0,8*« 6 + 0,9*« f> Incidenca moški / Incidence males Umrljivost moški / Mortality males Incidenca ženske / Incidence females Umrljivost ženske / Mortality females Leto/Year o o o 1 o TO C ro Q. Q. CU O fD i/i c > ra 4—> ro 13 E E 13 u Incidenca moški / Incidence males Umrljivost moški / Mortality males Incidenca ženske / Incidence females Umrljivost ženske / Mortality females Leto/Year * Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05 * Average annual change is statistically significant at 0.05 significance level 40 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Slika 5: Figure 5: O. Ä o 2 "K CU "O -O 13 2 u ö Q. o o fl CL) 03 "O e) 41 Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950-2016. Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950-2016. MOŠKI/MALES o o Q o o o. O o ■— o ru CTi CT\ c\i r\i CM rsi Pljuča / Lung (C33-C34) Koža, razen melanoma / Skin, non-melanoma (C44) - Debelo črevo in danka / Colorectum (C18-C20) Mehur/Bladder (C67) ŽENSKE/FEMALES ■Prostata/Prostate (C61) ■ Glava in vrat / Head and neck (C00-C14,C30-C32) Želodec / Stomach (C16) Koža, melanom / Skin, melanoma (C43) Leto/Year LnLnLnLD___. . . ____ ty\ CM rsl fN fN - Dojka/Breast (C50) Koža, razen melanoma/Skin, non-melanoma (C44) - Debelo črevo in danka/Colorectum (C18-C20) Pljuča / Lung (C33-C34) - Maternično telo / Corpus uteri (C54) Koža, melanom / Skin, melanoma (C43) Maternični vrat / Cervix uteri (C53) Želodec / Stomach (CI 6) * Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05 * Average annual change is statistically significant at 0.05 significance level Leto/Year Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Slika 6: Pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2007-2011 in 2012-2016 po spolu. Figure 6: Five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2007-2011 and 2012-2016 by sex. MOŠKI/MALES Modo Testis (C62) Prostata Prostate (C61) Ščitnica Thyroid gland (C73) Koža, melanom Skin, melanoma (C43) Hodgkinova bolezen Hodgkin's disease (C81) Kosti Bone (C40-C41) Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma (C82-C85) Limfatična levkemija Lymphoblastic leukaemia (C91) Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction (C19-C20) Ledvica z ledvičnim mehom Kidney with renal pelvis (C64-C65) Grlo Larynx (C32) Debelo črevo Colon (CI 8) Vezivno in mehko tkivo Connective and soft tissue (C48-C49) Sečni mehur Bladder (C67) Usta Mouth (C00-C09) Želodec Stomach (CI 6) 2relo Pharynx (C10-C14) Levkemije, drugo Leukaemias, other (C92-C95) Sapnik, sapnici in pljuča Trachea, bronchus and lung (C33-C34) Jetra in intrahepatični vodi Liver and intrahepatic bile ducts (C22) Požiralnik Oesophagus (CI 5) Trebušna slinavka Pancreas (C25) Vsi raki, razen kožnega All cancer sites but skin (C00-C96 brez C44) Preživetje je več kot 50 % (62,1 %vseh ugotovljenih rakov v 201 ¿-2016) Preživetje je 1:0—50 (25,3 % vseh ugotovljenih rakov v 2012-2016) Preživetje je manj kot 10 % (3,0 % vseh ugotovljenih rafeiv v 2012-2016) 70 2012-2016 (N = 31.342) 2007-2011 (N = 28.887) i 90 100 Preživetje (%) 42 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Slika 6: Nadaljevanje. Figure 6: Continued. 95,6 5 97,1 91,0 H 87,9 j —i 87,8 H 86,0 B —i ŽENSKE/FEMALES Ščitnica Thyroid gland (C73) Koža, melanom Skin, melanoma (c43) Hodgkinova bolezen Hodgkin's disease (C81) Dojka Breast (C50) Maternično telo Corpus uteri (C54) Usta Mouth (C00-C09) Ledvica z ledvičnim mehom Kidney with renal pelvis (C64-C65) Maternični vrat Cervix uteri (C53) Limfatična levkemija Lymphoblastic leukaemia (C91) Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma (C82-C85) Debelo črevo Colon (C18) Kosti Bone (C40-C41) Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction (C19-C20) Vezivno in mehko tkivo Connective and soft tissue (C48-C49) Grlo Larynx (C32) Žrelo Pharynx (CI 0-C14) Sečni mehur Bladder (C67) Jajčnik Ovary (C56) Levkemije, drugo Leukaemias, other (C92-C95) Želodec Stomach (CI 6) Sapnik, sapnici in pljuča Trachea, bronchus and lung (C33-C34) Požiralnik Oesophagus (CI 5) Jetra in intrahepatic™ vodi Liver and intrahepatic bile ducts (C22) Trebušna slinavka Pancreas (C25) Vsi raki, razen kožnega All cancer sites but skin (C00-C96 but C44) 43 2012-2016 (N = 25.522) 2007-2011 (N = 23.598) 10-50%:survival (19j0% of allicancers diagnosed in 2012-2016) Lesstihan 10%:survival (4|5% of allicancers diagnosed in 2012-2016) 90 100 Survival (%) Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Slika 7a: Časovni trend grobe letne incidenčne stopnje raka materničnega vratu (C53) po stadijih s povrečno letno spremembo za tri obdobja: pred pričetkom presejalnega programa ZORA (1987-1996), v času pilotnega presejanja (1997-2002) in od pričetka presejalnega programa ZORA (2003-2016), Slovenija 1987-2016. Figure 7a: Time trend of crude annual incidence rates for cervical cancer (C53) by stage with avarage annual change for three periods: before the start of screening program ZORA (1987-1996), during pilot screening (1997-2002) and since the start of screening programme ZORA (2003-2016), Slovenia 1987-2016. C53 o 9 ° o o o O o o o . D. aj o. O 2 tn (D ra "O _a i3 ü OSOOOOOOOO*— '— i— — oSooooooooo^ooooo rN^rNfNrslfNrMrNfNrvjrMfNrMfNrNfNrM • Vsi stadiji /Ali stages Omejen / Localized Razširjen / Regional Razsejan / Distant Leto/Year "Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05 "Average annual change is statistically significant at 0.05 significance level Slika 7b: Delež žensk z rakom materničnega vratu (C53) glede na udeležbo v presejalnem programu ZORA in FIGO stadij, Slovenija 2012-2016. Figure 7b: Proportion of women with cervical cancer (C53) according to attendance in organised screening programme ZORA and FIGO stage, Slovenia 2012-2016. 2 CD ro Ol 2?Sf I i-ssš o-S jSž Q.< .En □ cc Û-M 2 O S ro OlN l/l C 4-< CI »S&E o eč 81 CL Q. Ugotovljen v programu ZORA Diagnosed in programme ZORA (N=331) Ni ugotovljen v programu ZORA Not diagnosed in programme ZORA (N=491) Vsi Ali (N=610) Ugotovljen v programu ZORA Diagnosed in programme ZORA (N=296) Ni ugotovljen v programu ZORA Not diagnosed in programme ZORA (N=314) IA IV Neznano /Unknown 100 % Delež / Proportion 44 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Slika 7c: Čisto preživetje bolnic z rakom materničnega vratu starih 20-64 let s 95 % intervalom zaupanja glede na udeležbo v presejalnem programu ZORA, Slovenija 2012-2016. Figure 7c: Net survival of cervical cancer (women aged 20-64 years) with 95% confidence interval according to attendance in organised screening programme ZORA, Slovenia 2012-2016. 20 0 1 2 3 4 5 "(število primerov; pet-letno čisto preživetje) / *(number of cases; five-year net survival) Čas v letih /Time in years — Ugotovljen v programu ZORA (N = 212; 91,7 %)* — Ni ugotovljen v programu ZORA (N = 239; 61,1 %)* Diagnosed in programme ZORA Not diagnosed in programme ZORA Slika 7d: Čisto preživetje bolnic z rakom materničnega vratu starih 20-64 let po FIGO stadiju glede na udeležbo v presejalnem programu ZORA, Slovenija 2012-2016. Figure 7d: Net survival of cervical cancer (women aged 20-64 years) by FIGO stage according to attendance in organised screening programme ZORA, Slovenia 2012-2016. 0 12 3 '(število primerov; pet-letno čisto preživetje) / *(number of cases; five-year net survival) 4 5 Čas v letih / Time in years Ugotovljen v programu ZORA, stadij IA (N = 104; 101,2 9 Diagnosed in programme ZORA, stage IA • Ugotovljen v programu ZORA, stadij IB (N = 66; 92,3 %)* Diagnosed in programme ZORA, stage IB • Ugotovljen v programu ZORA, stadij 11+ (N = 42; 67,4 %)' Diagnosed in programme ZORA, stage 11+ Ni ugotovljen v programu ZORA, stadij IA (N = 21; 100,99 Not diagnosed in programme ZORA, stage IA . Ni ugotovljen v programu ZORA, stadij IB (N = 66; 91,8 i Not diagnosed in programme ZORA, stage IB • Ni ugotovljen v programu ZORA, stadij 11+ (N = 142; 43,81 Not diagnosed in programme ZORA, stage 11+ 45 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Slika 8a: Časovni trend grobe letne incidenčne stopnje raka dojk pri ženskah (C50) po stadijih s povrečno letno spremembo za dve obdobji: pred pričetkom presejalnega programa DORA (1987-2010) in od pričetka presejalnega programa DORA (2011-2016), Slovenija 1987-2016. Figure 8a: Time trend of crude annual incidence rates for breast cancer in women (C50) by stage with avarage annual change for two periods: before the start of screening program DORA (1987-2010) and since the start of screening programme DORA (2011-2016), Slovenia 1987-2016. C50 o 9 ° o o o O o o •— o ro S Ü3 n ^ Q_ -t—" o 2 CL) ra "O -D 3 2 ü 13 140 120 100 60 40 20 + 2,6* +3, 1*<* +4,y % + 4,2* % -0,2 % +2,7* % + 1,5* % 1-2,1 % ogooooooooogooooo rN^rNfNrslfNrMrNfNrvjrMfNrMfNrNfNrM • Vsi stadiji /Ali stages Omejen / Localized Razširjen / Regional Razsejan / Distant Leto/Year "Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05 "Average annual change is statistically significant at 0.05 significance level Slika 8b: Delež žensk z rakom dojke (C50) glede na udeležbo v presejalnem programu DORA in UICC stadij, Slovenija 2012-2016. Figure 8b: Proportion of women with breast cancer (C50) according to attendance in organised screening programme DORA and UICC stage, Slovenia 2012-2016. O QJ ro C7> Sai . D. aj o. O 2 tn (D ra "O _a i3 ü OSOOOOOOOO*— '— i— — oSooooooooo^ooooo rN^rNfNrslfNrMrNfNrvjrMfNrMfNrNfNrM • Vsi stadiji/Ali stages Omejen / Localized Razširjen / Regional Razsejan / Distant Leto/Year "Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05 "Average annual change is statistically significant at 0.05 significance level Slika 9b: Delež bolnikov z rakom debelega črevesa in danke (C18-C20) glede na udeležbo v presejalnem programu Svit in UICC stadij, Slovenija 2012-2016. Figure 9b: Proportion of patients with colon and rectum cancer (C18-C20) according to attendance in organised screening programme Svit and UICC stage, Slovenia 2012-2016. O 0) tu Ol SJ o "> u tu ^L,«1 tu 2 ju Œ c eng1 oi S~P.ro o U Q_' Q. Vsi All (N=7178) Ugotovljen v programu Svit Diagnosed in programme Svit (N=1490) Ni ugotovljen v programu Svit Not diagnosed in programme Svit (N=5688) Vsi Ali (N=4111) Ugotovljen v programu Svit Diagnosed in programme Svit (N=1489) Ni ugotovljen v programu Svit Not diagnosed in programme Svit (N=2622) 111+ IV Neznano /Unknown 100 % Delež / Proportion 48 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Slika 9c: Čisto preživetje bolnikov z rakom debelega črevesa in danke starih 50-74 let s 95 % intervalom zaupanja glede na udeležbo v presejalnem programu Svit, Slovenija 2012-2016. Figure 9c: Net survival of colorectal cancer (patients aged 50-74 years) with 95% confidence interval according to attendance in organised screening programme Svit, Slovenia 2012-2016. 0 1 2 3 4 5 •(število primerov; pet-letno čisto preživetje) / *(number of cases; five-year net survival) Čas v letih /Time in years — Ugotovljen v programu Svit (N = 1489; 90,7 %)* — Ni ugotovljen v programu Svit (N = 2575; 56,1 %)* Diagnosed in programme Svit Not diagnosed in programme Svit Slika 9d: Čisto preživetje bolnikov z rakom debelega črevesa in danke starih 50-74 let po UICC stadiju glede na udeležbo v presejalnem programu Svit, Slovenija 2012-2016. Figure 9d: Net survival of colorectal cancer (patients aged 50-74 years) by UICC stage according to attendance in organised screening programme Svit, Slovenia 2012-2016. 0 12 3 '(število primerov; pet-letno čisto preživetje) / *(number of cases; five-year net survival) 4 5 Čas v letih / Time in years Ugotovljen v programu Svit, stadij I (N = 590; 101,2 %)* Diagnosed in programme Svit, stage I • Ugotovljen v programu Svit, stadij II (N = 270; 96,7 %)* Diagnosed in programme Svit, stage II • Ugotovljen v programu Svit, stadij III+ (N = 495; 71,9 %)* Diagnosed in programme Svit, stage 111+ Ni ugotovljen v programu Svit, stadij I (N = 330; 96,0 %)* Not diagnosed in programme Svit, stage I ■ Ni ugotovljen v programu Svit, stadij II (N = 574; 81,6 %)* Not diagnosed in programme Svit, stage II ■ Ni ugotovljen v programu Svit, stadij 111+ (N = 1560; 40,8 %)* Not diagnosed in programme Svit, stage III+ 49 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 2007-2016 in 2019. Table 1: Observed and estimated cancer incidence, Slovenia 2007-2016 and 2019. Povprečne letne opazovane vrednosti 2007-2011 Povprečne letne opazovane vrednosti 2012-2016 Ocena za 2019 Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število Incidenčna stopnja na 100.000 Število Incidenčna stopnja na 100.000 Število (95 % napovedni interval) Incidenčna stopnja na 100.000 (95 % napovedni interval) Povprečne vrednost etne opazovane 2007-2011 Average a values nnual observed 2012-2016 Estimation for 2019 Number Incidence rate per 100,000 Number Incidence rate per 100,000 N (95% prec rmber iction interval) Incidence r (95% pred ate per 100,000 iction interval) Vse lokacije All sites M+Ž 12795 627,9 14252 691,5 15844 15496-16192 761 745-778 C00-C96 M 6916 686,6 7753 759,3 8726 8456-8996 840 814-866 Ž 5879 570,5 6499 625,0 7118 6898-7337 683 662-704 C00-C14 Usta in žrelo 272 27,1 274 26,9 271 228-314 26 22-30 Mouth and pharynx Ž 70 6,8 77 7,4 80 62-99 8 6-9 C15 Požiralnik 69 6,9 72 7,0 66 45-87 6 4-8 Oesophagus Ž 17 1,6 15 1,5 16 5-26 2 1-3 C16 Želodec 292 29,0 292 28,6 287 178-395 28 17-38 Stomach Ž 188 18,3 171 16,4 159 127-192 15 12-18 C18 Debelo črevo 510 50,6 489 47,9 502 436-569 48 42-55 Colon Ž 394 38,2 373 35,9 382 330-434 37 32-42 C19-C20 Rektum in rektosigmoidna zveza 409 40,6 365 35,8 341 294-388 33 28-37 Rectum and rectosigmoid junction Ž 255 24,7 209 20,1 173 140-206 17 13-20 C22 Jetra in intrahepatični vodi 118 11,7 155 15,2 175 139-211 17 13-20 Liver and intrahepatic bile ducts Ž 46 4,5 55 5,3 65 43-87 6 4-8 C23-C24 Žolčnik in žolčevodi 65 6,5 84 8,2 105 76-133 10 7-13 Gallbladder and billiary tract Ž 101 9,8 106 10,2 103 77-130 10 7-12 C25 Trebušna slinavka 164 16,3 195 19,1 220 180-260 21 17-25 Pancreas Ž 176 17,1 183 17,6 197 160-235 19 15-23 C32 Grlo 99 9,9 86 8,4 81 57-106 8 6-10 Larynx Ž 11 1,0 13 1,3 14 4-24 1 0-2 C33-C34 Sapnik, sapnici in pljuča Trachea, bronchus and lung Ž 870 361 86,4 35,0 923 457 90,4 44,0 954 572 870-1038 511-632 92 55 84-100 49-61 C43 Maligni melanom kože 227 22,5 286 28,0 350 302-399 34 29-38 Malignant melanoma of skin Ž 245 23,8 256 24,7 266 223-309 26 21-30 C44 Druge maligne neoplazme kože 1014 100,7 1342 131,4 1701 1593-1809 164 153-174 Skin, other malignomas Ž 1067 103,5 1312 126,1 1548 1447-1650 149 139-158 C48-C49 Vezivno in mehko tkivo 27 2,7 32 3,1 33 19-47 3 2-5 Connective and soft tissue Ž 37 3,6 44 4,2 48 29-67 5 3-6 C50 Dojka 10 1,0 13 1,3 15 5-26 1 0-3 Breast Ž 1189 115,4 1322 127,1 1422 1323-1521 136 127-146 C53 Maternični vrat - - - - - - - - Cervix uteri Ž 140 13,5 120 11,5 106 82-130 10 8-13 C54 Maternično telo - - - - - - - Corpus uteri Ž 296 28,8 344 33,1 389 337-440 37 32-42 C56 Jajčnik Ovary Ž 169 16,4 156 15,0 135 106-165 13 10-16 C61 Prostata 1393 138,2 1567 153,5 1834 1718-1950 177 165-188 Prostate Ž - - - - - - - - C62 Modo 100 10,0 113 11,0 125 94-156 12 9-15 Testis Ž - - - - - - - - C64-C65 Ledvica z ledvičnim mehom 229 22,7 247 24,2 268 225-312 26 22-30 Kidney with renal pelvis Ž 117 11,4 135 12,9 153 119-186 15 11-18 C67 Sečni mehur 214 21,2 248 24,3 278 233-323 27 22-31 Bladder Ž 79 7,6 93 8,9 107 79-135 10 8-13 C70-C72 Centralni in avtonomni živčni sistem 83 8,2 93 9,1 110 83-137 11 8-13 Central and autonomic nervous system Ž 65 6,3 69 6,7 75 52-98 7 5-9 C73 Ščitnica 36 3,6 44 4,3 52 32-72 5 3-7 Thyroid gland Ž 118 11,5 138 13,2 159 127-191 15 12-18 C81 Hodgkinova bolezen 26 2,6 24 2,4 25 12-38 2 1-4 Hodgkin's disease Ž 25 2,4 24 2,3 28 14-41 3 1-4 C82-C85 Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma Ž 150 148 14,9 14,4 210 200 20,6 19,3 282 243 239-325 202-283 27 23 23-31 19-27 C90 Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms Ž 65 59 6,5 5,7 70 63 6,9 6,0 72 62 50-94 42-82 7 6 5-9 4-8 C91-C95 Levkemije 158 15,7 171 16,8 180 143-216 17 14-21 Leukaemias Ž 121 11,8 131 12,6 144 113-176 14 11-17 50 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2016. Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2016. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število Number Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000 SSS* - svetovni standard ASR** - World standard SSS* - evropski standard ASR** - European standard SSS* - slovenski standard ASR** - Slovenian standard C00-C96 Vse lokacije All sites M+Ž M Ž 15072 8117 6955 730,1 792,8 668,5 350,4 403.8 311.9 497,4 588,3 432,9 590,4 712,4 504,0 C00-C14 Usta in žrelo Mouth and pharynx Ž 255 98 24,9 9,4 14,1 5,1 19,3 6,8 21,6 7,7 C15 Požiralnik Oesophagus Ž 50 14 4,9 1,3 2,7 0,6 3,8 0,9 4,3 1,0 C16 Želodec Stomach Ž 272 171 26,6 16,4 12,6 6,1 19,2 9,1 23,6 10,9 C18 Debelo črevo Colon Ž 514 393 50,2 37,8 24,2 15,1 36,6 22,2 45,8 27,0 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction Ž 357 204 34,9 19,6 17,7 8,0 26,0 11,7 31,2 14,2 C22 Jetra in intrahepatični vodi Liver and intrahepatic bile ducts Ž 140 61 13,7 5,9 6,5 2,1 9,9 3,3 12,2 4,0 C23-C24 Žolčnik in žolčevodi Gallbladder and billiary tract Ž 100 97 9,8 9,3 4,4 3,1 6,9 4,8 8,6 6,0 C25 Trebušna slinavka Pancreas Ž 194 195 18,9 18,7 9,2 6,9 13,8 10,3 17,1 12,7 C32 Grlo Ž 92 17 9,0 1,6 4,7 0,8 6,7 1,1 7,7 1,3 C33-C34 Sapnik, sapnici in pljuča Trachea, bronchus and lung Ž 966 555 94,3 53,3 47,1 23,9 69,2 34,2 82,6 39,5 C43 Maligni melanom kože Malignant melanoma of skin Ž 304 276 29,7 26,5 16,7 15,0 23,1 19,6 27,2 22,0 C44 Druge maligne neoplazme kože Skin, other malignomas Ž 1491 1459 145,6 140,2 69,3 56,1 105,7 81,5 131,5 97,7 C48-C49 Vezivno in mehko tkivo Connective and soft tissue Ž 30 46 2,9 4,4 2,4 3,4 2,6 3,6 2,7 3,7 C50 Dojka Breast Ž 14 1386 1,4 133,2 0,6 72,2 0,9 97,5 1,1 110,6 C53 Maternični vrat Cervix uteri Ž 123 11,8 7,8 9,8 10,8 C54 Maternično telo Corpus uteri Ž 361 34,7 16,1 22,9 26,4 C56 Jajčnik Ovary Ž 129 12,4 6,0 8,5 9,8 C61 Prostata Prostate Ž 1690 165,1 81,0 119,8 147,9 C62 Modo Testis Ž 107 10,5 9,5 10,3 11,0 C64-C65 Ledvica z ledvičnim mehom Kidney with renal pelvis Ž 250 142 24,4 13,6 12,5 5,4 18,3 8,0 21,7 9,9 C67 Sečni mehur Bladder Ž 252 115 24,6 11,1 11,6 3,9 17,7 5,9 22,0 7,2 C70-C72 Centralni in avtonomni živčni sistem Central and autonomic nervous system Ž 102 60 10,0 5,8 7,1 3,9 8,5 4,5 9,3 4,9 C73 Ščitnica Thyroid gland Ž 36 166 3,5 16,0 2,3 11,5 2,9 13,6 3,3 14,9 C81 Hodgkinova bolezen Hodgkin's disease Ž 30 29 2,9 2,8 2,6 3,0 2,8 3,0 2,9 3,1 C82-C85 Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma Ž 242 205 23.6 19.7 13,1 9,3 18,2 12,9 21,6 15,1 C90 Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms Ž 82 47 8,0 4,5 3,9 1,8 5,9 2,7 7.2 3.3 C91-C95 Levkemije Leukaemias Ž 169 137 16,5 13,2 9,1 6,9 12,6 8,5 15,1 9,5 51 * SSS - starostno standardizirana incidenčna stopnja na 100.000 ** ASR - age-standardised incidence rate per 100,000 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2016. Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2016. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število novih Mikroskopsko potrjeni primeri Ugotovljeni z drugimi preiskavami Registrirani samo iz zdravniških poročil o vzroku smrti primerov Number of new cases Število %* Število %* Število %* Microscopically confirmed cases Confirme investi 1 by other gations Registered from death certificates only Number %* Number %* Number %* C00-C96 Vse lokacije All sites M+Z M 15072 8117 14337 7715 95,1 95,0 703 388 4.7 4.8 32 14 0,2 0,2 Z 6955 6622 95,2 315 4,5 18 0,3 C00 Ustnica 15 15 100 0 0 0 0 Lip Z 10 10 - 0 - 0 - C01 Baza jezika 22 22 100 0 0 0 0 Base of tongue Z 7 7 - 0 - 0 - C02 Jezik, drugi deli 13 13 - 0 - 0 - Tongue, other & unspecified parts Z 17 17 100 0 0 0 0 C03 Dlesen 6 6 - 0 - 0 - Gum Z 10 10 - 0 - 0 - C04 Ustno dno 24 24 100 0 0 0 0 Floor of mouth Z 8 8 - 0 - 0 - C05 Nebo 10 10 - 0 - 0 - Palate Z 7 7 - 0 - 0 - C06 Usta, drugi deli 13 13 - 0 - 0 - Mouth, other & unspecified parts Z 7 7 - 0 - 0 - C07 Parotidna žleza 11 11 - 0 - 0 - Parotid gland Z 8 8 - 0 - 0 - C08 Druge in neopredeljene velike žleze slinavke 0 0 - 0 - 0 - Other & unspecified major salivary glands Z 2 2 - 0 - 0 - C09 Tonzila 41 41 100 0 0 0 0 Tonsil Z 13 13 - 0 - 0 - C10 Orofarinks 40 40 100 0 0 0 0 Oropharynx Z 4 4 - 0 - 0 - C11 Nazofarinks 8 8 - 0 - 0 - Nasopharynx Z 1 1 - 0 - 0 - C12 Piriformni sinus 32 32 100 0 0 0 0 Pyriform sinus Z 1 1 - 0 - 0 - C13 Hipofarinks 20 20 100 0 0 0 0 Hypopharynx Z 3 3 - 0 - 0 - C14 Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu 0 0 - 0 - 0 - Other and ill-defined sites in the lip, oral cavity and pharynx Z 0 0 - 0 - 0 - C15 Požiralnik 50 48 96,0 2 4,0 0 0 Oesophagus Z 14 13 - 1 - 0 - C16 Želodec 272 270 99,3 2 0,7 0 0 Stomach Z 171 160 93,6 10 5,8 1 0,6 C17 Tanko črevo 25 25 100 0 0 0 0 Small intestine Z 19 19 100 0 0 0 0 C18 Debelo črevo 514 497 96,7 17 3,3 0 0 Colon Z 393 370 94,1 20 5,1 3 0,8 C19 Rektosigmoidna zveza 64 64 100 0 0 0 0 Rectosigmoid junction Z 40 39 97,5 1 2,5 0 0 C20 Rektum 293 288 98,3 5 1,7 0 0 Rectum Z 164 160 97,6 4 2,4 0 0 C21 Anus in analni kanal 10 10 - 0 - 0 - Anus and anal canal Z 11 11 - 0 - 0 - C22 Jetra in intrahepatični vodi 140 81 57,9 58 41,4 1 0,7 Liver and intrahepatic bile ducts Z 61 37 60,7 23 37,7 1 1,6 C23 Žolčnik 18 11 61,1 7 38,9 0 0 Gallbladder Z 37 26 70,3 10 27,0 1 2,7 C24 Drugi in neopredeljeni deli biliarnega trakta 82 55 67,1 27 32,9 0 0 Billiary tract, other and unspecified parts Z 60 31 51,7 28 46,7 1 1,7 Nadaljevanje —> Continued —> 52 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število novih primerov Number of new cases Mikroskopsko potrjeni primeri Ugotovljeni z drugimi preiskavami Registrirani samo iz zdravniških poročil o vzroku smrti Število %* Število %* Število %* Microscopically confirmed cases Confirme investi 1 by other gations Registered from death certificates only Number %* Number %* Number %* C25 Trebušna slinavka Pancreas M Ž 194 195 134 121 69,1 62,1 59 73 30,4 37,4 1 1 0,5 0,5 C26 Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs Ž 1 3 0 2 - 1 1 - 0 0 - C30 Nosna votlina in srednje uho Nasal cavity and middle ear Ž 2 5 2 5 - 0 0 - 0 0 - C31 Obnosni sinusi Accessory sinuses Ž 2 2 2 2 - 0 0 - 0 0 - C32 Grlo Larynx Ž 92 17 92 17 100 100 0 0 0 0 0 0 0 0 C33 Sapnik Trachea Ž 0 0 0 0 - 0 0 - 0 0 - C34 Sapnica in pljuča Bronchus and lung Ž 966 555 881 505 91,2 91,0 81 50 8,4 9,0 4 0 0,4 0 C37 Timus Thymus Ž 5 7 5 7 - 0 0 - 0 0 - C38 Srce, mediastinum, plevra Heart, mediastinum, pleura Ž 4 3 4 2 - 0 1 - 0 0 - C39 Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs Ž 0 0 0 0 - 0 0 - 0 0 - C40 Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs Ž 5 5 5 5 - 0 0 - 0 0 - C41 Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts Ž 5 4 5 4 - 0 0 - 0 0 - C43 Maligni melanom kože Malignant melanoma of skin Ž 304 276 304 276 100 100 0 0 0 0 0 0 0 0 C44 Druge maligne neoplazme kože Skin, other malignomas Ž 1491 1459 1487 1459 99,7 100 4 0 0,3 0 0 0 0 0 C45 Mezoteliom Mesothelioma Ž 29 14 29 14 100 0 0 0 0 0 0 C46 Kaposijev sarkom Kaposi's sarcoma Ž 1 1 1 1 - 0 0 - 0 0 - C47 Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system Ž 2 2 2 2 - 0 0 - 0 0 - C48 Peritonej in retroperitonej Peritoneum and retroperitoneum Ž 6 14 6 13 - 0 1 - 0 0 - C49 Drugo vezivno in mehko tkivo Other connective and soft tissue Ž 24 32 24 31 100 96,9 0 1 0 3,1 0 0 0 0 C50 Dojka Breast Ž 14 1386 13 1380 99,6 1 2 0,1 0 4 0,3 C51 Žensko zunanje spolovilo Vulva Ž 57 57 100 0 0 0 0 C52 Nožnica Vagina Ž 14 14 - 0 - 0 - C53 Maternični vrat Cervix uteri Ž 123 123 100 0 0 0 0 C54 Maternično telo Corpus uteri Ž 361 360 99,7 1 0,3 0 0 C55 Maternica, neopredeljeno Uterus, unspecified Ž 18 15 83,3 2 11,1 1 5,6 C56 Jajčnik Ovary Ž 129 125 96,9 4 3,1 0 0 53 Nadaljevanje —> Continued —> Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število novih primerov Number of new cases Mikroskopsko potrjeni primeri Ugotovljeni z drugimi preiskavami Registrirani samo iz zdravniških poročil o vzroku smrti Število %* Število %* Število %* Microscopically confirmed cases Confirme investi 1 by other gations Registered from death certificates only Number %* Number %* Number %* C57 Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs M Ž 19 18 94,7 1 5,3 0 0 C58 Posteljica Placenta Ž 0 0 - 0 - 0 - C60 Penis Penis Ž 17 17 100 0 0 0 0 C61 Prostata Prostate Ž 1690 1642 97,2 44 2,6 4 0,2 C62 Modo Testis Ž 107 107 100 0 0 0 0 C63 Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs Ž 3 3 - 0 - 0 - C64 Ledvica razen meha Kidney, except renal pelvis Ž 228 131 210 115 92,1 87,8 18 16 7,9 12,2 0 0 0 0 C65 Ledvični meh Renal pelvis Ž 22 11 21 9 95,5 1 2 4,5 0 0 0 C66 Sečevod Ureter Ž 15 5 13 4 86,7 2 1 13,3 0 0 0 C67 Sečni mehur Bladder Ž 252 115 244 112 96,8 97,4 7 2 2,8 1,7 1 1 0,4 0,9 8 6 C Drugi in neopredeljeni sečni organi Other and unspecified urinary organs Ž 2 1 2 1 - 0 0 - 0 0 - C69 Oko in očesni adneksi Eye and adnexa Ž 10 11 10 10 - 0 1 - 0 0 - C70 Meninge Meninges Ž 2 0 2 0 - 0 0 - 0 0 - C71 Možgani Brain Ž 97 55 82 45 84,5 81,8 15 9 15,5 16,4 0 1 0 1,8 C72 Hrbtni mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS Ž 3 5 2 4 - 1 1 - 0 0 - C73 Ščitnica Thyroid gland Ž 36 166 36 166 100 100 0 0 0 0 0 0 0 0 C74 Nadledvična žleza Adrenal gland Ž 4 6 4 6 - 0 0 - 0 0 - C75 Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures Ž 1 0 1 0 - 0 0 - 0 0 - C76 Druga in slabo opredeljena mesta Other and ill-defined sites Ž 3 18 2 7 38,9 1 11 61,1 0 0 0 C77 Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes Ž 20 17 19 15 95,0 88,2 1 2 5,0 11,8 0 0 0 0 C78 Metastaze dihal in prebavil Metastases of respiratory and digestive organs Ž 37 41 21 26 56,8 63,4 15 15 40.5 36.6 1 0 2,7 0 C79 Metastaze, drugje Metastases of other sites Ž 15 13 9 10 60,0 6 3 40,0 0 0 0 C80 Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site Ž 69 66 57 46 82,6 69,7 12 18 17,4 27,3 0 2 0 3,0 C81 Hodgkinova bolezen Hodgkin's disease Ž 30 29 30 29 100 100 0 0 0 0 0 0 0 0 C82 Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma Ž 60 57 60 57 100 100 0 0 0 0 0 0 0 0 C83 Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma Ž 159 122 159 122 100 100 0 0 0 0 0 0 0 0 Nadaljevanje —> Continued —> 54 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 8: Nadaljevanje. Table 8: Continued. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število novih Mikroskopsko potrjeni primeri Ugotovljeni z drugimi preiskavami Registrirani samo iz zdravniških poročil o vzroku smrti primerov Number of new cases Število %* Število %* Število %* Microscopically confirmed cases Confirme investi d by other gations Registered from death certificates only Number %* Number %* Number %* C84 Limfomi celic T in kožni limfom celic T M 19 19 100 0 0 0 0 Peripheral and cutaneous T-cell lymphomas Ž 16 16 100 0 0 0 0 C85 Druge in neopredeljene vrste ne-Hodgkinovega limfoma 4 4 - 0 - 0 - Other and unspecified types of non-Hodgkin's lymphoma Ž 10 10 - 0 - 0 - C88 Maligne imunoproliferativne bolezni 5 5 - 0 - 0 - Malignant immunoproliferative diseases Ž 3 3 - 0 - 0 - C90 Difuzni plazmocitom in maligne neoplazme plazmocitov 82 82 100 0 0 0 0 Multiple myeloma and malignant plasma cell neoplasms Ž 47 47 100 0 0 0 0 C91.0 Limfatična levkemija, akutna 7 7 - 0 - 0 - Lymphoblastic leukaemia, acute Ž 11 11 - 0 - 0 - C91.1—C91.9 Limfatična levkemija, druga Lymphoid leukaemia, other Ž 76 56 74 55 97,4 98,2 0 0 0 0 2 1 2,6 1,8 C92 Mieloična levkemija 65 65 100 0 0 0 0 Myeloid leukaemia Ž 52 52 100 0 0 0 0 C93 Monocitna levkemija 4 4 - 0 - 0 - Monocytic leukaemia Ž 2 2 - 0 - 0 - C94 Druge opredeljene levkemije 17 16 94,1 1 5,9 0 0 Other leukaemias of specified cells Ž 15 15 100 0 0 0 0 C95 Levkemija z neopredeljenim celičnim tipom 0 0 - 0 - 0 - Leukaemia, unspecified cell type Ž 1 1 - 0 - 0 - C96 Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva 86 86 100 0 0 0 0 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and relatedtissue Ž 104 104 100 0 0 0 0 Zgoraj neupoštevani Not included above Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število novih primerov Number of new cases Mikroskopsko potrjeni primeri Ugotovljeni z drugimi preiskavami Registrirani samo iz zdravniških poročil o vzroku smrti Število %* Število %* Število %* Microscopically confirmed cases Confirme investi d by other gations Registered from death certificates only Number %* Number %* Number %* D03 Melanom, in situ Melanoma, in situ M Ž 139 140 139 140 100 100 0 0 0 0 0 0 0 0 D05 Dojka, in situ Breast, in situ Ž 1 136 1 136 100 0 0 0 0 0 0 D06 Maternični vrat, in situ (CIN III) Cervix uteri, in situ (CIN III) Ž 1094 1094 100 0 0 0 0 D09.0 Sečni mehur, in situ Bladder, in situ Ž 176 60 176 60 100 100 0 0 0 0 0 0 0 0 D32.0, D42.0 Meninge, benigna neoplazma in neoplazma negotovega značaja Benign neoplasm and neoplasm of uncertain behaviour of meninges Ž 34 95 25 65 73,5 68,4 9 30 26.5 31.6 0 0 0 0 D33.0-D33.2 Možgani, benigna neoplazma Benign neoplasm of brain Ž 2 1 1 1 - 1 0 - 0 0 - D39.1 Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior Ž 52 52 100 0 0 0 0 D43.0-D43.2 Možgani, neopredeljeno CNS, uncertain or unknown Ž 14 7 5 2 - 9 5 - 0 0 - * Odstotki niso računani, če je število novih primerov manjše od 15 * Percentages are not calculated when number of new cases is less than 15 SS Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 4: Incidenca raka po lokaciji, spolu in starosti, Slovenija 2016. Table 4: Cancer incidence by site, by sex and by age, Slovenia 2016. Šifra MKB Primarna lokacija Spol Vse starosti Starost Age ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ C00-C96 Vse lokacije All sites M+Z M Z 15072 8117 6955 24 12 12 16 7 9 10 4 6 33 18 15 29 16 13 93 42 51 144 66 78 215 78 137 361 128 233 541 220 321 956 491 465 1329 693 636 2053 1214 839 2318 1394 924 2059 1269 790 2013 1167 846 2878 1298 1580 C00 Ustnica Lip Z 15 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 0 2 0 0 1 2 0 1 0 0 0 0 0 1 2 6 7 C01 Baza jezika Base of tongue Z 22 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 2 0 4 1 7 3 6 1 2 0 0 0 0 1 C02 Jezik, drugi deli Tongue, other & unspecified parts Z 13 17 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 2 2 0 2 0 3 3 3 4 0 3 1 2 0 1 C03 Dlesen Gum Z 6 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 1 0 2 2 4 1 1 1 1 0 1 C04 Ustno dno Floor of mouth Z 24 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 2 0 3 2 2 0 10 2 2 2 0 1 1 0 1 1 C05 Nebo Palate Z 10 7 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 2 1 1 0 2 3 4 0 0 0 1 0 0 0 C06 Usta, drugi deli Mouth, other & unspecified parts Z 13 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 3 1 1 0 4 2 4 1 0 1 0 0 0 1 C07 Parotidna žleza Parotid gland Z 11 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 3 1 0 2 2 2 1 0 0 1 2 1 2 0 0 0 C08 Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands Z 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 C09 Tonzila Tonsil Z 41 13 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 3 1 4 1 4 3 4 3 10 0 5 1 5 0 5 2 0 1 C10 Orofarinks Oropharynx Z 40 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 1 5 1 10 0 8 0 10 2 2 0 1 0 1 0 C11 Nazofarinks Nasopharynx Z 8 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 2 0 2 1 0 0 1 0 1 0 C12 Piriformni sinus Pyriform sinus Z 32 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 1 5 0 7 0 5 0 4 0 1 0 5 0 2 0 C13 Hipofarinks Hypopharynx Z 20 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 0 5 1 5 0 5 0 1 1 1 0 0 0 C14 Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx Z 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C15 Požiralnik Oesophagus Z 50 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 4 1 5 1 7 3 13 1 7 0 6 3 2 1 4 4 C16 Želodec Stomach Z 272 171 0 0 0 0 0 0 0 0 0 0 0 1 2 0 1 0 2 3 7 4 20 9 16 17 39 16 47 15 33 20 48 22 57 64 C17 Tanko črevo Small intestine Z 25 19 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 3 0 1 6 0 2 0 2 3 1 4 5 1 4 4 4 2 C18 Debelo črevo Colon Z 514 393 0 0 0 0 0 1 0 1 0 1 0 0 0 4 4 0 11 4 11 8 25 22 32 27 70 39 73 44 110 74 78 60 100 108 C19 Rektosigmoidna zveza Rectosigmoid junction Z 64 40 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 4 1 5 3 5 3 11 5 6 4 10 6 11 3 11 13 C20 Rektum Rectum Z 293 164 0 0 0 0 0 0 0 0 0 0 1 0 2 0 2 1 5 3 10 5 19 8 41 13 44 15 46 25 47 32 40 20 36 42 C21 Anus in analni kanal Anus and anal canal Z 10 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 3 1 2 1 2 3 1 3 1 2 1 0 C22 Jetra in intrahepatični vodi Liver and intrahepatic bile ducts Z 140 61 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 9 3 11 4 16 7 33 10 22 9 22 11 25 17 C23 Žolčnik Gallbladder Z 18 37 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 3 1 2 3 1 8 3 2 2 8 7 13 C24 Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts Z 82 60 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 1 2 3 7 4 10 3 15 2 12 9 18 9 17 27 C25 Trebušna slinavka Pancreas Z 194 195 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 1 1 5 7 11 5 11 12 28 20 36 25 35 32 33 28 32 65 C26 Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs Z 1 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 1 1 Nadaljevanje —> Continued —> 56 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Vse starosti All ages Starost Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ C30 Nosna votlina in srednje uho Nasal cavity and middle ear M Ž 2 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 1 0 0 1 0 2 C31 Obnosni sinusi Accessory sinuses Ž 2 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 1 C32 Grlo Larynx Ž 92 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 2 0 8 1 16 3 19 3 18 5 10 3 8 2 10 0 C33 Sapnik Trachea Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C34 Sapnica in pljuča Bronchus and lung Ž 966 555 0 0 0 0 0 0 1 0 0 0 0 1 1 1 2 1 7 1 13 11 62 30 113 76 181 105 194 108 138 66 123 64 131 91 C37 Timus Thymus Ž 5 7 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 1 1 0 0 2 3 1 1 0 0 0 0 C38 Srce, mediastinum, plevra Heart, mediastinum, pleura Ž 4 3 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 2 0 0 C39 Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C40 Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs Ž 5 5 0 0 1 0 0 0 3 0 0 0 0 0 0 0 0 0 1 1 0 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 C41 Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts Ž 5 4 1 0 0 0 0 0 0 0 0 0 1 0 0 0 2 0 0 0 1 0 0 0 0 0 0 2 0 0 0 1 0 0 0 1 C43 Maligni melanom kože Malignant melanoma of skin Ž 304 276 0 0 0 0 0 1 1 0 1 1 6 9 15 12 9 8 9 23 19 16 29 31 23 29 42 25 38 33 37 19 36 21 39 48 C44 Druge maligne neoplazme kože Skin, other malignomas Ž 1491 1459 0 0 0 1 0 0 1 0 0 1 6 8 6 7 23 26 26 47 43 54 84 70 93 98 163 143 208 165 228 151 254 210 356 478 C45 Mezoteliom Mesothelioma Ž 29 14 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 1 1 0 1 2 4 3 6 3 6 2 8 3 1 0 C46 Kaposijev sarkom Kaposi's sarcoma Ž 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 C47 Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system Ž 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 2 0 0 0 0 0 0 0 0 0 0 C48 Peritonej in retroperitonej Peritoneum and retroperitoneum Ž 6 14 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 2 1 1 4 0 2 0 2 1 2 C49 Drugo vezivno in mehko tkivo Other connective and soft tissue Ž 24 32 2 3 2 0 0 0 0 1 0 0 0 2 2 1 0 1 1 1 1 3 1 2 1 3 3 3 2 4 5 1 3 2 1 5 C50 Dojka Breast Ž 14 1386 0 0 0 0 0 0 0 0 0 1 0 8 0 14 0 50 0 75 0 116 0 161 1 146 2 210 4 191 0 129 3 131 4 154 C51 Žensko zunanje spolovilo Vulva Ž 57 0 0 0 0 0 0 1 1 0 1 2 7 4 1 6 11 23 C52 Nožnica Vagina Ž 14 0 0 0 0 0 1 0 0 0 1 2 1 2 1 2 2 2 C53 Maternični vrat Cervix uteri Ž 123 0 0 0 0 0 3 8 13 17 14 9 14 12 10 7 5 11 C54 Maternično telo Corpus uteri Ž 361 0 0 0 0 0 0 2 4 7 20 19 53 52 61 34 52 57 C55 Maternica, neopredeljeno Uterus, unspecified Ž 18 0 0 0 0 0 0 0 1 2 0 2 0 1 5 1 1 5 C56 Jajčnik Ovary Ž 129 0 0 0 0 0 1 0 1 5 7 16 15 15 18 15 16 20 C57 Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs Ž 19 0 0 0 0 0 0 0 1 0 0 1 2 1 4 1 3 6 C58 Posteljica Placenta Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C60 Penis Penis Ž 17 0 0 0 0 0 0 0 1 0 1 1 2 1 2 1 7 1 C61 Prostata Prostate Ž 1690 0 0 0 0 0 0 0 0 0 14 60 127 314 394 344 253 184 57 Nadaljevanje —> Continued —> Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost Age ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ C62 Modo Testis M Ž 107 0 0 0 2 8 16 22 7 20 12 12 5 2 0 1 0 0 C63 Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 C64 Ledvica razen meha Kidney, except renal pelvis Ž 228 131 0 0 0 0 0 0 0 0 0 0 0 0 1 0 3 2 5 1 4 3 21 9 32 8 35 14 35 16 37 27 27 20 28 31 C65 Ledvični meh Renal pelvis Ž 22 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 1 4 0 6 0 2 3 4 1 4 6 C66 Sečevod Ureter Ž 15 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 4 2 3 2 1 0 5 1 C67 Sečni mehur Bladder Ž 252 115 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 8 3 13 2 16 8 37 13 37 18 41 13 39 17 59 41 CO 6 C Drugi in neopredeljeni sečni organi Other and unspecified urinary organs Ž 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 C69 Oko in očesni adneksi Eye and adnexa Ž 10 11 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 2 1 2 1 0 0 0 1 0 1 2 3 1 3 C70 Meninge Meninges Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 C71 Možgani Brain Ž 97 55 3 1 2 2 2 0 3 0 0 2 1 0 2 2 2 2 3 2 6 2 9 3 7 6 13 5 11 5 12 8 9 8 12 7 C72 Hrbtni mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS Ž 3 5 1 0 0 1 0 0 0 1 1 0 0 0 0 1 1 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 C73 Ščitnica Thyroid gland Ž 36 166 0 0 0 0 0 3 0 5 0 2 2 7 1 10 4 11 5 16 3 8 3 10 5 15 3 27 5 20 2 15 2 9 1 8 C74 Nadledvična žleza Adrenal gland Ž 4 6 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 0 1 0 0 1 1 0 1 0 0 0 0 C75 Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 C76 Druga in slabo opredeljena mesta Other and ill-defined sites Ž 3 18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 2 0 1 0 2 1 1 1 9 C77 Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes Ž 20 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 3 1 5 2 6 3 1 0 0 1 4 9 C78 Metastaze dihal in prebavil Metastases of respiratory and digestive organs Ž 37 41 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 1 2 0 3 2 9 6 11 4 11 26 C79 Metastaze, drugje Metastases of other sites Ž 15 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 2 0 3 2 1 3 0 1 0 0 7 5 C80 Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site Ž 69 66 0 0 0 0 0 0 0 0 0 0 0 2 1 0 1 0 0 0 1 2 5 2 7 6 16 5 10 5 11 4 6 10 11 30 C81 Hodgkinova bolezen Hodgkin's disease Ž 30 29 0 0 0 1 1 1 4 3 0 3 1 3 2 6 4 3 2 1 3 0 2 1 2 0 6 2 1 1 1 1 1 1 0 2 C82 Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma Ž 60 57 0 0 0 0 0 0 1 1 0 0 1 0 2 1 0 1 4 2 0 2 6 3 6 7 6 10 11 13 8 5 11 6 4 6 C83 Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma Ž 159 122 0 0 1 0 0 0 0 1 1 1 5 0 1 3 5 2 2 2 7 3 8 4 17 11 16 11 30 20 21 22 18 15 27 27 C84 Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas Ž 19 16 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 3 2 1 3 2 1 3 3 2 1 0 4 1 1 4 C85 Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma Ž 4 10 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 0 1 1 0 0 3 1 2 0 2 Nadaljevanje —> Continued —> 58 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 8: Nadaljevanje. Table 8: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost Age ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ C88 Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases M Ž 5 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 1 1 0 0 2 1 C90 Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms Ž 82 47 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 2 1 6 5 7 4 10 3 13 5 13 11 11 7 18 11 C91.0 Limfatična levkemija, akutna Lymphoblastic leukaemia, acute Ž 7 11 1 3 0 4 1 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 1 0 1 C91.1-C91.9 Limfatična levkemija, druga Lymphoid leukaemia, other Ž 76 56 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 2 8 2 5 4 9 8 14 11 9 8 12 4 15 17 C92 Mieloična levkemija Myeloid leukaemia Ž 65 52 1 1 0 0 0 0 1 1 1 0 0 2 2 1 0 0 1 0 2 1 4 3 4 3 7 9 6 5 6 4 12 6 18 16 C93 Monocitna levkemija Monocytic leukaemia Ž 4 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 3 0 C94 Druge opredeljene levkemije Other leukaemias of specified cells Ž 17 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 3 1 1 0 1 1 3 0 1 1 4 2 1 5 1 4 C95 Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type Ž 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 C96 Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue Ž 86 104 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 2 0 4 0 4 6 2 6 4 6 8 8 14 13 9 16 18 30 36 Zgoraj neupoštevani Not included above Šifra MKB Primarna lokacija Spol Vse starosti Starost Age ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ D03 Melanom, in situ Melanoma, in situ M Ž 139 140 0 0 0 0 0 0 0 2 1 0 1 2 6 5 4 5 5 8 8 17 8 7 10 7 21 15 17 22 22 20 16 19 20 11 D05 Dojka, in situ Breast, in situ Ž 1 136 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 5 0 18 0 23 0 25 0 29 1 23 0 6 0 2 0 2 D06 Maternični vrat, in situ (CIN III) Cervix uteri, in situ (CIN III) Ž 1094 0 0 0 0 100 222 223 205 122 73 51 37 32 15 10 4 0 D09.0 Sečni mehur, in situ Bladder, in situ Ž 176 60 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 1 1 0 4 3 7 3 21 6 37 3 24 7 24 14 29 7 26 16 D32.0, D42.0 Meninge, benigna neoplazma in neoplazma negotovega značaja Benign neoplasm and neoplasm of uncertain behaviour of meninges Ž 34 95 0 0 0 0 0 0 0 0 1 0 0 0 1 0 2 5 1 3 2 5 0 14 3 9 3 8 5 13 4 11 8 10 4 17 D33.0-D33.2 Možgani, benigna neoplazma Benign neoplasm of brain Ž 2 1 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 D39.1 Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior Ž 52 0 0 0 0 0 2 5 5 5 6 2 9 5 1 3 3 6 D43.0-D43.2 Možgani, neopredeljeno CNS, uncertain or unknown Ž 14 7 0 0 1 1 0 0 2 0 0 0 1 0 0 1 1 0 0 0 0 0 1 0 0 0 1 1 0 0 2 0 3 0 2 4 59 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) po lokaciji in spolu, Slovenija 2016. Table 5: Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2016. Šifra MKB Primarna lokacija Spol Vse starosti Starost Age KS CR ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ 0-74 M+Ž 730,1 22,5 14,7 10,9 35,1 28,2 73,6 101,0 136,8 238,0 366,7 618,0 891,2 1414,0 1931,1 2420,8 2627,6 2770,7 41,5 C00-C96 Vse lokacije All sites M 792,8 21,9 12,5 8,4 37,0 30,2 64,2 88,5 94,5 161,8 290,6 625,4 923,9 1671,6 2410,2 3333,2 3651,0 3959,0 48,9 Ž 668,5 23,2 17,1 13,4 33,0 26,0 83,7 114,7 183,8 321,0 446,8 610,3 858,2 1156,2 1485,5 1681,5 1894,9 2222,7 35,3 C00 Ustnica Lip Ž 1,5 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,2 0 2,5 0 2,6 0 0 1,3 2,7 0 1,4 0 0 0 0 0 3,1 4,5 18,3 9,8 0,1 0,0 C01 Baza jezika 2,1 0 0 0 0 0 0 0 0 0 1,3 2,5 5,3 9,6 10,4 5,3 0 0 0,2 Base of tongue Ž 0,7 0 0 0 0 0 0 0 0 1,4 0 0 1,3 4,1 1,6 0 0 1,4 0,0 C02 Jezik, drugi deli Tongue, other & unspecified parts Ž 1,3 1,6 0 0 0 0 0 0 0 0 0 0 0 1,6 0 0 0 0 1.3 1.4 1,3 2,8 2,5 0 2,7 0 4,1 4,1 5,2 6,4 0 6,4 3,1 4,5 0 1,4 0,1 0,1 C03 Dlesen Gum Ž 0,6 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2,5 0 0 1,3 0 2,8 3,5 6,4 2,6 2,1 3.1 2.2 0 1,4 0,0 0,1 C04 Ustno dno Floor of mouth Ž 2,3 0,8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,8 0 2,6 0 3,8 2,6 2,7 0 13,8 2,8 3,5 3,2 0 2,1 3,1 0 3,1 1,4 0,2 0,1 C05 Nebo Palate Ž 1,0 0,7 0 0 0 0 0 0 0 0 0 0 0 1,6 0 0 0 1,3 0 1,4 0 0 2,5 1,3 1,3 0 2,8 4,1 6,9 0 0 0 3,1 0 0 0 0,1 0,0 C06 Usta, drugi deli Mouth, other & unspecified parts Ž 1,3 0,7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,4 1,3 0 3,8 1,3 1,3 0 5,5 2,8 6,9 1,6 0 2,1 0 0 0 1,4 0,1 0,0 C07 Parotidna žleza Parotid gland Ž 0,8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1,3 0 4,0 1,4 0 2,6 2,7 2,7 1,4 0 0 1,6 5,3 2,1 6,3 0 0 0 0,1 0,1 C08 Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands Ž 0,0 0,2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,4 0 0 0 0 0 0 0 0 0 0 0 0 0 1,4 0,0 0,0 C09 Tonzila Tonsil Ž 4,0 1,2 0 0 0 0 0 0 0 0 0 0 0 0 0 1,5 1,2 0 3,8 1,4 5.3 1.4 5,1 3,9 5,3 4,0 13,8 0 8,6 1,6 13,1 0 15,6 4,5 0 1,4 0,3 0,1 C10 Orofarinks Oropharynx Ž 3,9 0,4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,3 0 2,6 1,4 6,4 1,3 13,3 0 11,0 0 17,3 3,2 5,3 0 3,1 0 3,1 0 0,3 0,0 C11 Nazofarinks Nasopharynx Ž 0,8 0,1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,3 0 1,3 0 2,8 0 3.5 1.6 0 0 3,1 0 3,1 0 0,0 0,0 C12 Piriformni sinus Pyriform sinus Ž 3,1 0,1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4,0 1,4 6,4 0 9,3 0 6,9 0 6,9 0 2,6 0 15,6 0 6,1 0 0,2 0,0 C13 Hipofarinks 2,0 0 0 0 0 0 0 0 0 0 2,6 1,3 6,7 6,9 8,6 2,6 3,1 0 0,1 Hypopharynx Ž 0,3 0 0 0 0 0 0 0 0 0 1,4 0 1,3 0 0 2,1 0 0 0,0 C14 Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx Ž 0,0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0,0 C15 Požiralnik Oesophagus Ž 4,9 1,3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,2 0 1,3 0 5.3 1.4 6,4 1,3 9,3 4,0 17,9 1,4 12,1 0 15,8 6,4 6,3 2,2 12,2 5,6 0,3 0,1 C16 Želodec Stomach Ž 26,6 16,4 0 0 0 0 0 0 0 0 0 0 0 1,6 2,7 0 1,2 0 2,5 4,1 9,2 5,6 25,5 11,8 21,3 22,9 53,7 22,0 81,3 24,1 86,7 42,6 150,2 49,3 173,9 90,0 1,4 0,7 C17 Tanko črevo Small intestine Ž 2,4 1,8 0 0 0 0 0 0 0 0 1,9 0 0 0 0 0 0 1,3 0 4,1 0 1,4 7,6 0 2,7 0 2,8 4,1 1,7 6,4 13,1 2,1 12,5 9,0 12,2 2,8 0,1 0,1 C18 Debelo črevo Colon Ž 50,2 37,8 0 0 0 0 0 2,2 0 2,2 0 2,0 0 0 0 5,9 4,8 0 13,9 5,5 14,5 11,1 31.8 28.9 42,7 36,4 96,4 53,7 126,2 70,7 288,9 157,5 244,0 134,4 305,0 151,9 3,1 1,9 Nadaljevanje —> Continued —> 60 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost Age KS CR ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ 0-74 C19 Rektosigmoidna zveza M 6,3 0 0 0 0 0 0 0 1,2 0 5,3 6,4 6,7 15,1 10,4 26,3 34,4 33,6 0,4 Rectosigmoid junction Z 3,8 0 0 0 0 0 0 0 1,3 1,4 1,4 3,9 4,0 6,9 6,4 12,8 6,7 18,3 0,2 C20 Rektum Rectum M Z 28,6 15,8 0 0 0 0 0 0 0 0 0 0 1,5 0 2,7 0 2,4 1,3 6,3 4,1 13,2 7,0 24,2 10,5 54,7 17,5 60,6 20,7 79,5 40,2 123,5 68,1 125,1 44,8 109,8 59,1 1,8 0,8 C21 Anus in analni kanal Anus and anal canal M Z 1,0 1,1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,4 0 0 0 0 4,0 1,3 2,8 1,4 3,5 4,8 2,6 6,4 3,1 4,5 3,1 0 0,1 0,1 C22 Jetra in intrahepatics vodi Liver and intrahepatic bile ducts M Z 13,7 5,9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,3 0 1,3 0 11,5 3,9 14,7 5,4 22,0 9,6 57,1 16,1 57,8 19,2 68,8 24,6 76,3 23,9 0,8 0,3 C23 Žolčnik Gallbladder M Z 1,8 3,6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2,6 4,0 1,3 2,8 4,1 1,7 12,9 7,9 4,3 6,3 17,9 21,4 18,3 0,1 0,1 C24 Drugi in neopredeljeni deli biliarnega trakta M 8,0 0 0 0 0 0 0 0 0 0 1,3 2,5 9,3 13,8 25,9 31,5 56,3 51,9 0,4 Billiary tract, other and unspecified parts Z 5,8 0 0 0 0 0 0 1,5 1,3 0 1,4 3,9 5,4 4,1 3,2 19,2 20,2 38,0 0,2 C25 Trebušna slinavka Pancreas M Z 18,9 18,7 0 0 0 0 0 0 0 0 0 0 0 0 2,7 0 0 0 1.3 1.4 6,6 9,7 14,0 6,6 14,7 16,2 38,6 27,6 62,2 40,2 91,9 68,1 103,2 62,7 97,6 91,4 1,2 0,8 C26 Druga in slabo opredeljena mesta v prebavnih organih M 0,1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,1 0,0 Other and ill-defined digestive organs Z 0,3 0 0 0 0 0 0 0 0 0 0 0 0 2,8 0 0 0 1,4 0,0 C30 Nosna votlina in srednje uho M 0,2 0 0 0 0 0 0 0 0 0 0 0 0 1,4 0 2,6 0 0 0,0 Nasal cavity and middle ear Z 0,5 0 0 0 0 0 0 0 0 0 0 0 1,3 0 1,6 0 2,2 2,8 0,0 C31 Obnosni sinusi Accessory sinuses M Z 0,2 0,2 0 0 0 0 0 0 0 2,2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,4 0 1,7 0 0 0 0 0 0 1,4 0,0 0,0 C32 Grlo Larynx M Z 9,0 1,6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,2 0 0 0 2,6 0 10,2 1,3 21,3 4,0 26,2 4,1 31,1 8,0 26,3 6,4 25,0 4,5 30,5 0 0,6 0,1 C33 Sapnik Trachea M Z 0,0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0,0 C34 Sapnica in pljuča M 94,3 0 0 0 2,1 0 0 1,3 2,4 8,8 17,2 79,0 150,6 249,2 335,4 362,5 384,8 399,6 6,0 Bronchus and lung Z 53,3 0 0 0 0 0 1,6 1,5 1,3 1,4 15,3 39,4 102,6 144,7 173,6 140,5 143,4 128,0 3,1 C37 Timus Thymus M Z 0,5 0,7 0 0 0 0 0 0 0 0 0 0 0 0 0 1,5 0 0 0 0 1.3 1.4 0 0 1,3 1,3 0 0 3,5 4,8 2,6 2,1 0 0 0 0 0,0 0,1 C38 Srce, mediastinum, plevra Heart, mediastinum, pleura M Z 0,4 0,3 0 1,9 0 0 0 0 0 0 0 0 0 0 1,3 0 0 0 0 0 0 0 0 0 0 0 0 0 1,7 0 2,6 0 3,1 4,5 0 0 0,0 0,0 C39 Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs M Z 0,0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0,0 C40 Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs M Z 0,5 0,5 0 0 1,8 0 0 0 6,2 0 0 0 0 0 0 0 0 0 1.3 1.4 0 1,4 0 1,3 0 1,3 0 1,4 0 0 0 0 0 0 0 0 0,0 0,0 61 Nadaljevanje —> Continued —> Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost Age KS CR ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ 0-74 C41 Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts M Ž 0,5 0,4 1,8 0 0 0 0 0 0 0 0 0 1,5 0 0 0 2,4 0 0 0 1,3 0 0 0 0 0 0 2,8 0 0 0 2,1 0 0 0 1,4 0,0 0,0 C43 Maligni melanom kože Malignant melanoma of skin M Ž 29,7 26,5 0 0 0 0 0 2,2 2,1 0 1,9 2,0 9,2 14,8 20,1 17,6 10,9 10,7 11,4 31,7 25,1 22,3 36,9 40,7 30,7 39,1 57,8 34,5 65,7 53,1 97,2 40,4 112,6 47,0 119,0 67,5 1,8 1,5 C44 Druge maligne neoplazme kože Skin, other malignomas M Ž 145,6 140,2 0 0 0 1,9 0 0 2,1 0 0 2,0 9,2 13,1 8,0 10,3 27,9 34,9 32,9 64,7 56,8 75,2 107,0 91,9 124,0 132,2 224,4 197,1 359,6 265,3 598,9 321,4 794,6 470,4 1085,8 672,4 7,8 6,0 C45 Mezoteliom Mesothelioma M Ž 2,8 1,3 0 0 0 0 0 0 0 0 1,9 0 0 0 0 0 0 0 1,3 0 0 1,4 1,3 0 1,3 2,7 5,5 4,1 10,4 4,8 15,8 4,3 25,0 6,7 3,1 0 0,2 0,1 C46 Kaposijev sarkom Kaposi's sarcoma M Ž 0,1 0,1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3.1 2.2 0 0 0,0 0,0 C47 Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system M Ž 0,2 0,2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,3 0 1,3 0 0 2,7 0 0 0 0 0 0 0 0 0 0 0,0 0,0 C48 Peritonej in retroperitonej Peritoneum and retroperitoneum M Ž 0,6 1,3 1,8 3,9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,3 0 0 0 0 0 0 1,3 2,8 1,4 1,7 6,4 0 4,3 0 4,5 3,1 2,8 0,0 0,1 C49 Drugo vezivno in mehko tkivo Other connective and soft tissue M Ž 2,3 3,1 3.7 5.8 3,6 0 0 0 0 2,2 0 0 0 3,3 2,7 1,5 0 1,3 1.3 1.4 1,3 4,2 1,3 2,6 1,3 4,0 4,1 4,1 3,5 6,4 13,1 2,1 9.4 4.5 3,1 7,0 0,2 0,2 C50 Dojka Breast M Ž 1,4 133,2 0 0 0 0 0 0 0 0 0 2,0 0 13,1 0 20,6 0 67,1 0 103,3 0 161,5 0 211,3 1,3 197,0 2,8 289,4 6,9 307,1 0 274,6 9,4 293,4 12,2 216,6 0,1 8,2 C51 Žensko zunanje spolovilo Vulva M Ž 5,5 0 0 0 0 0 0 1,5 1,3 0 1,4 2,6 9,4 5,5 1,6 12,8 24,6 32,4 0,2 C52 Nožnica Vagina M Ž 1,3 0 0 0 0 0 1,6 0 0 0 1,4 2,6 1,3 2,8 1,6 4,3 4,5 2,8 0,1 C53 Maternični vrat Cervix uteri M Ž 11,8 0 0 0 0 0 4,9 11,8 17,4 23,4 19,5 11,8 18,9 16,5 16,1 14,9 11,2 15,5 0,8 C54 Maternično telo Corpus uteri M Ž 34,7 0 0 0 0 0 0 2,9 5,4 9,6 27,8 24,9 71,5 71,7 98,1 72,4 116,5 80,2 1,9 C55 Maternica, neopredeljeno Uterus, unspecified M Ž 1,7 0 0 0 0 0 0 0 1,3 2,8 0 2,6 0 1,4 8,0 2,1 2,2 7,0 0,1 C56 Jajčnik Ovary M Ž 12,4 0 0 0 0 0 1,6 0 1,3 6,9 9,7 21,0 20,2 20,7 28,9 31,9 35,8 28,1 0,7 C57 Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs M Ž 1,8 0 0 0 0 0 0 0 1,3 0 0 1,3 2,7 1,4 6,4 2,1 6,7 8,4 0,1 C58 Posteljica Placenta M Ž 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 C60 Penis Penis M Ž 1,7 0 0 0 0 0 0 0 1,2 0 1,3 1,3 2,7 1,4 3,5 2,6 21,9 3,1 0,1 Nadaljevanje —> Continued —> 62 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost Age KS CR ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ 0-74 C61 Prostata Prostate M Ž 165,1 0 0 0 0 0 0 0 0 0 18,5 76,4 169,3 432,4 681,2 903,6 791,5 561,2 11,4 C62 Modo Testis M Ž 10,5 0 0 0 4,1 15,1 24,4 29,5 8,5 25,3 15,9 15,3 6,7 2,8 0 2,6 0 0 0,8 C63 Drugi in neopredeljeni moški spolni organi M 0,3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2,6 3,1 3,1 0,0 Other and unspecified male genital organs Ž Ledvica razen meha M 22,3 0 0 0 0 0 0 1,3 3,6 6,3 5,3 26,7 42,7 48,2 60,5 97,2 84,5 85,4 1,5 C64 Kidney, except renal pelvis Ž 12,6 0 0 0 0 0 0 0 2,7 1,4 4,2 11,8 10,8 19,3 25,7 57,5 44,8 43,6 0,7 C65 Ledvični meh Renal pelvis M Ž 2,1 1,1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2,6 0 0 0 0 1,3 5,5 0 10,4 0 5.3 6.4 12,5 2,2 12,2 8,4 0,1 0,0 C66 Sečevod Ureter M Ž 1,5 0,5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2,7 0 0 0 6,9 3,2 7,9 4,3 3,1 0 15,3 1,4 0,1 0,0 C67 Sečni mehur Bladder M Ž 24,6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2,5 0 10,6 4,2 16,6 2,6 21,3 10,8 50,9 17,9 64,0 28,9 107,7 27,7 122,0 38,1 180,0 57,7 1,4 0,5 C68 Drugi in neopredeljeni sečni organi M 0,2 0 0 0 0 0 0 0 0 0 0 0 0 0 1,7 0 3,1 0 0,0 Other and unspecified urinary organs Ž 0,1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,4 0,0 C69 Oko in očesni adneksi Eye and adnexa M Ž 1,0 1,1 1,8 1,9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,3 0 1,3 0 2,5 1,3 2,7 1,3 0 0 0 1,6 0 2,1 6,3 6,7 3.1 4.2 0,0 0,0 C70 Meninge Meninges M Ž 0,2 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,7 0 2,6 0 0 0 0 0 0,0 0,0 C71 Možgani M 9,5 5,5 3,6 4,2 6,2 0 1,5 2,7 2,4 3,8 7,9 11,5 9,3 17,9 19,0 31,5 28,2 36,6 0,6 Brain Ž 5,3 1,9 3,8 0 0 4,0 0 2,9 2,7 2,8 2,8 3,9 8,1 6,9 8,0 17,0 17,9 9,8 0,3 C72 Hrbtni mozeg, možganski živci in drugi deli CŽS M 0,3 1,8 0 0 0 1,9 0 0 1,2 0 0 0 0 0 0 0 0 0 0,0 Spinal cord, cranial nerves and other parts of CNS Ž 0,5 0 1,9 0 2,2 0 0 1,5 0 1,4 0 0 1,3 0 0 0 0 0 0,0 C73 Ščitnica Thyroid gland M Ž 3,5 16,0 0 0 0 0 0 6,7 0 11,0 0 4,0 3,1 11,5 1,3 14,7 4,8 14,8 6,3 22,0 4,0 11,1 3,8 13,1 6,7 20,2 4,1 37,2 8,6 32,2 5,3 31,9 6,3 20,2 3,1 11,3 0,2 1,2 C74 Nadledvična žleza Adrenal gland M Ž 0,4 0,6 1,8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.3 1.4 0 1,4 1,3 1,3 0 1,3 0 0 1,7 1,6 0 2,1 0 0 0 0 0,0 0,0 C75 Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures M Ž 0,1 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,3 0 0 0 0 0 0 0 0 0 0 0 0,0 0,0 C76 Druga in slabo opredeljena mesta M 0,3 0 0 0 0 0 0 0 0 0 0 0 1,3 0 0 0 3,1 3,1 0,0 Other and ill-defined sites Ž 1,7 0 0 0 0 0 0 0 0 0 1,4 1,3 1,3 2,8 1,6 4,3 2,2 12,7 0,1 C77 Metastaza in neopredeljena maligna neoplazma bezgavk M 2,0 0 0 0 0 0 0 0 0 0 0 1,3 4,0 6,9 10,4 2,6 0 12,2 0,1 Metastasis and unspecified malignant neoplasm of lymph nodes Ž 1,6 0 0 0 0 0 0 0 0 0 1,4 0 1,3 2,8 4,8 0 2,2 12,7 0,1 63 Nadaljevanje —> Continued —> Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost Age KS CR ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ 0-74 C78 Metastaze dihal in prebavil Metastases of respiratory and digestive organs M Ž 3,6 3,9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,3 0 0 0 1,4 0 0 1,3 1,3 2,8 0 5,2 3,2 23,6 12,8 34,4 9,0 33,6 36,6 0,2 0,1 C79 Metastaze, drugje Metastases of other sites M Ž 1,5 1,2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,4 1,3 0 1,3 1,3 2,7 0 4,1 2,8 1.7 4.8 0 2,1 0 0 21,4 7,0 0,1 0,1 C80 Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site M Ž 6,7 6,3 0 0 0 0 0 0 0 0 0 0 0 3,3 1,3 0 1,2 0 0 0 1,3 2,8 6,4 2,6 9,3 8,1 22,0 6,9 17,3 8,0 28,9 8,5 18,8 22,4 33,6 42,2 0,4 0,2 C81 Hodgkinova bolezen Hodgkin's disease M Ž 2,9 2,8 0 0 0 1,9 2,1 2,2 8,2 6,6 0 6,0 1,5 4,9 2.7 8.8 4,8 4,0 2,5 1,4 4,0 0 2,5 1,3 2,7 0 8,3 2,8 1,7 1,6 2,6 2,1 3.1 2.2 0 2,8 0,2 0,2 C82 Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma M Ž 5,9 5,5 0 0 0 0 0 0 2,1 2,2 0 0 1,5 0 2,7 1,5 0 1,3 5,1 2,8 0 2,8 7,6 3,9 8,0 9,4 8,3 13,8 19,0 20,9 21,0 10,6 34,4 13,4 12,2 8,4 0,4 0,3 C83 Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma M Ž 15,5 11,7 0 0 1,8 0 0 0 0 2,2 1,9 2,0 7,6 0 1.3 4.4 6,1 2,7 2,5 2,8 9,2 4,2 10,2 5,2 22.7 14.8 22,0 15,2 51,9 32,2 55,2 46,8 56,3 33,6 82,4 38,0 1,0 0,7 C84 Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas M Ž 1,9 1,5 0 0 1,8 0 0 0 0 0 0 0 0 0 0 0 1,2 0 1,3 0 1,3 4,2 2,5 1,3 4,0 2,7 1,4 4,1 5,2 3,2 2,6 0 12,5 2,2 3,1 5,6 0,1 0,1 C85 Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma M Ž 0,4 1,0 0 0 0 0 0 0 0 0 1,9 0 0 0 0 0 0 0 1.3 1.4 0 0 0 0 0 1,3 0 1,4 1,7 0 0 6,4 3,1 4,5 0 2,8 0,0 0,1 C88 Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases M Ž 0,5 0,3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,3 0 1,4 0 0 1,6 2,6 2,1 0 0 6,1 1,4 0,0 0,0 C90 Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms M Ž 8,0 4,5 0 0 0 0 0 0 0 0 0 0 1,5 0 0 0 0 0 1,3 0 2,6 1,4 7,6 6,6 9.3 5.4 13,8 4,1 22,5 8,0 34,1 23,4 34,4 15,7 54,9 15,5 0,5 0,2 C91.0 Limfatična levkemija, akutna Lymphoblastic leukaemia, acute M Ž 0,7 1,8 5,8 0 7,6 2,1 0 2,1 0 1,9 0 0 0 1,3 0 0 0 0 0 0 0 1,3 0 0 1,3 1,4 1,4 0 0 0 0 0 2,2 0 1,4 0,1 0,1 C91.1 C91.9 Limfatična levkemija, druga Lymphoid leukaemia, other M Ž 7,4 5,4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5,3 2,8 10,2 2,6 6,7 5,4 12,4 11,0 24,2 17,7 23,6 17,0 37,5 9,0 45.8 23.9 0,4 0,3 C92 Mieloična levkemija Myeloid leukaemia M Ž 6,3 5,0 1,8 1,9 0 0 0 0 2,1 2,2 1,9 0 0 3,3 2,7 1,5 0 0 1,3 0 2,6 1,4 5,1 3,9 5,3 4,0 9,6 12,4 10,4 8,0 15,8 8,5 37,5 13,4 54,9 22,5 0,3 0,2 C93 Monocitna levkemija Monocytic leukaemia M Ž 0,4 0,2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2,6 0 0 4,5 9,2 0 0,0 0,0 Nadaljevanje —> Continued —> 64 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 8: Nadaljevanje. Table 8: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost Age KS CR ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ 0-74 C94 Druge opredeljene levkemije M 1,7 0 0 0 0 0 0 0 1,2 1,3 4,0 1,3 1,3 4,1 1,7 10,5 3,1 3,1 0,1 Other leukaemias of specified cells Ž 1,4 0 0 0 0 0 0 0 0 1,4 1,4 0 1,3 0 1,6 4,3 11,2 5,6 0,0 C95 Levkemija z neopredeljenim celičnim tipom M 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 Leukaemia, unspecified cell type Ž 0,1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2,1 0 0 0,0 C96 Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva M 8,4 0 0 0 0 0 1,5 0 0 0 0 7,6 8,0 8,3 13,8 34,1 50,1 91,5 0,4 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue Ž 10,0 0 0 0 0 2,0 1,6 1,5 2,7 5,5 5,6 2,6 5,4 11,0 22,5 19,2 40,3 50,6 0,4 Zgoraj neupoštevani Not included above Šifra MKB Primarna lokacija Spol Vse starosti Starost Age KS CR ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ 0-74 D03 Melanom, in situ Melanoma, in situ M Ž 13,6 13,5 0 0 0 0 0 0 0 4,4 1,9 0 1,5 3,3 8,0 7,4 4,8 6,7 6,3 11,0 10,6 23,7 10,2 9,2 13,3 9,4 28,9 20,7 29,4 35,4 57,8 42,6 50,1 42,6 61,0 15,5 0,9 0,9 D05 Dojka, in situ Breast, in situ M Ž 0,1 13,1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4,0 0 6,9 0 25,1 0 30,2 0 33,7 0 40,0 1,7 37,0 0 12,8 0 4,5 0 2,8 0,0 0,9 D06 Maternični vrat, in situ (CIN III) M Cervix uteri, in situ (CIN III) Ž 105,2 0 0 0 0 200,0 364,5 327,9 275,0 168,1 101,6 66,9 49,9 44,1 24,1 21,3 9,0 0 8,2 D09.0 Sečni mehur, in situ Bladder, in situ M Ž 17,2 5,8 0 0 0 0 0 0 0 0 0 0 1,5 0 1,3 0 1,2 1,3 1,3 0 5,3 4,2 8,9 3,9 28,0 8,1 50,9 4,1 41,5 11,3 63,0 29,8 90,7 15,7 79,3 22,5 1,0 0,3 D32.0, D42.0 Meninge, benigna neoplazma in neoplazma negotovega značaja Benign neoplasm and neoplasm of uncertain behaviour of meninges M Ž 3,3 9,1 0 0 0 0 0 0 0 0 1,9 0 0 0 1,3 0 2,4 6,7 1,3 4,1 2,6 7,0 0 18,4 4,0 12,1 4,1 11,0 8,6 20,9 10,5 23,4 25,0 22,4 12,2 23,9 0,2 0,5 D33.0 Možgani, benigna neoplazma M 0,2 0 0 2,1 0 0 0 0 0 0 0 0 0 1,4 0 0 0 0 0,0 D33.2 Benign neoplasm of brain Ž 0,1 1,9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 D39.1 Jajčnik, neopl. negotovega značaja Ovary, neopl. of uncertain behavior M Ž 5,0 0 0 0 0 0 3,3 7,4 6,7 6,9 8,4 2,6 12,1 6,9 1,6 6,4 6,7 8,4 0,3 D43.0 -43.2 Možgani, neopredeljeno CNS, uncertain or unknown M Ž 1,4 0,7 0 0 1,8 1,9 0 0 4,1 0 0 0 1,5 0 0 1,5 1,2 0 0 0 0 0 1,3 0 0 0 1,4 1,4 0 0 5,3 0 9,4 0 6,1 5,6 0,1 0,0 65 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 6a: Incidenca po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2016. Table 6a: Incidence by statistical regions, by sex and by selected primary cancer site, Slovenia 2016. Statistična regija / Statistical region Šifra MKB ICD code Primarna lokacija Primary site Spol Sex ru o__ 3 ru a 1 'šE Continued —> 68 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Histološka vrsta Histologic type Skupaj All sites Primarna lokacija (šifra MKB) Primary site (ICD code) C00-C96 C10 C11 C12 C13 C14 C15 C16 C17 C18 C19 H C H C H C H C H C H C H C H C H C H C H C Vse vrste/All types 13699 638 44 0 8 1 33 0 23 0 0 0 59 2 427 3 44 0 864 3 103 0 Small cell carcinoma 192 59 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 Non-small cell carcinoma 71 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1459 68 43 0 7 1 33 0 23 0 0 0 43 1 4 0 0 0 0 0 0 0 Basal cell carcinoma 2446 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 383 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 6724 274 0 0 0 0 0 0 0 0 0 0 15 1 385 2 26 0 857 1 101 0 Other specified carcinomas 135 4 1 0 0 0 0 0 0 0 0 0 0 0 4 0 2 0 2 0 1 0 Carcinoma, unspecified 76 115 0 0 0 0 0 0 0 0 0 0 0 0 11 0 1 0 5 2 1 0 Malignant thymoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 616 7 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrosarcoma 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Rhabdomyosarcoma 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 6 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 21 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 72 1 0 0 0 0 0 0 0 0 0 0 0 0 22 1 15 0 0 0 0 0 Malignat fibroepithelial tumors 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 40 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 73 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 130 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Non Hodgkin lymphoma 426 29 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Hodgkin lymphoma 58 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Plasma cell tumors 126 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic lymphoid leukemia 115 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leukemia except chronic lymphoid 151 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other lymphoreticular neoplasms 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic myeloproliferative diseases 123 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Myelodysplastic syndromes 94 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 5 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 69 Nadaljevanje —> Continued —> Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Histološka vrsta Histologic type Skupaj All sites Primarna lokacija (šifra MKB) Primary site (ICD code) C00-C96 C20 C21 C22 C23 C24 C25 C26 C30 C31 C32 H C H C H C H C H C H C H C H C H C H C H C Vse vrste/All types 13699 638 446 2 21 0 97 21 36 1 81 5 189 66 2 0 7 0 4 0 109 0 Small cell carcinoma 192 59 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Non-small cell carcinoma 71 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1459 68 1 0 18 0 0 0 1 0 0 0 0 0 0 0 3 0 2 0 104 0 Basal cell carcinoma 2446 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 383 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 6724 274 436 1 3 0 96 19 29 0 76 4 176 58 1 0 0 0 0 0 1 0 Other specified carcinomas 135 4 0 0 0 0 0 0 3 0 3 0 4 0 0 0 0 0 1 0 2 0 Carcinoma, unspecified 76 115 7 1 0 0 0 2 2 1 2 1 8 8 0 0 0 0 0 0 2 0 Malignant thymoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 616 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 Fibrosarcoma 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 13 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Rhabdomyosarcoma 12 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 Synovial sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 21 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 72 1 1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 Malignat fibroepithelial tumors 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 40 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 73 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 130 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Non Hodgkin lymphoma 426 29 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Hodgkin lymphoma 58 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Plasma cell tumors 126 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic lymphoid leukemia 115 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leukemia except chronic lymphoid 151 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other lymphoreticular neoplasms 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic myeloproliferative diseases 123 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Myelodysplastic syndromes 94 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 5 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Nadaljevanje —> Continued —> 70 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Histološka vrsta Histologic type Skupaj All sites Primarna lokacija (šifra MKB) Primary site (ICD code) C00-C96 C33 C34 C37 C38 C39 C40 C41 C43 C44 C45 H C H C H C H C H C H C H C H C H C H C H C Vse vrste/All types 13699 638 0 0 1160 226 12 0 5 1 0 0 10 0 9 0 577 3 2885 61 40 3 Small cell carcinoma 192 59 0 0 180 56 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Non-small cell carcinoma 71 24 0 0 68 23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1459 68 0 0 347 25 2 0 0 1 0 0 0 0 0 0 0 0 421 28 0 0 Basal cell carcinoma 2446 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2439 30 0 0 Transitional cell carcinoma 383 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 6724 274 0 0 535 105 0 0 0 0 0 0 0 0 0 0 0 0 13 0 0 0 Other specified carcinomas 135 4 0 0 25 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Carcinoma, unspecified 76 115 0 0 3 15 0 0 0 0 0 0 0 0 0 0 0 0 1 3 0 0 Malignant thymoma 10 0 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 616 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 577 3 0 0 0 0 Fibrosarcoma 8 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 Liposarcoma 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 Rhabdomyosarcoma 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 6 0 0 0 1 0 0 0 2 0 0 0 0 0 0 0 0 0 1 0 0 0 Kaposi sarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 5 0 1 0 0 0 0 0 0 0 Chondrosarcoma 9 0 0 0 0 0 0 0 0 0 0 0 3 0 5 0 0 0 0 0 0 0 Ewing sarcoma/PNET 6 0 0 0 0 0 0 0 0 0 0 0 2 0 3 0 0 0 0 0 0 0 Other specified sarcomas 6 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 21 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 Malignant complex mixed and stromal tumors 72 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignat fibroepithelial tumors 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 40 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 40 3 Malignant gonadal stromal tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 73 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 130 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Non Hodgkin lymphoma 426 29 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Hodgkin lymphoma 58 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Plasma cell tumors 126 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic lymphoid leukemia 115 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leukemia except chronic lymphoid 151 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other lymphoreticular neoplasms 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic myeloproliferative diseases 123 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Myelodysplastic syndromes 94 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 5 6 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 71 Nadaljevanje —> Continued —> Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Histološka vrsta Histologic type Skupaj All sites Primarna lokacija (šifra MKB) Primary site (ICD code) C00-C96 C46 C47 C48 C49 C50 C51 C52 C53 C54 C55 H C H C H C H C H C H C H C H C H C H C H C Vse vrste/All types 13699 638 2 0 4 0 19 0 54 1 1312 81 57 0 14 0 123 0 360 0 15 0 Small cell carcinoma 192 59 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Non-small cell carcinoma 71 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1459 68 0 0 0 0 0 0 0 0 0 0 43 0 13 0 99 0 0 0 0 0 Basal cell carcinoma 2446 30 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 383 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 6724 274 0 0 0 0 9 0 0 0 1294 34 3 0 1 0 16 0 301 0 0 0 Other specified carcinomas 135 4 0 0 0 0 0 0 0 0 12 0 0 0 0 0 5 0 43 0 1 0 Carcinoma, unspecified 76 115 0 0 0 0 0 0 0 0 6 47 2 0 0 0 0 0 0 0 0 0 Malignant thymoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 3 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 616 7 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 Fibrosarcoma 8 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 1 0 Fibrohistiocytic sarcoma 5 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 17 0 0 0 0 0 6 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 13 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 4 0 Rhabdomyosarcoma 12 0 0 0 0 0 1 0 6 0 0 0 0 0 0 0 1 0 0 0 2 0 Synovial sarcoma 5 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 6 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 2 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 9 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 6 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 6 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 21 1 0 0 0 0 0 0 14 1 0 0 0 0 0 0 0 0 0 0 3 0 Malignant complex mixed and stromal tumors 72 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2 0 16 0 4 0 Malignat fibroepithelial tumors 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 40 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 73 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 28 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 130 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 3 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Non Hodgkin lymphoma 426 29 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Hodgkin lymphoma 58 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Plasma cell tumors 126 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic lymphoid leukemia 115 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leukemia except chronic lymphoid 151 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other lymphoreticular neoplasms 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic myeloproliferative diseases 123 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Myelodysplastic syndromes 94 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 5 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Nadaljevanje —> Continued —> 72 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Histološka vrsta Histologic type Skupaj All sites Primarna lokacija (šifra MKB) Primary site (ICD code) C00-C96 C56 C57 C58 C60 C61 C62 C63 C64 C65 C66 H C H C H C H C H C H C H C H C H C H C H C Vse vrste/All types 13699 638 118 7 15 3 0 0 17 0 1640 2 107 0 3 0 314 11 27 3 17 0 Small cell carcinoma 192 59 1 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 1 0 0 Non-small cell carcinoma 71 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1459 68 1 0 0 0 0 0 17 0 0 0 0 0 1 0 0 0 0 0 0 0 Basal cell carcinoma 2446 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 383 7 0 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 27 1 17 0 Adenocarcinoma 6724 274 107 3 12 3 0 0 0 0 1627 2 0 0 1 0 310 9 0 0 0 0 Other specified carcinomas 135 4 5 0 2 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 Carcinoma, unspecified 76 115 0 4 1 0 0 0 0 0 2 0 0 0 0 0 4 2 0 1 0 0 Malignant thymoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 616 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrosarcoma 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 17 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 Leiomyosarcoma 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Rhabdomyosarcoma 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 21 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 72 1 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignat fibroepithelial tumors 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 40 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 73 0 1 0 0 0 0 0 0 0 0 0 70 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 28 0 0 0 0 0 0 0 0 0 0 0 26 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 11 0 0 0 0 0 0 0 0 0 0 0 10 0 0 0 0 0 0 0 0 0 Malignant gliomas 130 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Non Hodgkin lymphoma 426 29 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Hodgkin lymphoma 58 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Plasma cell tumors 126 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic lymphoid leukemia 115 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leukemia except chronic lymphoid 151 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other lymphoreticular neoplasms 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic myeloproliferative diseases 123 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Myelodysplastic syndromes 94 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 5 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 73 Nadaljevanje —> Continued —> Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Histološka vrsta Histologic type Skupaj All sites Primarna lokacija (šifra MKB) Primary site (ICD code) C00-C96 C67 8 6 C C69 C70 C71 C72 C73 C74 C75 C76 H C H C H C H C H C H C H C H C H C H C H C Vse vrste/All types 13699 638 342 14 3 0 20 0 2 0 127 0 6 0 192 10 10 0 1 0 7 2 Small cell carcinoma 192 59 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Non-small cell carcinoma 71 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1459 68 5 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Basal cell carcinoma 2446 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 383 7 332 6 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 6724 274 3 0 0 0 0 0 0 0 0 0 0 0 187 5 7 0 0 0 5 2 Other specified carcinomas 135 4 1 0 0 0 1 0 0 0 0 0 0 0 4 3 0 0 0 0 0 0 Carcinoma, unspecified 76 115 1 7 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 Malignant thymoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 Malignant melanoma 616 7 0 0 0 0 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrosarcoma 8 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Rhabdomyosarcoma 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 21 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 72 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignat fibroepithelial tumors 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 40 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 73 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 28 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 130 0 0 0 0 0 0 0 0 0 124 0 6 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 1 0 0 0 2 0 0 0 0 0 1 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Non Hodgkin lymphoma 426 29 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Hodgkin lymphoma 58 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Plasma cell tumors 126 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic lymphoid leukemia 115 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leukemia except chronic lymphoid 151 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other lymphoreticular neoplasms 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic myeloproliferative diseases 123 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Myelodysplastic syndromes 94 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 Malignant tumor, unspecified 5 6 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 Nadaljevanje —> Continued —> 74 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Histološka vrsta Histologic type Skupaj All sites Primarna lokacija (šifra MKB) Primary site (ICD code) C00-C96 C77 C78 C79 C80 C81 C82 C83 C84 C85 C88 H C H C H C H C H C H C H C H C H C H C H C Vse vrste/All types 13699 638 28 6 27 20 17 2 71 32 58 1 114 3 257 24 35 0 12 2 8 0 Small cell carcinoma 192 59 0 0 2 0 1 0 4 2 0 0 0 0 0 0 0 0 0 0 0 0 Non-small cell carcinoma 71 24 0 0 0 0 1 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1459 68 15 4 0 0 2 1 4 0 0 0 0 0 0 0 0 0 0 0 0 0 Basal cell carcinoma 2446 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 383 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 6724 274 6 1 20 10 9 0 39 14 0 0 0 0 0 0 0 0 0 0 0 0 Other specified carcinomas 135 4 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 Carcinoma, unspecified 76 115 2 1 4 9 0 1 10 8 0 0 0 0 0 0 0 0 0 0 0 0 Malignant thymoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 616 7 3 0 1 0 3 0 7 4 0 0 0 0 0 0 0 0 0 0 0 0 Fibrosarcoma 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Rhabdomyosarcoma 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 5 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 21 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 72 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignat fibroepithelial tumors 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 40 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 73 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 11 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 130 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Non Hodgkin lymphoma 426 29 0 0 0 0 0 0 0 0 0 0 114 3 257 24 35 0 12 2 8 0 Hodgkin lymphoma 58 1 0 0 0 0 0 0 0 0 58 1 0 0 0 0 0 0 0 0 0 0 Plasma cell tumors 126 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic lymphoid leukemia 115 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leukemia except chronic lymphoid 151 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other lymphoreticular neoplasms 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chronic myeloproliferative diseases 123 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Myelodysplastic syndromes 94 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 5 6 1 0 0 1 0 0 1 2 0 0 0 0 0 0 0 0 0 0 0 0 75 Nadaljevanje —> Continued —> Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Histološka vrsta Histologic type Skupaj All sites Primarna lokacija (šifra MKB) Primary site (ICD code) C00-C96 C90 C91 C92 C93 C94 C95 C96 H C H C H C H C H C H C H C H C Vse vrste/All types 13699 638 126 3 145 2 114 3 6 0 31 0 1 0 189 1 Small cell carcinoma 192 59 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Non-small cell carcinoma 71 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1459 68 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Basal cell carcinoma 2446 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 383 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 6724 274 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified carcinomas 135 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Carcinoma, unspecified 76 115 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant thymoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 616 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrosarcoma 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Rhabdomyosarcoma 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 21 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 72 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignat fibroepithelial tumors 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 40 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 73 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 130 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Non Hodgkin lymphoma 426 29 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Hodgkin lymphoma 58 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Plasma cell tumors 126 3 126 3 0 0 0 0 0 0 0 0 0 0 0 0 Chronic lymphoid leukemia 115 2 0 0 115 2 0 0 0 0 0 0 0 0 0 0 Leukemia except chronic lymphoid 151 3 0 0 30 0 114 3 6 0 0 0 1 0 0 0 Other lymphoreticular neoplasms 3 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 Chronic myeloproliferative diseases 123 0 0 0 0 0 0 0 0 0 31 0 0 0 92 0 Myelodysplastic syndromes 94 1 0 0 0 0 0 0 0 0 0 0 0 0 94 1 Other specified malignant tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 5 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 76 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 8: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2016. Table 8: Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2016. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število novih primerov Number of new cases Stadij Omejen Razširjen Razsejan Neznan Število %* Število %* Število %* Število %* Stage Localized Regional Distant Unknown Number %* Number %* Number %* Number %* C00 C80 Vse lokacije All sites M+Z M Z 13904 7491 6413 7774 4134 3640 55,9 55,2 56,7 3542 1921 1621 25.5 25.6 25,3 2403 1334 1069 17,3 17,8 16,7 185 102 83 1.3 1.4 1,3 C00 Ustnica Lip Z 15 10 14 9 93,3 1 1 6,7 0 0 0 0 0 0 C01 Baza jezika Base oftongue Z 22 7 2 1 9,1 19 6 86,4 1 0 4,5 0 0 0 C02 Jezik, drugi deli Tongue, other & unspecified parts Z 13 17 8 11 64,7 5 6 35,3 0 0 0 0 0 0 C03 Dlesen Gum Z 6 10 1 2 - 5 8 0 0 - 0 0 - C04 Ustno dno Floor of mouth Z 24 8 4 4 16,7 20 4 83,3 0 0 0 0 0 0 C05 Nebo Palate Z 10 7 5 2 - 4 5 - 1 0 - 0 0 - C06 Usta, drugi deli Mouth, other & unspecified parts Z 13 7 4 3 - 8 4 - 1 0 - 0 0 - C07 Parotidna žleza Parotid gland Z 11 8 7 7 - 3 1 - 1 0 - 0 0 - C08 Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands Z 0 2 0 0 - 0 2 - 0 0 - 0 0 - C09 Tonzila Tonsil Z 41 13 9 3 22,0 29 10 70,7 3 0 7,3 0 0 0 C10 Orofarinks Oropharynx Z 40 4 2 0 5,0 37 4 92,5 1 0 2,5 0 0 0 C11 Nazofarinks Nasopharynx Z 8 1 0 0 - 6 1 - 2 0 - 0 0 - C12 Piriformni sinus Pyriform sinus Z 32 1 2 0 6,3 29 1 90,6 1 0 3,1 0 0 0 C13 Hipofarinks Hypopharynx Z 20 3 1 0 5,0 17 3 85,0 2 0 10,0 0 0 0 C14 Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx Z 0 0 0 0 - 0 0 - 0 0 - 0 0 - C15 Požiralnik Oesophagus Z 50 14 7 2 14,0 22 5 44,0 19 5 38,0 2 2 4,0 C16 Želodec Stomach Z 272 170 52 37 19,1 21,8 111 76 40,8 44,7 103 49 37,9 28,8 6 8 2,2 4,7 C17 Tanko črevo Small intestine Z 25 19 10 7 40,0 36,8 7 9 28,0 47,4 8 3 32,0 15,8 0 0 0 0 C18 Debelo črevo Colon Z 514 390 131 87 25,5 22,3 268 218 52,1 55,9 109 80 21,2 20,5 6 5 1,2 1,3 C19 Rektosigmoidna zveza Rectosigmoid junction Z 64 40 13 7 20,3 17,5 30 28 46,9 70,0 20 5 31,3 12,5 1 0 1,6 0 C20 Rektum Rectum Z 293 164 74 38 25,3 23,2 167 84 57,0 51,2 50 37 17,1 22,6 2 5 0,7 3,0 C21 Anus in analni kanal Anus and anal canal Z 10 11 2 4 7 6 1 1 - 0 0 C22 Jetra in intrahepatični vodi Liver and intrahepatic bile ducts Z 139 60 53 20 38,1 33,3 32 14 23,0 23,3 47 21 33,8 35,0 7 5 5,0 8,3 C23 Žolčnik Gallbladder Z 18 36 3 9 16,7 25,0 6 11 33,3 30,6 9 16 50,0 44,4 0 0 0 0 C24 Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts Z 82 59 16 10 19,5 16,9 38 23 46,3 39,0 25 21 30.5 35.6 3 5 3,7 8,5 C25 Trebušna slinavka Pancreas Z 193 194 11 9 5,7 4,6 66 64 34,2 33,0 104 108 53,9 55,7 12 13 6,2 6,7 C26 Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs Z 1 3 0 0 - 1 2 - 0 1 - 0 0 - 77 Nadaljevanje —> Continued —> Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število novih primerov Number of new cases Stadij Omejen Razširjen Razsejan Neznan Število %* Število %* Število %* Število %* Stage Localized Regional Distant Unknown Number %* Number %* Number %* Number %* C30 Nosna votlina in srednje uho Nasal cavity and middle ear M 1 2 5 0 0 - 1 4 - 1 1 - 0 0 - C31 Obnosni sinusi 1 2 2 0 0 - 2 1 - 0 1 - 0 0 - C32 Grlo Larynx 1 92 17 45 10 48,9 58,8 46 7 50,0 41,2 1 0 1,1 0 0 0 0 0 C33 Sapnik Trachea 1 0 0 0 0 - 0 0 - 0 0 - 0 0 - C34 Sapnica in pljuča Bronchus and lung 1 962 555 178 106 18,5 19,1 285 155 29,6 27,9 484 288 50,3 51,9 15 6 1,6 1,1 C37 Timus Thymus 1 5 7 3 5 - 1 1 - 0 1 - 1 0 - C38 Srce, mediastinum, plevra Heart, mediastinum, pleura 1 4 3 2 1 - 2 1 - 0 0 - 0 1 - C39 Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs 1 0 0 0 0 - 0 0 - 0 0 - 0 0 - C40 Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs 1 5 5 3 1 - 2 2 - 0 1 - 0 1 - C41 Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts 1 5 4 0 0 - 4 1 - 0 3 - 1 0 - C43 Maligni melanom kože Malignant melanoma of skin 1 304 276 234 218 77,0 79,0 58 53 19.1 19.2 10 5 3,3 1,8 2 0 0,7 0 C44 Druge maligne neoplazme kože Skin, other malignomas 1 1491 1459 1474 1453 98,9 99,6 16 1,1 0,4 0 0 0 0 1 0 0,1 0 C45 Mezoteliom Mesothelioma 1 29 14 10 5 34,5 19 65,5 0 0 0 0 0 0 C46 Kaposijev sarkom Kaposi's sarcoma 1 1 1 1 1 - - 0 0 - 0 0 - C47 Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system 1 2 2 1 1 - 1 1 - 0 0 - 0 0 - C48 Peritonej in retroperitonej Peritoneum and retroperitoneum 1 6 14 0 0 - - 2 6 - 0 0 - C49 Drugo vezivno in mehko tkivo Other connective and soft tissue 1 24 32 7 7 29,2 21,9 21 50,0 65,6 4 4 16,7 12,5 1 0 4,2 0 C50 Dojka Breast 1 14 1382 8 795 57,5 4 497 36,0 2 86 6,2 0 4 0,3 C51 Žensko zunanje spolovilo Vulva 1 57 34 59,6 17 29,8 4 7,0 2 3,5 C52 Nožnica Vagina 1 14 7 - 5 - 2 - 0 - C53 Maternični vrat Cervix uteri 1 123 60 48,8 46 37,4 15 12,2 2 1,6 C54 Maternično telo Corpus uteri 1 361 268 74,2 63 17,5 28 7,8 2 0,6 C55 Maternica, neopredeljeno Uterus, unspecified 1 17 7 41,2 5 29,4 4 23,5 1 5,9 C56 Jajčnik Ovary 1 129 18 14,0 12 9,3 99 76,7 0 0 C57 Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs 1 19 2 10,5 4 21,1 13 68,4 0 0 C58 Posteljica Placenta 1 0 0 - 0 - 0 - 0 - C60 Penis Penis 1 17 9 52,9 6 35,3 1 5,9 1 5,9 C61 Prostata Prostate 1 1686 1164 69,0 385 22,8 119 7,1 18 1,1 Nadaljevanje —> Continued —> 78 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 8: Nadaljevanje. Table 8: Continued. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število novih primerov Number of new cases Stadij Omejen Razširjen Razsejan Neznan Število %* Število %* Število %* Število %* Stage Localized Regional Distant Unknown Number %* Number %* Number %* Number %* C62 Modo Testis M Ž 107 79 73,8 20 18,7 8 7,5 0 0 C63 Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs Ž 3 3 - 0 - 0 - 0 - C64 Ledvica razen meha Kidney, except renal pelvis Ž 228 131 138 82 60.5 62.6 51 27 22,4 20,6 37 18 16,2 13,7 2 4 0,9 3,1 C65 Ledvični meh Renal pelvis Ž 22 11 8 5 36,4 7 3 31,8 7 3 31,8 0 0 0 C66 Sečevod Ureter Ž 15 5 10 3 66,7 2 1 13,3 3 0 20,0 0 1 0 C67 Sečni mehur Bladder Ž 251 114 197 76 78,5 66,7 32 31 12,7 27,2 20 7 8,0 6,1 2 0 0,8 0 C68 Drugi in neopredeljeni sečni organi Other and unspecified urinary organs Ž 2 1 2 0 - 0 1 - 0 0 - 0 0 - C69 Oko in očesni adneksi Eye and adnexa Ž 10 11 6 6 - 3 5 - 1 0 - 0 0 - C70 Meninge Meninges Ž 2 0 1 0 - 1 0 - 0 0 - 0 0 - C71 Možgani Brain Ž 97 54 96 54 99,0 100 1 0 1,0 0 0 0 0 0 0 0 0 0 C72 Hrbtni mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS Ž 3 5 3 5 - 0 0 - 0 0 - 0 0 - C73 Ščitnica Thyroid gland Ž 36 166 19 137 52,8 82,5 15 21 41,7 12,7 2 8 5,6 4,8 0 0 0 0 C74 Nadledvična žleza Adrenal gland Ž 4 6 1 1 - 2 3 - 1 2 - 0 0 - C75 Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures Ž 1 0 1 0 - 0 0 - 0 0 - 0 0 - C76 Druga in slabo opredeljena mesta Other and ill-defined sites Ž 3 18 0 0 0 1 14 77,8 2 4 22,2 0 0 0 C77 Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes Ž 20 17 0 0 0 0 0 0 0 0 1 1 5,0 5,9 19 16 95.0 94.1 C78 Metastaze dihal in prebavil Metastases of respiratory and digestive organs Ž 36 41 0 0 0 0 0 0 0 0 36 41 100 100 0 0 0 0 C79 Metastaze, drugje Metastases of other sites Ž 15 13 0 0 0 0 0 0 15 13 100 0 0 0 C80 Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site Ž 69 64 0 0 0 0 0 0 0 0 69 64 100 100 0 0 0 0 Stadij (Ann-Arbor) Šifra MKB Primarna lokacija Število primerov I II III+IV Neznan Spol Število %* Število %* Število %* Število %* Sex Number of Stage (Ann-Arbor) ICD code Primary site new cases I II III+IV Unknown Number %* Number %* Number %* Number %* C81 Hodgkinova bolezen Hodgkin's disease M Ž 30 29 3 0 10,0 0 7 11 23,3 37,9 19 17 63,3 58,6 1 1 3.3 3.4 C82- Ne-Hodgkinov limfom M 242 45 18,6 33 13,6 141 58,3 23 9,5 C85 Non-Hodgkin's lymphoma Ž 205 45 22,0 22 10,7 117 57,1 21 10,2 * Odstotki niso računani, če je število novih primerov manjše od 15 * Percentages are not calculated when number of new cases is less than 15 79 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 9: Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti, Slovenija 2016. Table 9: Incidence of non-Hodgkin's malignant lymphomas* by site, by sex and by age, Slovenia 2016. Šifra MKB-8 Primarna lokacija Primary site Spol Sex Vse starosti Starost Age ICD-8 code All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ Vsi NHL All NHL M+Ž M 447 242 0 0 2 2 0 0 3 1 3 2 6 6 7 3 9 6 13 8 16 8 24 16 47 26 48 23 80 45 60 30 58 34 71 32 Ž 205 0 0 0 2 1 0 4 3 5 8 8 21 25 35 30 24 39 142 Slinavke 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 Salivary glands Ž 2 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 146 Orofarinks 8 0 0 0 0 0 0 0 1 1 1 0 2 1 0 0 1 1 Oropharynx Ž 10 0 0 0 1 0 0 2 0 0 0 0 1 2 0 1 1 2 147 Epifarinks 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Epipharynx Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 151 Želodec 13 0 0 0 0 0 0 0 0 0 1 0 1 1 3 2 3 2 Stomach Ž 10 0 0 0 0 0 0 1 0 0 0 0 2 0 1 3 0 3 152 Tanko črevo 5 0 0 0 0 0 1 0 0 0 0 0 1 0 3 0 0 0 Small intestine Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 153 Debelo črevo 2 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 Colon Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 155 Jetra 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liver Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 160 Nos, obnosne votline, drugo 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Nose, sinuses, etc. Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 162 Sapnik, sapnica, pljuča 2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 Trachea, bronchus, lung Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 163 Plevra, mediastinum, drugo 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Pleura, mediastinum, etc. Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 170 Kosti 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 Bone Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 171 Mehka tkiva 4 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 1 0 Soft tissues Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 173 Koža, drugi malignomi 9 0 1 0 1 0 0 0 0 2 1 0 0 0 0 2 1 1 Skin, other malignancies Ž 7 0 0 0 0 0 0 0 0 0 3 0 1 0 1 0 2 0 174 Dojka 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 Breast Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 186 Modo Testis Ž 2 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 190 Oko 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Eye Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 191 Možgani 5 0 0 0 0 0 0 0 0 0 0 0 2 0 2 1 0 0 Brain Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 193 Ščitnica 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Thyroid Ž 4 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 202 Bezgavke 185 0 1 0 0 2 5 3 4 5 4 13 18 20 34 25 26 25 Lymph nodes Ž 161 0 0 0 1 1 0 1 3 5 4 8 17 20 28 24 21 28 * Vključeni so samo citološko in histološko potrjeni primeri * All cases included have been verified citologically and histologically 80 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 10: Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, po spolu, Slovenija 2016. Table 10: Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), by sex, Slovenia 2016. Šifra ICD-O-3 ICD-O-3code Histološka vrsta Histology type Spol Sex Število Number Incidenčna stopnja na 100.000 Incidence rate per 100,000 Vse vrste All types M+Ž M Ž 791 440 351 38,3 43,0 33,7 9727, 9728, 9835, 9836, 9811-9818 Neoplazme nezrelih celic B Precursor lymphoid neoplasms B Ž 3 10 0,3 1,0 9835, 9836, 9811 Limfoblastni limfom B / levkemija B, BDO B lymphoblastic lymphoma / leukaemia, NOS Ž 2 9 0,2 0,9 9812 Limfoblastni limfom B / levkemija B z rekurentnimi citogenetskimi anomalijami B lymphoblastic lymphoma / leukaemia with recurrent genetic abnormalities Ž 1 1 0,1 0,1 9729, 9837 Neoplazme nezrelih celic T Precursor lymphoid neoplasms T Ž 5 0 0,5 0,0 9729, 9837 Limfoblastni limfom T / levkemija T T Lymphoblastic lymphoma / leukaemia Ž 5 0 0,5 0,0 9591-9597, 9670-9699, 9712, 9731-9738, 9760-9764, 9823, 9826, 9833, 9940 Periferni B-celični limfom / neoplazme zrelih celic B Mature B-cell neoplasms Ž 383 293 37,4 28,2 9670, 9823 Kronična limfatična levkemija B / drobnocelični limfocitni limfom Chronic lymphocytic leukaemia / small lymphocytic lymphoma Ž 73 61 7,1 5,9 9689 Splenični limfom robne cone Splenic marginal zone lymphoma Ž 4 6 0,4 0,6 9591 Ne-Hodgkinovi limfomi, BDO; primarni vranični limfom / levkemija, nerazvrščeni; difuzni drobnocelični limfom B rdeče pulpe; posebna oblika dlakastocelične levkemije Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, unclassifiable; splenic diffuse red pulp small B-cell lymphoma; hairy cell leukaemia-variant Ž 3 9 0,3 0,9 9940 Dlakastocelična levkemija Hairy cell leukaemia Ž 11 0 1,1 0,0 9671 Limfoplazmacitni limfom Lymphoplasmacytic lymphoma Ž 3 0 0,3 0,0 9761 Waldenstromova makroglobulinemija Waldenstrom macroglobulinemia Ž 5 3 0,5 0,3 9732, 9733 Multipli mielom Plasma cell myeloma Ž 80 46 7,8 4,4 9731, 9734 Solitarni kostni in zunajkostni plazmacitom Solitary plasmacytoma of bone and extraosseous Ž 2 1 0,2 0,1 9699, nodalni B-celični limfom robne cone, nodalni Marginal zone B-cell lymphoma, nodal Ž 20 17 2,0 1,6 9699, ekstranodalni B-celični limfom robne cone, ekstranodalni Marginal zone B-cell lymphoma, extranodal Ž 12 12 1,2 1,2 9690 Folikularni limfom, BDO Follicular lymphoma, NOS Ž 4 2 0,4 0,2 9691, 9695 Folikularni limfom, gradus 1 in 2 Follicular lymphoma, grade 1 and 2 Ž 11 21 1,1 2,0 9698 Folikularni limfom, gradus 3 Follicular lymphoma, grade 3 Ž 12 5 1,2 0,5 9597 Primarni kožni limfom folikularnih centrov Primary cutaneous follicle centre lymphoma Ž 1 0 0,1 0,0 9673 Limfom plaščnih celic Mantle cell lymphoma Ž 18 6 1,8 0,6 9735 Plazmablastni limfom Plasmablastic lymphoma Ž 2 0 0,2 0,0 9680 Difuzni velikocelični limfom B (DLBCL), BDO; primarni DLBCL CŽS; primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCL povezan s kroničnim vnetjem; nerazvrščeni B-celični limfom, mejni primer med difuznim velikoceličnim limfomom B in Burkittovim limfomom Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; primary DLBCL of the CNS;primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma Ž 111 95 10,8 9,1 9687, 9826 Burkittov limfom / levkemija Burkitt lymphoma / leukaemia Ž 8 4 0,8 0,4 81 Nadaljevanje —> Continued —> Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra ICD-O-3 ICD-O-3code Histološka vrsta Histology type Spol Sex Število Number Incidenčna stopnja na 100.000 Incidence rate per 100,000 9679 Primarni mediastinalni (timični) velikocelični limfom B Primary mediastinal (thymic) large B-cell lymphoma M Ž 2 5 0,2 0,5 9596 Neopredeljivi limfom s celicami B, z lastnostmi difuznega limfoma z velikimi celicami B in klasičnega Hodgkinovega limfoma B-cell lymphoma, unclassifiable, with features between DLBCL and classical HL Ž 1 0 0,1 0,0 Neoplazme zrelih celic T/NK 19 1,9 Mature T- and NK-cell neoplasms Ž 17 1,6 9827, 9831, 9834, 9948 Levkemične neoplazme zrelih celic T/NK Leukaemic mature T- and NK-cell neoplasms Ž 0 1 0,0 0,1 9834 Prolimfocitna levkemija T 0 0,0 T-cell prolymphocytic leukaemia Ž 1 0,1 9700, 9701, 9708, Neoplazme zrelih (ekstranodalnih) celic T/NK 4 0,4 9709, 9716-9719 Mature (extranodal) T- and NK-cell neoplasms Ž 5 0,5 9717 Limfom T z enteropatijo 0 0,0 Enteropathy-associated T-cell lymphoma Ž 1 0,1 9700 Fungoidna mikoza 2 0,2 Mycosis fungoides Ž 2 0,2 9718 Primarne kožne CD30+ T-celične limfoproliferativne bolezni 0 0,0 Primary cutaneous CD30+ T-cell lymphoproliferative disorder Ž 1 0,1 9709 Primarni kožni periferni limfomi T, redki tipi 2 0,2 Primary cutaneous T-cell lymphoma, rare types Ž 1 0,1 9702, 9705, 9714 Zrele (nodalne) neoplazme celic T/NK Mature (nodal) T- and NK-cell neoplasms Ž 15 11 1,5 1,1 9702 Periferni limfom T (BDO- in ALK-negativen ALCL) 3 0,3 Peripheral T-cell lymphoma (NOS and ALK negative ALCL) Ž 4 0,4 9705 Angioimunoblastni limfom T 7 0,7 Angioimmunoblastic T-cell lymphoma Ž 3 0,3 9714 Anaplastični velikocelični limfom, ALK-pozitivni 5 0,5 Anaplastic large cell lymphoma, ALK positive Ž 4 0,4 9650-9667 Hodgkinov limfom (HL) Hodgkin lymphoma (HL) Ž 30 29 2,9 2,8 9659 HL z nodularno limfocitno predominanco Nodular lymphocyte predominant HL Ž 1 0 0,1 0,0 9650 Klasični HL Classical HL Ž 0 2 0,0 0,2 9663, 9664, 9665, 9667 Klasični HL, tip nodularne skleroze Nodular sclerosis classical HL Ž 14 16 1.4 1.5 9651 Z limfociti bogat klasični HL Lymphocyte-rich classical HL Ž 1 0,2 0,1 9652 Mešanocelični tip klasičnega HL Mixed cellularity classical HL Ž 12 1,2 0,9 9653, 9654 Klasični HL, tip limfocitne deplecije Lymphocyte-depleted classical HL Ž 1 1 0,1 0,1 9590, 9832 Neopredeljeni limfomi / levkemije Unspecified lymphoma / leukemia Ž 1 0,0 0,1 9590 Maligni limfom, BDO Malignant lymphoma, NOS Ž 1 0,0 0,1 9750-9759 Neoplazme histiocitov in dendriticnih celic Histiocytic and dendritic cell neoplasms Ž 1 0,0 0,1 9751 Histiocitoza Langerhansovih celic, NOS Langerhans cell histiocytosis, NOS Ž 1 0,0 0,1 82 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 11a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2016, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemsko terapijo ali obsevani, po izbrani primarni lokaciji raka. Table 11a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2016, that were treated by surgery, systemic therapy or radiotherapy during their first treatment by selected primary cancer site. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Število kakorkoli zdravljenih* Number of all treated* Število operiranih Number of treated by surgery Število zdravljenih s sistemskim zdravljenjem Number of treated sistemic therapy Število obsevanih Number of treated by radiotherapy Število Number %** Število Number %** Število Number %** Število Number %** C00-C96 Vse lokacije All sites 15040 12218 81,2 9553 63,5 4150 27,6 3290 21,9 C00-C14 Usta in žrelo Mouth and pharynx 353 328 92,9 196 55,5 38 10,8 228 64,6 C15 Požiralnik Oesophagus 64 39 60,9 13 - 27 42,2 28 43,8 C16 Želodec Stomach 442 297 67,2 223 50,5 159 36,0 83 18,8 C18 Debelo črevo Colon 904 782 86,5 754 83,4 181 20,0 4 - C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction 561 483 86,1 428 76,3 195 34,8 230 41,0 C22 Jetra in intrahepatični vodi Liver and intrahepatic bile ducts 199 68 34,2 24 12,1 43 21,6 1 - C23-C24 Žolčnik in žolčevodi Gallbladder and billiary tract 195 85 43,6 80 41,0 18 9,2 4 - C25 Trebušna slinavka Pancreas 387 158 40,8 90 23,3 102 26,4 5 - C32 Grlo Larynx 109 95 87,2 52 47,7 4 - 69 63,3 C33-C34 Sapnik, sapnici in pljuča Trachea, bronchus and lung 1517 1076 70,9 336 22,1 463 30,5 656 43,2 C43 Maligni melanom kože Malignant melanoma of skin 580 575 99,1 574 99,0 5 - 30 5,2 C44 Druge maligne neoplazme kože Skin, other malignomas 2950 2889 97,9 2746 93,1 23 0,8 122 4,1 C48-C49 Vezivno in mehko tkivo Connective and soft tissue 76 68 89,5 58 76,3 27 35,5 28 36,8 C50 Dojka Breast 1396 1355 97,1 1222 87,5 1228 88,0 880 63,0 C53 Maternični vrat Cervix uteri 123 116 94,3 84 68,3 3 - 61 49,6 C54 Maternično telo Corpus uteri 361 340 94,2 327 90,6 51 14,1 111 30,7 C56 Jajčnik Ovary 129 109 84,5 103 79,8 79 61,2 1 - C61 Prostata Prostate 1686 1198 71,1 874 51,8 403 23,9 187 11,1 C62 Modo Testis 107 107 100,0 107 100,0 67 62,6 0 - C64-C65 Ledvica z ledvičnim mehom Kidney with renal pelvis 392 309 78,8 294 75,0 22 5,6 9 - C67 Sečni mehur Bladder 365 332 91,0 329 90,1 50 13,7 34 9,3 C70-C72 Centralni in avtonomni živčni sistem Central and autonomic nervous system 161 133 82,6 115 71,4 67 41,6 92 57,1 C73 Ščitnica Thyroid gland 202 193 95,5 185 91,6 174 86,1 111 55,0 C81 Hodgkinova bolezen Hodgkin's disease 59 58 98,3 0 - 56 94,9 28 47,5 C82-C85 Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma 447 340 76,1 52 11,6 282 63,1 114 25,5 C90 Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms 129 100 77,5 4 - 92 71,3 24 18,6 C91-C95 Levkemije Leukaemias 303 130 42,9 1 - 128 42,2 9 - 83 * Število kakorkoli zdravljenih v okviru prvega zdravljenja, ne glede na način zdravljenja (vključno z drugimi zdravljenji, ki ne spadajo pod operacijo, sistemsko zdravljenje ali obsevanje) * Number of all treated patients regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy) ** Odstotki niso računani, če je število zdravljenih manjše od 15 ** Percentages are not calculated for less than 15 cases Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 11b: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2016, ki so bili v okviru prvega zdravljenja operirani*, po izbrani primarni lokaciji raka in bolnici posega. Table 11b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2016, that were treated by surgery during their first treatment* by selected primary cancer site and treatment institution. Šifra MKB ICDcode Primarna lokacija Primary site cB E 3 Ë.S S = fr ru S? = .12 TÍE S = u "§ s 3 : Continued —> Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Vse starosti All ages Starost Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ C32 Grlo Larynx M Ž 42 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 4 1 8 2 9 1 7 1 6 0 6 2 C33 Sapnik Trachea Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 C34 Sapnica in pljuča Bronchus and lung Ž 814 392 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 11 7 43 19 88 38 131 69 162 60 127 51 105 48 146 99 C37 Timus Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C38 Srce, mediastinum, plevra Heart, mediastinum, pleura Ž 5 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 2 1 1 1 0 0 1 2 2 C39 Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C40 Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs Ž 1 7 0 0 0 0 0 0 0 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 0 2 C41 Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts Ž 1 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 0 1 0 1 C43 Maligni melanom kože Malignant melanoma of skin Ž 79 49 0 0 0 0 0 0 0 0 0 0 0 2 0 0 1 1 3 3 5 2 4 1 9 5 6 3 13 5 10 4 13 4 15 19 C44 Druge maligne neoplazme kože Skin, other malignomas Ž 13 21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 2 0 0 4 9 17 C45 Mezoteliom Mesothelioma Ž 31 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 3 2 3 2 6 0 2 1 12 3 3 1 C46 Kaposijev sarkom Kaposi's sarcoma Ž 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 C47 Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C48 Peritonej in retroperitonej Peritoneum and retroperitoneum Ž 6 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 1 1 1 0 0 3 3 1 8 C49 Drugo vezivno in mehko tkivo Other connective and soft tissue Ž 12 10 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 2 0 0 2 0 2 2 0 0 1 1 1 3 0 4 1 C50 Dojka Breast Ž 8 384 0 0 0 0 0 0 0 0 0 0 0 1 0 3 0 3 0 8 0 8 0 24 0 22 1 33 2 46 1 46 3 45 1 145 C51 Žensko zunanje spolovilo Vulva Ž 24 0 0 0 0 0 0 0 0 0 1 0 2 1 1 1 4 14 C52 Nožnica Vagina Ž 7 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 3 C53 Maternični vrat Cervix uteri Ž 41 0 0 0 0 0 0 0 0 3 0 4 5 6 6 2 4 11 C54 Maternično telo Corpus uteri Ž 50 0 0 0 0 0 0 0 0 0 0 0 0 5 14 8 10 13 C55 Maternica, neopredeljeno Uterus, unspecified Ž 42 0 0 0 0 0 0 0 0 0 2 5 2 1 6 4 2 20 C56 Jajčnik Ovary Ž 147 0 0 0 0 0 0 2 1 2 8 15 18 19 16 17 13 36 C57 Drugi in neopredeljeni ženski spolni organi Other and unspecified parts offemale genital organs Ž 15 0 0 0 0 0 0 0 0 0 1 1 1 0 2 1 2 7 C58 Posteljica Placenta Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C60 Penis Penis Ž 10 0 0 0 0 0 0 0 0 0 1 1 1 0 3 2 1 1 C61 Prostata Prostate Ž 404 0 0 0 0 0 0 0 0 0 1 4 10 22 27 51 81 208 C62 Modo Testis Ž 4 0 0 0 0 0 0 1 0 0 0 2 0 0 0 0 0 1 C63 Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 C64 Ledvica razen meha Kidney, except renal pelvis Ž 97 64 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 0 3 0 7 1 12 6 11 4 12 6 20 7 29 40 C65 Ledvični meh Renal pelvis Ž 5 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 2 1 0 2 Nadaljevanje —> Continued —> 88 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Vse starosti All ages Starost Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ C66 Sečevod Ureter M Ž 1 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 1 1 2 C67 Sečni mehur Bladder Ž 145 62 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 1 2 5 1 12 2 11 5 25 3 21 6 69 41 C68 Drugi in neopredeljeni sečni organi Other and unspecified urinary organs Ž 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 C69 Oko in očesni adneksi Eye and adnexa Ž 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 C70 Meninge Meninges Ž 3 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1 0 0 0 C71 Možgani Brain Ž 109 74 1 0 1 0 2 0 1 0 1 0 1 0 3 0 1 2 2 2 3 2 11 3 15 3 10 8 11 9 15 13 14 12 17 20 C72 Hrbtni mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS Ž 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 1 C73 Ščitnica Thyroid gland Ž 8 18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 2 0 1 1 1 1 0 4 2 4 0 7 C74 Nadledvična žleza Adrenal gland Ž 3 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 2 0 C75 Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures Ž 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 C76 Druga in slabo opredeljena mesta Other and ill-defined sites Ž 2 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 1 1 0 0 0 0 0 1 C77 Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes Ž 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 C78 Metastaze dihal in prebavil Metastases of respiratory and digestive organs Ž 19 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 2 0 3 0 4 2 3 2 6 9 C79 Metastaze, drugje Metastases of other sites Ž 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 1 0 C80 Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site Ž 46 68 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 5 2 4 5 9 7 2 9 7 6 3 3 16 34 C81 Hodgkinova bolezen Hodgkin's disease Ž 4 7 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 0 1 3 0 1 1 1 C82 Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma Ž 4 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 0 1 0 0 1 1 1 4 C83 Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma Ž 36 31 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 1 2 3 5 2 4 4 12 7 8 13 C84 Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas Ž 9 4 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2 0 3 0 0 0 1 0 0 2 2 1 C85 Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma Ž 49 43 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 1 1 2 8 4 10 7 7 10 20 19 C88 Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 C90 Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms Ž 53 46 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 3 3 4 3 8 1 15 7 6 8 15 24 C91 Limfatična levkemija Lymphoid leukaemia Ž 46 33 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 1 0 0 3 3 4 0 6 3 0 3 10 4 21 19 C92 Mieloična levkemija Myeloid leukaemia Ž 53 46 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 3 0 1 0 2 6 6 5 9 9 11 4 20 19 C93 Monocitna levkemija Monocytic leukaemia Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 C94 Druge opredeljene levkemije Other leukaemias of specified cells Ž 2 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 2 C95 Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type Ž 11 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 2 1 6 4 C96 Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue Ž 41 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 0 2 2 6 0 7 3 24 27 89 Nadaljevanje —> Continued —> Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Tabela 13: Nadaljevanje. Table 13: Continued. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Vse starosti Starost Age ages 0- 5- l0- l5- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80+ C97 Maligne neoplazme na več neodvisnih (primarnih) mestih Malignant neoplasms of independant (primary) multiple sites M Ž 55 21 O O 0 0 0 0 0 0 0 0 O O 0 0 0 0 0 0 0 0 l 0 l 0 6 l 5 3 5 2 l0 2 27 l3 Zgoraj neupoštevani Not included above D32 Meninge, benigna neoplazma Benign neoplasm of meninges M Ž 7 l6 O 0 0 0 0 0 0 0 0 0 O 0 0 0 0 0 0 0 0 0 0 0 0 2 2 l l 0 l 0 l 2 2 ll D33 CŽS, benigna neoplazma Benign neoplasm of brain and other parts of CNS Ž 0 0 0 O 0 0 0 0 0 0 0 0 0 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 D43 CŽS, neopredeljeno CNS, uncertain or unknown Ž 0 l O O 0 0 0 0 0 0 0 0 O O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 l D45 Policitemija vera (Prava policitemija) Polycythaemia vera Ž 0 l O O 0 0 0 0 0 0 0 0 O O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 l 0 0 0 0 D47 Limfatičo, krvotvorno in sorodno tkivo, neopredeljeno Lymphoid, haematopoietic and related tissue, uncertain or unknown Ž 2 3 0 0 0 0 0 0 0 0 0 0 O O 0 0 0 0 0 0 0 0 0 0 l 0 0 0 0 l 0 0 0 0 l 2 * Vir: Nacionalni inštitut za javno zdravje * Source: National Institute of Public Health Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 90 Tabela 14: Eno-, tro- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2012-2016 po spolu. Table 14: One-, three- and five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in period 2012-2016 by sex. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Eno-letno preživetje (95 % interval zaupanja) Tro-letno preživetje (95 % interval zaupanja) Pet-letno preživetje (95 % interval zaupanja) One-year survival (95% confidence interval) Three-year survival (95% confidence interval) Five-year survival (95% confidence interval) C00-C96 brez C44** Vse lokacije All sites M+Z M Z 73.7 72,0 75.8 73,3-74,1 71,5-72,6 75,2-76,3 62,1 59,9 64,8 61,7-62,6 59,3-60,6 64,1-65,4 58.0 56,3 60.1 57,5-58,5 55,5-57,0 59,4-60,9 C00-C14 Usta in žrelo Mouth and pharynx Z 72,3 85,0 69,9-74,8 81,3-88,9 51,0 72,5 48,3-54,0 67,6-77,9 43,7 65,9 40,7-46,9 59,0-73,6 C15 Požiralnik Oesophagus Z 41,2 39,0 36.3-46,8 29.4-51,7 14,7 13,7 11,3-19,2 7,7-24,2 10,5 14,2 7,4-14,8 8,0-25,1 C16 Želodec Stomach Z 52,9 48,6 50,2-55,7 45,2-52,2 34,6 34,2 32,0-37,5 30,9-37,8 31.6 30.7 28,7-34,7 27,2-34,7 C18 Debelo črevo Colon Z 79,7 75,2 77,9-81,5 73,2-77,4 67,3 64,0 65,1-69,6 61,5-66,5 62,0 61,0 59,2-64,8 58,1-64,1 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction Z 85,0 79,0 83,2-86,8 76,4-81,8 70,6 64,3 68,2-73,2 61,0-67,9 66,2 57,7 63,2-69,4 53,9-61,9 C22 Jetra in intrahepatični vodi Liver and intrahepatic bile ducts Z 33,0 31,8 29,7-36,7 26,5-38,1 16,6 12,9 13,9-19,7 9,3-17,9 11,7 8,0 9,2-14,9 4,8-13,2 C23-C24 Žolčnik in žolčevodi Gallbladder and billiary tract Z 36,0 30,5 31,5-41,1 26,7-34,9 18,6 16,3 15,0-23,1 13,2-20,1 14,7 13,6 11,2-19,3 10,5-17,7 C25 Trebušna slinavka Pancreas Z 22,1 23,8 19,6-24,9 21,1-26,8 7,4 9,1 5,8-9,3 7,4-11,3 4,8 6,0 3.4-6,7 4.5-8,1 C32 Grlo Larynx Z 86,3 82,8-90,0 69,8 65,0-75,0 62,3 56,4-68,7 C33-C34 Sapnik, sapnici in pljuča Trachea, bronchus and lung Z 40,7 49,6 39,2-42,2 47,5-51,7 20,0 28,3 18,8-21,3 26,5-30,3 15,4 22,0 14,2-16,8 20,2-24,1 C43 Maligni melanom kože Malignant melanoma of skin Z 97,9 97,8 96,7-99,1 96,6-98,9 91,9 93,7 89,7-94,1 91,7-95,8 90,5 91,0 87,5-93,7 88,2-93,9 C44 Druge maligne neoplazme kože Skin, other malignomas Z ** ** ** ** ** ** C48-C49 Vezivno in mehko tkivo Connective and soft tissue Z 78,6 79,4 72,1-85,7 74,0-85,2 61,8 60,9 53,8-70,8 54,3-68,4 57,2 53,8 48,2-67,8 46,6-62,1 C50 Dojka Breast Z 97,0 96,4-97,5 92,3 91,4-93,2 87,7 86,4-89,0 C53 Maternični vrat Cervix uteri Z 86,3 83,4-89,2 73,4 69,7-77,3 68,9 64,5-73,7 C54 Maternično telo Corpus uteri Z 92,2 90,8-93,7 84,3 82,3-86,5 80,8 78,2-83,6 C56 Jajčnik Ovary Z 75,0 71,9-78,2 52,5 48,9-56,3 40,2 36,5-44,3 C61 Prostata Prostate Z 96,9 96,3-97,5 93,8 92,8-94,7 92,8 91,5-94,2 C62 Modo Testis Z 98,6 97,5-99,6 98,2 96,9-99,5 97,5 95,8-99,2 C64-C65 Ledvica z ledvičnim mehom Kidney with renal pelvis Z 78,6 78,5 76,2-81,2 75,2-81,9 68,8 71,0 65,8-71,9 67,1-75,2 64,9 69,7 61,4-68,7 65,2-74,5 C67 Sečni mehur Bladder Z 74,8 69,8 72,2-77,5 65,4-74,5 61,4 52,9 58,2-64,8 47,8-58,4 55,7 44,4 51,6-60,0 38,4-51,4 C70-C72 Centralni in avtonomni živčni sistem Central and autonomic nervous system Z 48,1 41,8 43.7-53,0 36.8-47,4 23,8 22,2 20,2-28,1 18,2-27,1 19,9 19,1 16,3-24,2 15,2-24,1 C73 Ščitnica Thyroid gland Z 93,5 96,7 89,9-97,3 95,3-98,2 90,3 95,9 85,6-95,4 94,0-97,9 90,6 95,6 85,2-96,4 93,1-98,1 C81 Hodgkinova bolezen Hodgkin's disease Z 92,8 92,2 88,1-97,7 87,3-97,4 85,8 90,0 79,2-92,8 83,7-96,7 82,0 87,8 74,1-90,7 80,3-96,0 C82-C85 Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma Z 77,3 75,9 74,6-80,1 73,2-78,8 69,3 65,5 66,1-72,7 62,3-69,0 66,7 61,5 62,9-70,8 57,7-65,4 C90 Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms Z 72,1 73,4 67.3-77,4 68.4-78,8 55,6 53,8 50,0-62,0 47,9-60,5 39,2 44,1 32,7-46,9 37,6-51,7 C91-C95 Levkemije Leukaemias Z 64,4 68,1 61,1-67,9 64,4-71,9 53,7 58,0 50,0-57,6 53,9-62,4 48,0 50,3 43,9-52,6 45,3-56,0 91 * Število v analizo vključenih bolnikov je manjše od 15 povprečno letno * Average number of patients included in the analysis is less than 15 yearly ** Preživetje bolnikov z nemelanomskim kožnim rakom se ne razlikuje v primerjavi s splošno populacijo ** Survival of patients with non-melanoma skin cancer does not differ in comparison with the general population Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 Izbor publikacij Selected publications IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiologije in Registra raka objavili v zadnjih petih letih (tudi v sodelovanju z drugimi raziskovalci) SELECTED PUBLICATIONS, published by the members of Epidemiology and Cancer Registry in the last five years (also in cooperation with other researchers) 2014 - Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Primic-Žakelj M, et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol 2014; 28: 1170-8. - Gutnik H, Matišc JP, Primic-Žakelj M, Strojan Fležar M. Microinvasive cervical squamous cell carcinoma in Slovenia during the period 2001-2007. Radiol Oncol 2014; 48: 282-8. - Ivanuš U, Primic-Žakelj M. Učinkovitost triažnega testa HPV pri ženskah s presejalno diagnozo APC-N in rezultati triažnega testiranja na HPV v 2013. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 45-52. - Ivanuš U, Primic-Žakelj M. Obravnava žensk z indikacijo za triažni test HPV. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2014: 48-69. - Jarm K, Ivanuš U, Krajc M, Primic-Žakelj M. Državna presejalna programa za raka materničnega vratu in dojke. In: Grmek-Košnik I, Hvalič Touzery S, Skela-Savič B, eds. Kronične bolezni sodobne družbe: od zgodnjega odkrivanja do paliativne oskrbe: zbornik prispevkov z recenzijo. Jesenice: Fakulteta za zdravstvo, 2014: 99-106. - Kadivec M, Krajc M, Hertl K, Jarm K, Primic-Žakelj M, Šval C. Državni presejalni program za raka dojke Dora - program zgodnjega odkrivanja raka dojke = Slovenian breast cancer screening programme Dora - programme for early breast cancer detection. In: Završnik J, ed. Bolezni dojke: [simpozij, Maribor 2014]. Maribor: Zdravstveni dom dr. Adolfa Drolca, 2014: 221-8. - Kloboves-Prevodnik V, Uhan Kastelic S, Pohar-Marinšek Ž, Žagar T, Ivanuš U. Atipične žlezne celice, neopredeljene: rezultati revizije citoloških preparatov in tveganje CIN2+. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 64-72. - Krajc M, Zadnik V, Novakovic S, Stegel V, Teugels E, Bešic N et al. Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening. Clinical genetics 2014; 85: 59-63. - Pogačnik A, Kloboves-Prevodnik V, Nolde N, Novakovic S, Ivanuš U, Primic-Žakelj M, et al. Nove triažne metode pri HPV-pozitivnih ženskah. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 36-40. - Primic-Žakelj M. Current situation and prospects of cancer in the Balkan area: what can we do together?. In: Book of abstracts = international scientific conference. Tirana: Academy of Sciences of Albania, 2014: 6-7. - Primic-Žakelj M, Ivanuš U. Državni presejalni program za raka materničnega vratu Zora: zgodba o uspehu. In: Petrovec M, Golle A, eds. Okužbe spolovil in spolno prenosljive bolezni: [zbornik predavanj], (Medicinski razgledi, ISSN 0353-3484, Supplement, letn. 53, 6). Ljubljana: Medicinski razgledi, 2014: 249-55. 92 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 - Primic-Žakelj M, Ivanuš U. Pregled dela in novosti v DP ZORA - 2013/2014. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 7-11. - Primic-Žakelj M, Ivanuš U. Presejalni programi za raka materničnega vratu - trenutno stanje in prihodnost. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2014: 27-36. - Primic-Žakelj M, Jarm K, Žagar T. Epidemiološke značilnosti raka prebavil v Sloveniji v zadnjem desetletju. In: Ivanecz A, Krebs B, Potrč S, eds. Simpozij z mednarodno udeležbo na temo Smernice in problemi zdravljenja malignomov želodca, trebušne slinavke in debelega črevesa ter danke. Zbornik predavanj. Maribor: Oddelek za abdominalno in splošno kirurgijo, Kirurška klinika UKC, 2014: 1-4. - Primic-Žakelj M, Žagar T, Jarm K. Zbolevnost za rakom dojke in preživetje = Breast cancer incidence and survival rate. In: Završnik J, ed. Bolezni dojke [simpozij, Maribor 2014]. Maribor: Zdravstveni dom dr. Adolfa Drolca, 2014: 115-24. - Primic-Žakelj M, Žagar T, Zadnik V. Epidemiološke značilnosti malignomov krvotvornega in limfatičnega tkiva. In: Primic-Žakelj M ed. XXII. seminar In memoriam dr. Dušana Reje. Malignomi krvotvornega in limfatičnega tkiva. Ljubljana: Zveza slovenskih društev za boj proti raku, 2014: 7-34. - Primic-Žakelj M, Žagar T, Zadnik V, Škrlec F. Linkage of the Slovenian Cancer Registry data to other state databases and to screening registries. In: European Union and European Network of Cancer Registries (ENCR). Towards a harmonised cancer information system in Europe, 2014: 71. - Strojan P, Zadnik V, Šifrer R, Lanišnik B, Didanovič V, Jereb S, et al. Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983-2009: role of human papillomavirus infection. Eur Arch Otorhinolaryngol 2014: 1-7. - Šeruga B, Zadnik V, Grašič-Kuhar C, Marinko T, Čufer T, Zakotnik B, et al. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. Cancer investigation 2014; 32: 99-104. - Škulj P, Babuder B, Zadnik V. Slora - Slovenija in rak, interaktivni spletni portal = Slora - Slovenia and cancer, an interactive web portal. In: Štemberger Kolnik T, ed. Zdravstvena nega v javnem zdravju = Nursing in public health : druga znanstvena konferenca z mednarodno udeležbo, Izola, 31. Januar 2014 = Second scientific conference with international participation. Zbornik prispevkov = Proceedings. Koper: Založba Univerze na Primorskem, 2014: 67-73. - Zadnik V. Rak debelega črevesa in danke: epidemiološke značilnosti in nevarnostni dejavniki. In: Ocvirk J, ed. Sodobna obravnava raka debelega črevesa in danke. Ljubljana: Europacolon Slovenija,združenje za boj proti raku debelega črevesa in danke, 2014: 22-4. - Zadnik V, Žagar T, Primic-Žakelj M. Nizkofrekvenčna polja in rak. In: Gajšek P, ed. Strokovni seminar Daljnovodi in zdravje, Ljubljana, 25. 9. 2014. Zbornik predavanj. Ljubljana: Inštitut za neionizirana sevanja, 2014: 19-21. - Zanetti R, Sacchetto L, Calvia M, Bordoni A, Hakulinen T, Primic-Žakelj M, et al. Economic evaluation of cancer registration in Europe. J Registry Manag 2014; 41: 31-7. - Žagar T, Primic-Žakelj M, Zadnik V, Škrlec F, Jarm K. Completeness of the cancer registry of the Republic of Slovenia using qualitative methods. In: International Association of Cancer Registries (IACR), 36th annual conference 2014. Ottawa, Canada, 26-28 June 2014. Ottawa: The National Cancer Institute, 2014: 109. 2015 - Allemani C, Weir HK, Carreira H, Harewood R, Primic-Zakelj M, ZagarT, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015; 385: 977-1010. - Borras JM, Barton M,Grau C, Corral J,Verhoeven R, Primic-Zakelj M,etal.The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. Radiother Oncol 2015; 116:45-50. 93 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 - Borras JM, Lievens Y, Dunscombe P, Coffey M, Malicki J, Primic-Žakelj M, et al. The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiother Oncol 2015; 116: 38-44. - Ivanuš U, Primic-Žakelj M. Test HPV doma za neodzivnice programa Zora: preliminarni rezultati. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana; 2015: 49-55. - Ivanuš U, Primic-Žakelj M. Vloga triažnega testa HPV in kolposkopije v programu ZORA. In: Smrkolj Š, ed. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD in Onkološki inštitut, 2015: 35-52. - Ivanuš U, Učakar V. Okužbam pripisljivi raki in preprečevanje s cepljenjem. In: Novakovic S, Zakotnik B, Žgajnar J, eds. Preprečevanje raka: dejstva, ki jih mora vedeti zdravstveni delavec: zbornik. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut, 2015: 89-102. - Jarm K, Krajc M, Primic-Žakelj M, Šval C, Puric F, Kadivec M, et al. Presejanje za raka dojk: program Dora. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana, 2015: 70-5. - Karalexi MA, Papathoma P, Thomopoulos TP, Ryzhov A, Zborovskaya A, Žagar T, et al. Childhood central nervous system tumour mortality and survival in Southern and Eastern Europe (1983-2014): Gaps persist across 14 cancer registries. Eur J Cancer 2015; 51: 2665-77. - Krajc M, Primic-Žakelj M. Dojenje, hormonska zdravila in drugi dejavniki, vpleteni v nastanek raka dojk. In: Primic-Žakelj M, ed. Kaj sporoča prenovljeni evropski kodeks proti raku. Ljubljana: Zveza slovenskih društev za boj proti raku, 2015: 77-86. - Papathoma P, Thomopoulos TP, Karalexi MA, Ryzhov A, Zborovskaya A, Žagar T, et al. Childhood central nervous system tumours: Incidence and time trends in 13 Southern and Eastern European cancer registries. Eur J Cancer 2015; 51: 1444-55. - Primic-Žakelj M. Redke rakave bolezni. In: Modic K, ed. Redke bolezni: 28 februar 2015. Ljubljana: Društvo BKB, 2015: 35-40. - Primic-Žakelj M. Kaj je evropski kodeks proti raku. In: Primic-Žakelj M, ed. Kaj sporoča prenovljeni evropski kodeks proti raku. Ljubljana: Zveza slovenskih društev za boj proti raku, 2015: 7-9. - Primic-Žakelj M, Čeh F. Najpogostejši raki pri moških2015. Zveza slovenskih društev za boj proti raku, 2015. - Primic-Žakelj M, Čeh F. 12 nasvetov proti raku : Evropski kodeks proti raku 2014-2015. Zveza slovenskih društev za boj proti raku, 2015. - Primic-Žakelj M, Ivanuš U. Pregled dela in novosti v DP Zora - 2014/2015. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana, 2015: 7-10. - Primic-Žakelj M, Žagar T. Preprečevanje raka v ustni votlini. In: Artnik B, Premik M, Jovanovič K, eds. Zbornik člankov in izvlečkov, Kongres ob 40-letnici strokovnih srečanj stomatologov Slovenije [tudi] 40 srečanje stomatologov Slovenije "Iz prakse za prakso" in pridruženi 10 Cvahtetovi dnevi javnega zdravja "Skrb za ustno zdravje", Portorož, 4 do 6 junij 2015. Ljubljana: Stomatološka sekcija Slovenskega zdravniškega društva, 2015: 22-9. - Rems M, Jarm K, Zadnik V, Primic-Žakelj M. Lokalna ponovitev bolezni pri bolnikih, operiranih zaradi nemetastatskega raka danke, zbolelih v obdobju 2003-2005 = Local recurence of rectal cancer in patients with nonmetastatic disease, diagnosed in 2003-2005. Zdrav vest 2015; 84: 277-86. - Sant M, Chirlaque Lopez MD, Agresti R, Sanchez Perez MJ, Holleczek B, Primic-Žakelj M, et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EUROCARE-5 study. Eur J Cancer 2015; 51: 2191-205. - Sant M, Minicozzi P, Primic-Zakelj M, Otter R, Francisci S, et al. Cancer survival in Europe, 2000-2007: Doing better, feeling worse? Eur J Cancer 2015; 51: 2101-3. - Schuz J, Espina C, Villain P, Herrero R, Leon ME, Primic-Žakelj M, et al. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer epidemiol 2015; 39 Suppl 1: S1-10. 94 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 - Strojan P, Zadnik V, Sifrer R, Lanisnik B, Didanovic V, Jereb S, et al. Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983-2009: role of human papillomavirus infection. Eur Arch Otorhinolaryngol 2015; 272: 3805-14. - Zadnik V. Epidemiologija raka jajčnika. In: Smrkolj S, Zobec Logar H, Šešek M, eds. Rak jajčnikov: zbornik. Ljubljana: Slovensko zdravniško društvo, Združenje za radioterapijo in onkologijo, 2015: 6-9. - Zadnik V. Epidemiološki trendi hormonsko odvisnih rakov = Epidemiological trends of hormon related-cancers. In: Černe K, ed. Kemijski povzročitelji hormonskih motenj od molekule do človeka = Endocrine disrupting chemicals - from molecule to man. Ljubljana: Slovensko toksikološko društvo, 2015: 22. - Zanetti R, Schmidtmann I, Sacchetto L, Binder-Foucard F, Bordoni A, Zadnik V, et al. Completeness and timeliness: Cancer registries could/should improve their performance. European journal of cancer. 2015; 51: 1091-8. - Zwitter M, Žagar T. Zdravljenje pljučnega raka: perspektiva dveh desetletij. In: Kovač V, Rajer M, eds. Prva šola pljučnega raka. Ljubljana: Slovensko zdravniško društvo, 2015: 116-20. 2016 - Avbelj M, Zupane D, ŽagarT, Kotnik P, Jakil M, Pirnat E, et al. Rak ščitnice pri otrocih. In: Bešič N, Zaletel K, eds. Dan ščitnice. Ljubljana: Slovenska sekcija za onkološko kirurgijo SZD, 2016: 27. - Barbaric J, Sekerija M, Agius D, Coza D, Dimitrova N, Primic Žakelj M, et al. Disparities in melanoma incidence and mortality in South-Eastern Europe: Increasing incidence and divergent mortality patterns. Is progress around the corner? Eur J Cancer. 2016; 55:47-55. - de Leede EM, Sibinga Mulder BG, Bastiaannet E, Poston GJ, Sahora K, Primic Žakelj M, et al. Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project. Eur J Surg Oncol. 2016; 42: 1414-9. - Deandrea S, Molina-Barcelo A, Uluturk A, Primic Žakelj M, Jarm K, Kraje M, etal. Presence, characteristics and equity of access to breast cancer screening programmes in 27 European countries in 2010 and 2014. Results from an international survey. Prev Med. 2016; 91: 250-63. - Ivanuš U, Primic Žakelj M, Jerman T, Florjančič M, Kuster M, Takac I, et al. HPV self-sampling response rate in randomised study among Slovenian non-responders to the organised cervical cancer screening program. In: EUROGIN 2016 abstracts: part I - main conference program. Salzburg: EUROGIN, 2016: 333-4. - Ivanuš U, Učakar V. Okužbam pripisljivi raki: novi pristopi v primarni in sekundarni preventivi. In: Kraigher A, BergerT, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health -networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 106-7. - Karalexi MA, Baka M, Ryzhov A, Zborovskaya A, Dimitrova N, ŽagarT, etal. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America. Eur J Cancer. 2016; 67: 183-90. - Karalexi MA, Georgakis MK, Dessypris N, Ryzhov A, Zborovskaya A, ŽagarT, etal. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data. Hematol Oncol. Epub ahead of print. - Kokalj M, Zadnik V, Ančin A, Plavc G, Didanovic V, Šifrer R, et al. Ploščatocelični karcinom neznanega izvora z zasevki v bezgavkah na vratu: vloga elektivnega obsevanja sluznice v področju glave in vratu = Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes: the role of elective irradiation of mucosal sites. Med Razgl. 2016; 55(S1): 297-301. - Kraje M, ZadnikV. Razvoj in implementacija orodja za določanje individualne ogroženosti z rakom dojk v slovenski populaciji. In: Kraigher A, BergerT, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016:116-7. 95 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 - Mandelj N, Zadnik V. Breme želodčnega raka v Sloveniji z oceno pripisljivih deležev zaradi prekomernega vnosa soli ter prenizkega vnosa sadja in zelenjave. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 119-20. - Primic Žakelj M. Prenovljen evropski kodeks proti raku = New edition of European code against cancer. Gastroenterolog. 2016; 20(S2): 5-11. - Primic Žakelj M, Ivanuš U. Zgodnje odkrivanje raka materničnega vratu - program Zora = Screening for cervical cancer in Slovenia - programme Zora. Gastroenterolog. 2016; 20(S2): 72-7. - Primic Žakelj M, Ivanuš U. Presejalni programi za raka. In: Novakovic S, editor. Razvojni trendi v onkologiji - onkologija čez desetletje: izbrana poglavja in državni program obvladovanja raka 2017-2021: zbornik. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut; 2016. p. 14-23. - Primic Žakelj M, Jarm K, Novak Mlakar D, Ivanuš U. Presejanje za raka: krhko ravnovesje med koristmi in škodo. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 110-1. - Primic Žakelj M, Žagar T. Epidemiologija raka dojk. In: Borštnar S, Duratovic Konjevic A, Grašič-Kuhar C, eds. Zbornik prispevkov, Šola raka dojk. Ljubljana: Združenje za senologijo, SZD, 2016: 6-11. - Strojan P, Kokalj M, Zadnik V, Anicin A, Plavc G, Didanovic V, et al. Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes: role of elective irradiation. Eur Arch Otorhinolaryngol. 2016; 273: 4561-9. - Zadnik V. Onkološka epidemiologija čez desetletje. In: Novakovic S, editor. Razvojni trendi v onkologiji - onkologija čez desetletje: izbrana poglavja in državni program obvladovanja raka 2017-2021: zbornik. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut, 2016: 9-13. - Zadnik V. Raziskovanje vpliva okolja na zbolevanje za rakom in ocenjevanje tveganja. In: Belovič B, Čemažar M, Perharič L, Primic Žakelj M, Zadnik V, Zdešar A, eds. Kemikalije v okolju in rak. Ljubljana: Zveza slovenskih društev za boj proti raku, 2016: 7-18. - Zadnik V, Ivanuš U. Epidemiologija raka materničnega telesa. In: Merlo S, Smrkolj Š, Šegedin B, eds. Rak materničnega telesa: zbornik. Ljubljana: Združenje za radioterapijo in onkologijo SZD: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD, 2016: 15-9. - Zadnik V, Krajc M. Epidemiological trends of hormone-related cancers in Slovenia. Arh Hig Rada Toksikol. 2016; 67: 83-92. - Zadnik V, Žagar T, Jarm K, Primic Žakelj M. Time trends and spatial patterns in the mesothelioma incidence in Slovenia, 1961-2013. In: Joining forces for better cancer registration in Europe. Luxembourg: Publication Office of the European Union, 2016: 32. - Zadnik V, Žagar T, Primic Žakelj M. Linkage to supplementary registration sources: key lessons learned in the last 30 years in Slovenia. In: Benider A, Zanetti R, Siesling S, Bray F, eds. The 38th Annual IACR Conference. Marrakech: IACR, 2016: 63. - Zadnik V, Žagar T, Primic Žakelj M. Cancer Patients' Survival: Standard Calculation Methods And Some Considerations Regarding Their Interpretation. Zdrav Varst. 2016; 55: 134-41. - Žagar T, Zadnik V, Jarm K, Ivanuš U, Primic Žakelj M. Redki raki. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 115. 2017 - Bonaventure A, Harewood R, Stiller CA, Gatta G, Primic-Žakelj M, Žagar T et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematol; 2017: 4: e202-17. 96 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 - Dimitrova N, Znaor A, Agius D, Eser S, Sekerija M, Primic-Žakelj M, et al. Breast cancer in South-Eastern European countries since 2000: Rising incidence and decreasing mortality at young and middle ages. Eur J Cancer; 2017:83:43-55. - Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Primic-Žakelj M et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. The Lancet Oncology. 2017 Aug;18(8):1022-39. PubMed PMID: 28687376. - Georgakis MK, Karalexi MA, Kalogirou El, Ryzhov A, Zborovskaya A, ŽagarTetal. Incidence, time trends and survival patterns of childhood pilocytic astrocytomas in Southern-Eastern Europe and SEER, US. J Neurooncol; 2017: 131:163-75. - Georgakis MK, Panagopoulou P, Papathoma P, Tragiannidis A, Ryzhov A, ŽagarTet al. Central nervous system tumours among adolescents and young adults (15-39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US. Eur J Cancer; 2017:86: 46-58. - Georgakis MK, Papathoma P, Ryzhov A, Zivkovic-Perisic S, EserS, ŽagarTet al. Malignant central nervous system tumors among adolescents and young adults (15-39 years old) in 14 Southern-Eastern European registries and the US Surveillance, Epidemiology, and End Results program: Mortality and survival patterns. Cancer; 2017: 123:4458-71. - Horvat M, Potočnik U, Repnik K, Kavalar R, Zadnik V, Potrč S et al. Single Nucleotide Polymorphisms in Genes MACC1, RADI 8, MMP7 and SDF-la As Prognostic Factors in Resectable Colorectal Cancer. Radiol Oncol; 2017: 51: 151-9. - Huang L, Jansen L, Balavarca Y, Molina-Montes E, Primic-Žakelj M, Zadnik Vet al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut; 2017: Epub ahead of print. - Karalexi MA, Georgakis MK, Dessypris N, Ryzhov A, Zborovskaya A, ŽagarTetal. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data. Hematol Oncol. 2017; 35:608-18. - Matz M, Coleman MP, Carreira H, Salmerón D, Primic-Žakelj M, ŽagarTet al. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 2017; 144: 396-404. - Matz M, Coleman MP, Sant M, Chirlague MD, Primic-Žakelj M, Žagar T et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017; 144:405-13. - Perharič L, Martinčič M, Uršič S, Kukec A, ZadnikV, Mazej D etal. Poglobljena ocena tveganja za zdravje otrok zaradi izpostavljenosti arzenu v občini Zagorje ob Savi. Ljubljana: Nacionalni inštitut za javno zdravje; 2017. - Ponti A, Anttila A, Ronco G, Primic-Žakelj M, Ivanuš U, Jarm K etal. Against cancer: cancer screening in the European Union. Lyon: International Agency for Research on Cancer; 2017. - Primic-Žakelj M. Program dela Zveze slovenskih društevza boj proti raku v letu 2017. Ljubljana: Zveza slovenskih društev in regijskih društevza boj proti raku; 2017: 34-38. - Primic-Žakelj M, Ivanuš U, eds. Zbornik predavanj, 7. izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 17. maj 2017. Ljubljana: Onkološki inštitut; 2017. - Ranfl M, ZadnikV. Epidemiologija rakov glave in vratu v Sloveniji 1983-2012 = Epidemiology of head and neck cancer in Slovenia 1983-2012. Medicinski razgledi 2017; 56: 277-91. - Rotovnik Kozjek N, Kompan L, ŽagarT, Mrevlje Ž. Influence of enteral glutamine on inflammatory and hormonal response in patients with rectal cancer during preoperative radiochemotherapy. Eur J Clin Nutr. 2017;71:671-3. - Skopec B, Škerget M, Žontar D, ZadnikV, Zver S. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients. Wien Klin Wochenschr. 2017; 129: 545-51. - VelenikV, Šečerov-Ermenc A, But-Hadžič J, ZadnikV. Health-related Quality of Life Assessed by the EORTC QLQ-C30 Questionnaire in the General Slovenian Population. Radiol Oncol. 97 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016 - Zadnik V. Epidemiologija raka zunanjega spolovila. In: Merlo S, Šegedin B, eds. Rak zunanjega spolovila: zbornik znanstvenih prispevkov. Ljubljana: Združenje za radioterapijo in onkologijo SZD, Sekcija internistične onkologije SZD, Onkološki inštitut; 2017: 10-3. - Zadnik V. Epidemiologija RDČD: breme raka debelega črevesa in danke. In: Sodobna obravnava raka debelega črevesa in danke: zbornik prezentacij: simpozij za strokovno javnost, 31. marec 2017, Maribor. Maribor: Medicinska fakulteta; 2017: 5-16. - Zadnik V. Rak in druge zdravstvene posledice kajenja. In: Belovic B, Primic-Žakelj M, Zdešar A, eds. Kajenje in zdravje - nikoli končana zgodba. Ljubljana: Zveza slovenskih društev za boj proti raku; 2017: 67-77. - Zadnik V. Vzpostavitev kliničnega registra melanom Registra raka Republike Slovenije. In: Boc M, Reberšek M, eds. 13. šola malignega melanoma, 10. marec 2017, Ljubljana. Ljubljana: Onkološki inštitut; 2017: 11-2. - Zadnik V, Primic-Žakelj M, Jarm K, Žagar T. Time trends and spatial patterns in the mesothelioma incidence in Slovenia, 1961-2014. Eur J Cancer Prev. 2017; 26: S191-S6. - Zadnik V, Primic-Žakelj M, Lokar K, Jarm K, Ivanuš U, Žagar T. Cancer burden in Slovenia with the time trends analysis. Radiol Oncol. 2017; 51: 47-55. - Zadnik V, Primic-Žakelj M, Žagar T. Cancer survival in children and adolescents in last 50 years in Slovenia. In: Grell 2017. Bruxelles: Belgian Cancer Registry; 2017: 47. - Zadnik V, Primic-Žakelj M, Žagar T, Škrlec F, Lokar K, Čampa A. Pregled obravnave bolnikov s kožnim melanomom v Sloveniji za incidenčna leta 2011-2016. Ljubljana: Onkološki inštitut, Epidemiologija in register raka, 2017. - Žagar T, Primic-Žakelj M, Zadnik V. Rare cancers in Slovenia. In: Ensuring quality and use of data from cancer registries in the 21st century. Utrecht: ENCR; 2017: 129. 2018 - Allemani C, Matsuda T, Di Carlo V, Harewood R, Primic Žakelj M, Žagar T, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391: 1023-75. - Blatnik J, Zadnik V, Artnik B. 30-year time trend of oral cancer in Slovenia, 1985 - 2014. European journal of public health. 2018; 28: Suppl. 4: 395-6. - Doganis D, Panagopoulou P, Tragiannidis A, Georgakis MK, Moschovi M, Žagar T, et al. Childhood nephroblastoma in Southern and Eastern Europe and the US: Incidence variations and temporal trends by human development index. Cancer epidemiology. 2018; 54: 75-81. - Doganis D, Panagopoulou P, Tragiannidis A, Vichos T, Moschovi M, Žagar T, et al. Survival and mortality rates of Wilms tumour in Southern and Eastern European countries: Socioeconomic differentials compared with the United States of America. European journal of cancer. 2018; 101: 38-46. - Georgakis MK, Dessypris N, Baka M, Moschovi M, Papadakis V, Žagar T, et al. Neuroblastoma among children in Southern and Eastern European cancer registries: Variations in incidence and temporal trends compared to US. International journal of cancer. 2018; 142: 1977-85. - Grašič Kuhar C, Strojan P, Zadnik V, Zakotnik B. Importance of magnesium sulfate supplementation in the prevention of hypomagnesemia and hypocalcemia during chemoradiation in head and neck cancer. Journal of trace elements in medicine and biology. 2018; 50: 327-31. - Horvat M, Zadnik V, Južnič Šetina T, Boltežar L, Pahole Goličnik J, Novakovic S, et al. Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone. Oncology letters. 2018; 15: 3602-9. - Huang L, Jansen L, Balavarca Y, Babaei M, Primic Žakelj M, Zadnik V, et al. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. BMC Med. 2018; 16: 125. 98 Institute of Oncology Ljubljana, Slovenian Cancer Registry Cancer in Slovenia 2016 - Huang L, Jansen L, Balavarca Y, van der Geest L, Primic Žakelj M, Zadnik V, et al. Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study. International journal of cancer. 2018; 143: 3227-39. - Moltara ME, Novakovic S, Boc M, Bucic M, Reberšek M, Zadnik V, et al. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma. Radiol Oncol. 2018; 52: 289-95. - Panagopoulou P, Georgakis MK, Baka M, Moschovi M, Papadakis V, Žagar t, et al. Persisting inequalities in survival patterns of childhood neuroblastoma in Southern and Eastern Europe and the effect of socio-economic development compared with those of the US. European journal of cancer. 2018; 96: 44-53. - Perharič L, Kukec A, Martinčič M, Šlejkovec Z, Mazej D, Uršič S, Zadnik V. Risk assessment for children health from environmental exposure to inorganic arsenic. European journal of public health. 2018; 28: Suppl. 4: 109. - Primic-Žakelj M, Zadnik V, Žagar T. Register raka Republike Slovenije. Arhivi, 2018; 1: 171-83. - Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Žagar T, et al. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocrine-related cancer. 2018; 25: 607-18. - Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster DH, Zadnik V, et al. Trends in incidence of thick, thin and in situ melanoma in Europe. European journal of cancer. 2018; 92: 108-18. - Škerget M, Skopec B, Zadnik V, Žontar D, Podgornik H, Reberšek K, et al. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction. Acta haematologica. 2018; 139: 228-34. - Tomšič S, Zadnik V. Epidemiologija rakov, povezanih s čezmernim pitjem alkoholnih pijač. In: Belovic B, Primic Žakelj M, Zdešar A, eds. Alkohol in rak. Ljubljana: Zveza slovenskih društev za boj proti raku. 2018, str. 99-112. - Tomšič S, Zadnik V, Žagar T. Epidemiologija raka trebušne slinavke. In: Ivanecz A, Krebs B, eds. Simpozij z mednarodno udeležbo na temo Rak trebušne slinavke, rak debelega črevesa in danke, jetrni zasevki. Maribor: Oddelek za abdominalno in splošno kirurgijo, Kirurška klinika UKC. 2018, str. 3-11. - Weberpals J, Jansen L, Silversmit G, Verbeeck J, van der Geest L, Zadnik V, et al. Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients. Clin Epidemiol. 2018; 10: 1109-25. - Zadnik V. Monitoring inequalities in the cancer burden in Europe. European journal of public health. 2018; 28: Suppl. 4: 212-3. - Zadnik V, Guillaume E, Lokar K, Žagar T, Primic Žakelj M, Launoy G, et al. Slovenian Version of The European Deprivation Index at Municipal Level. Zdravstveno varstvo. 2018; 57: 47-54. - Zadnik V, Krajc M. Razvoj in implementacija orodja za določanje individualne ogroženosti z rakom dojk v slovenski populaciji. Onkologija. 2018; 2: 6-10. - Zadnik V, Lokar K. Register raka Republike Slovenije kot podlaga za spremljanje bremena ginekoloških rakov. In: Istenič A. Ženske in ginekološki raki. Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije. 2018, str. 9-17. - Zadnik V, Lokar K, Tomšič S, Škrlec F, Žagar T. Estimating fractions of cancers attributable to socioeconomic inequalities in Slovenia. In: Data linkage and cancer registries. Ispra: European Commission. 2018, str. 35. - Zadnik V, Lokar K, Žagar T. Bayesian spatial modelling of socioeconomic environment and cancer incidence in Slovenia. In: IACR 2018: 40th annual scientific conference. Arequipa: IACR. 2018, str. 37. - Zadnik V, Žagar T. Population-based cancer registries: monitoring the cancer burden within and between countries: a case of Slovenian Cancer Registry. European journal of public health. 2018; 28: Suppl. 4: 213. 99 Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2016